



EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

Noticias en la Web

Nueva vacuna en Chile contra el neumococo: qué cambia desde septiembre

1 sep. Desde el 1 de septiembre, el Programa Nacional de Inmunizaciones incorporará la vacuna PCV20 para lactantes, en reemplazo de la PCV13. La nueva fórmula amplía de 13 a 20 los serotipos del neumococo que cubre.

A partir del 1 de septiembre, el Programa Nacional de Inmunizaciones (PNI) incorpora al calendario infantil la vacuna antineumocócica conjugada 20 valente (PCV20), en reemplazo de la PCV13 que se usaba hasta ahora.



La nueva fórmula amplía de 13 a 20 los serotipos del neumococo cubiertos y refuerza la protección de los lactantes frente a enfermedades graves como la neumonía, la meningitis y la sepsis. El esquema de dosis no cambia.

Por qué se actualiza el calendario

La actualización responde a una recomendación del Comité Asesor de Vacunas y Estrategias de Inmunización (CAVEI) y a dos señales epidemiológicas. Según datos oficiales, los casos confirmados de enfermedad neumocócica invasora subieron de 400 en 2022 (2 por cada 100 mil habitantes) a 773 en 2025 (3,8 por cada 100 mil).

María Paz Bertoglia, epidemióloga y académica del Instituto de Salud Pública de la Universidad Andrés Bello, explica que parte de ese aumento se debe al rebote esperable tras el período de restricciones sanitarias, pero que a él se suma el llamado reemplazo de serotipos: al reducirse los tipos cubiertos por la vacuna anterior, otros no contemplados encuentran espacio para circular.

A eso se agrega un factor estacional. La positividad de virus respiratorios llegó a 56,1% en la semana epidemiológica 33 de este año, el registro más alto de 2026, y una infección viral previa facilita que el neumococo se vuelva invasor. “Por eso el Ministerio de Salud reforzó la vigilancia epidemiológica y el diagnóstico precoz durante este período. También pesa la resistencia a los antimicrobianos que la Organización Mundial de la Salud viene advirtiendo desde 2024, un fenómeno que reduce las opciones de tratamiento en los cuadros más severos”, añade la especialista.

Qué protección ofrece la nueva vacuna

Según Bertoglia, la ventaja central de la nueva vacuna es de cobertura: “Al ampliar el número de serotipos incluidos, reduce el riesgo de enfermedad invasora frente a variantes que hoy circulan sin control y suma protección frente a cuadros no invasores, como la otitis media, que explican buena parte del consumo de antibióticos en la infancia”.

La vacuna está destinada a todos los lactantes del país, de forma gratuita, tanto en la red pública como en los vacunatorios privados en convenio. El esquema se mantiene sin cambios: los lactantes de término reciben dosis a los 2 y 4 meses más un refuerzo a los 12 meses, mientras que los prematuros reciben

dosis a los 2, 4 y 6 meses más el refuerzo a los 12 meses. Bertoglia precisa que no se trata de una dosis extra, sino de una vacuna que protege más, y que quienes ya iniciaron su esquema con PCV13 no deben reiniciarlo. Los vacunatorios usarán primero las dosis de la fórmula anterior que aún tengan disponibles para cerrar los esquemas ya comenzados.

Qué se sabe de su seguridad

La PCV20 cuenta con autorización de las principales agencias regulatorias y años de uso en programas nacionales de distintos países. Según la académica UNAB, su perfil de seguridad no difiere sustantivamente del de la PCV13. Las reacciones más frecuentes se concentran en las primeras 48 horas y son locales, como molestia, enrojecimiento o hinchazón en el sitio de la inyección; algunos lactantes presentan irritabilidad, somnolencia, menos apetito o fiebre, manifestaciones leves y transitorias.

En los niños nacidos a las 28 semanas de gestación o menos, se recomienda vigilar la respiración durante las 48 a 72 horas posteriores a las dosis de la serie primaria, por un riesgo potencial de apnea descrito para las vacunas inyectables en este grupo. Se trata de una medida de observación, no de una contraindicación.

Qué queda pendiente

La actualización no incluye por ahora a las personas mayores, el grupo que concentra la mayor mortalidad por esta enfermedad. Según datos del Departamento de Estadísticas e Información de Salud (DEIS), los fallecimientos se concentraron en personas de 60 años y más, con cerca del 78% de las muertes en 2024 y 2025. El Ministerio de Salud comprometió el reemplazo de la vacuna polisacárida que se usa en ese grupo para 2027. La epidemióloga señala que cerrar esa brecha es el complemento natural de la decisión que comienza a aplicarse esta semana.

El llamado a padres, madres y cuidadores es revisar el carné de vacunación de sus hijos e hijas, verificar si hay dosis pendientes y acudir al vacunatorio cuando corresponda. Los registros pueden consultarse en línea a través del Portal Paciente, con ClaveÚnica.

En un lactante, las señales que no deben esperar son la dificultad para respirar, el rechazo a la alimentación, la fiebre alta o la temperatura anormalmente baja, la irritabilidad o la somnolencia extremas, los vómitos persistentes y la rigidez de cuello. Ante cualquier duda, los profesionales de la red de salud y los canales de Salud Responde están disponibles para orientar.

Fuente: El Mostrador. Disponible en <https://n9.cl/pcs18>

Nicaragua: Mechnikov Institute consolidates vaccine production

Sep 1. The Mechnikov Institute, a biotechnology plant established through cooperation with Russia, is now operating in Nicaragua to produce vaccines and is seeking to expand its capacity to meet the needs of Nicaraguan healthcare and international markets.



Roberto Lopez, president of the Nicaraguan Social Security Institute (INSS), told Revista Vision Sandinista that the plant aims to help guarantee the population's access to vaccines while maintaining costs that ensure its sustainability.

An article released in the magazine's latest issue stated that the biotechnology plant has produced eight million vaccines destined for Nicaragua this year. In 2025 alone, it produced 2.1 million doses of injectable vaccines.

The institute has exported vaccines to Cuba, Venezuela, and Ecuador, while exploring opportunities to expand its presence in other markets, including Mexico.

The facility also expanded its production lines this year, manufactured 4.5 million doses of Convasell to fight COVID-19, and serves as a platform for incorporating vaccines from other countries.

Russian and Nicaraguan authorities are reportedly studying the possibility of packaging the HPV vaccine in this nation and producing a dengue vaccine that could be available by 2029.

Fuente: MWAKILISHI. Disponible en <https://n9.cl/if19wp>

GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial

Sep 1. GSK's seasonal, mRNA-based influenza vaccine is progressing to a Phase III study after securing a safety and efficacy win in a mid-stage trial – potentially poising it to become a market competitor to Moderna's newly approved mRNA shot, mFlusvia.

The British pharma company is opting to progress its candidate based on the positive results of the Flu-028 study (NCT07204964) presented at the OPTIONS XIII Conference for the Control of Influenza, taking place from 30 August 2 to September in Washington DC, in which recipients given GSK's multivalent jab experienced higher immune responses than those given the marketed comparator standard and high-dose flu shots. The experimental vaccine also maintained an "acceptable" safety and short-term inflammatory response profile, GSK claims.



During the Phase IIa trial, GSK randomised 971 adult volunteers to receive varying dose levels and forms of its experimental vaccine or a choice of marketed comparators – including a standard and high-dose shot. Individuals recruited to this study received varying doses depending on their age, with participants split into younger (18-64) and older (65-plus) age categories.

With these positive efficacy results in hand and a grip established on which tested vaccine configuration should move forward, GSK will progress an optimised B-strain haemagglutinin (HA) form of its vaccine to Phase III. The company hopes this trial will begin in September 2026.

Pioneering the next generation of seasonal flu vaccines

Upon the initiation of GSK's Phase III trial, it will become the first to evaluate an mRNA-based flu vaccine targeting both HA and neuraminidase (NA) in the late-stages. According to Sanjay Gurunathan, GSK's head of vaccines and infectious disease R&D, this approach could help to "better protect people from flu" due to its capacity to target two primary flu surface proteins, which both play a key role in the virus' ability to bind and enter host cells.

New preventative options for seasonal flu could be particularly beneficial for public health as an estimated one billion cases and 650,000 deaths globally are linked to the virus each year.

If GSK's vaccine reaches the market, it will come into direct competition with Moderna's newly approved, mRNA-based seasonal flu shot, mFlusvia, which secured the US Food and Drug Administration's (FDA) blessing in August 2026. mFlusvia obtained the regulatory greenlight at the end of a tumultuous regulatory road defined by the FDA's initial refusal to review the vaccine entirely.

According to a sales and consensus forecast from GlobalData, parent company of Clinical Trials Arena, mFlusvia will make \$831m in 2032.

Is mRNA back in the limelight?

While many researchers and drugmakers have touted the potential of mRNA-based vaccines and medicines for treating and preventing everything from infectious diseases to cancer, notably its use in the Covid-19 pandemic, the modality has been under significant scrutiny from the Trump administration – particularly from the US Health Secretary, Robert F Kennedy Jr (RFK Jr) who has long questioned its safety.

After RFK Jr publicly cut government funding to 22 mRNA vaccine development initiatives worth \$500m back in August 2025, private equity financing focused on the modality also dried up in 2025 – declining 82% compared to 2023.

However, the Moderna's landmark Phase III melanoma success for its mRNA-based cancer vaccine, intismeran autogene, has piqued analyst interest due to its potential to offer additive efficacy in the adjuvant setting over SoC Keytruda (pembrolizumab) alone. This, some say, could reignite interest in the modality despite political challenges.

However, Jefferies senior equity research analyst, Andrew Tsai, previously told Pharmaceutical Technology, sister publication to Clinical Trials Arena, that investors were unlikely to immediately flock back to placing capital in mRNA-based therapies in a hurry – with their long-term interest likely hinging on the drug class's success in a broad range of solid tumours.

"GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Fuente: Yahoo Finance. Disponible en <https://n9.cl/6lf0w>

Scientists Take A Step Towards A Universal Vaccine Against Pneumonia And Meningitis

Sep 3. A new experimental vaccine could offer protection against several forms of *Streptococcus pneumoniae*, showing promise for a future vaccine that will not have to fight each bacterial strain separately.

The bacterium, commonly called pneumococcus, can live in the nose and throat without causing any symptoms. But when the body's defenses are compromised and weakened, it can target other parts of the body and cause symptoms like pneumonia, meningitis, bloodstream infections and other serious diseases.

About The Study

One of the primary challenges of preventing these infections is that *S. pneumoniae* exists in more than 100 serotypes, or distinct versions of the bacterium. The current vaccines available to fight them only cover a selection of these types.

A new study published in *Science Advances* has found a different strategy. Instead of developing the vaccine around the sugar coating that differs between serotypes, researchers targeted proteins that is shared across pneumococcal strains.

Current Pneumococcal Vaccines Have A Limitation

Existing pneumococcal vaccines work by instructing the immune system to recognise some components of the bacterium's outer shell.

Pneumococcal conjugate vaccines, or PCVs, combine these bacterial sugars with a carrier protein to produce a stronger immune response. Vaccines that target multiple serotypes have helped reduce invasive pneumococcal disease significantly.

But when vaccination reduces the prevalence of the serotypes that is included in a vaccine, other serotypes that are not covered can become more common. This phenomenon is known as serotype replacement.

Some of these replacement strains can also acquire antibiotic-resistance genes, which becomes another challenge.

This is why researchers have been exploring a vaccine that could provide protection across almost all pneumococcal serotypes, rather than having to continuously expand the list of strains covered.

Also read: Fall Vaccines 2026: US Doctors Issue COVID, Flu And RSV Jab Guidance

How Is The New Vaccine Developed?

Researchers opted for a reverse strategy to develop this universal vaccine. Instead of growing the bacterium and looking for useful components, researchers started with its genetic information.

They studied thousands of *S. pneumoniae* genomes to identify proteins that were conserved across different serotypes. The team looked for proteins that would:

- ♦ Be present on or accessible from the bacterial surface
- ♦ Be sufficiently different from human proteins
- ♦ Be capable of producing a strong immune response

From this analysis, researchers selected three proteins: zinc metalloprotease B (ZmpB), pneumococcal adherence and virulence factor A (PavA), and a YfhO-like protein.

These were combined with two immune-stimulating ingredients, CpG and chitosan, to create the experimental vaccine called ZPY-CpG-Ch.

Also read: 84% Cancer Patients Report Benefit From Ivermectin-Mebendazole: What The Study Found & Why More Trials Are Needed

Effects Of The Vaccine On Mice

Researchers tested the vaccine in both adult and mice to compare its performance with the 13-valent pneumococcal conjugate vaccine, PCV13.



In one experiment, vaccinated mice were exposed to serotype 1, a highly virulent strain of *S. pneumoniae*. The experimental vaccine produced 80% to 100% survival. The researchers also tested the vaccine against serotypes that are not covered by PCV13.

ZPY-CpG-Ch provided complete protection against serotypes 11A and 33F, while protection against serotype 8 was 50%.

The study found that the vaccine's protective effect was associated largely with a type of immune response that is be important in defense against pneumococcal infection.

The researchers also found that antibodies produced after vaccination could help kill pneumococci in laboratory experiments.

When these antibodies were transferred into unvaccinated mice, they provided protection against a lethal pneumococcal strain.

Despite the promising results, the researchers are not claiming that ZPY-CpG-Ch is ready for people.

The biggest limitation is that the work is still preclinical. The vaccine has been tested in mice but not in human clinical trials. The researchers also challenged the animals with only a small number of pneumococcal serotypes.

If the vaccine eventually proves to be safe and effective in humans, it could lead to wider protection against pneumococcal diseases.

Fuente: Health and me. Disponible en <https://n9.cl/cynskz>

Indonesia, CEPI test 100-day vaccine push in pandemic drill

Sep 4. Indonesia's Health Ministry, in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), conducted a two-day preparedness simulation titled "Mission 100 Days" to evaluate national response speed against potential novel pandemic threats, known as "Disease X".

The exercise makes Indonesia the third country in the world, following South Korea and Rwanda, to test its end-to-end pandemic response architecture alongside CEPI, covering biosurveillance, rapid vaccine development, manufacturing, and medical logistics distribution.

Health Minister Budi Gunadi Sadikin emphasized that national biosecurity capabilities should be funded and prioritized with the same gravity as military defense.

"Pandemics have claimed more lives than wars. The Black Death is estimated to have killed around 200 million people, more than the victims of World War II. Therefore, we must invest in health like defense to save lives," Sadikin said on Friday.

During the Tabletop Exercise (TTX), more than 120 experts from government ministries, research institutions, regulatory bodies, and industry stakeholders evaluated the feasibility of developing and producing a viable vaccine within 100 days of identifying a new pathogen.

Participants worked through a fictional outbreak scenario featuring "Nipah-X," a mutated, lethal zoonotic pathogen capable of spilling over from livestock to humans and sustaining human-to-human transmission.

To support the 100-day target, Indonesia is streamlining its early detection framework by introducing Point-of-Care Testing (POCT) rapid kits in primary health centers and expanding regional genomic sequencing infrastructure.

On the industrial side, the government has engaged domestic pharmaceutical manufacturers, including PT Bio Farma, PT Etana Biotechnologies Indonesia, and PT Biotis Pharmaceuticals, to guarantee rapid mass-production capacity during a health crisis.

CEPI Executive Director Richard Hatchett highlighted Indonesia's strategic significance in regional health security, praising its research infrastructure and regulatory readiness.

"Indonesia is a strategic partner of CEPI. Simulation exercises like this help build relationships and operational readiness, as well as identify gaps that must be closed to enable a much faster response to the next outbreak," Hatchett stated.

Meanwhile, Food and Drug Authority (BPOM) Head Taruna Ikrar affirmed that accelerated vaccine approval timelines will not compromise safety or efficacy standards.

BPOM is finalizing a conditional approval framework to complement existing Emergency Use Authorization (EUA) protocols.

"Accelerating innovation must go hand in hand with meeting safety, quality, and efficacy standards. Acceleration must not mean compromising on these standards," Ikrar stressed.

Fuente: ANTARA. Disponible en <https://n9.cl/hwvnja>

Moderna advances mRNA cancer push, eyes in vivo CAR-T and Korea trials

Sep 7. U.S. drugmaker Moderna is expanding its cancer drug development following the phase 3 success of its personalized messenger RNA (mRNA) cancer vaccine.



Beyond combination therapy with immunotherapy, the company is evaluating the potential for a vaccine-only regimen and is expected to broaden its research to "in vivo chimeric antigen receptor T cells (CAR-T)," which kill cancer cells directly in the body with a single injection.

On the 7th, according to the pharmaceutical and biotech industry, Moderna is developing a range of mRNA-based cancer vaccines and therapies. Its personalized cancer vaccine "intismeran autogene," which recently delivered phase 3 results in combination with Merck's (MSD) immunotherapy Keytruda, is also undergoing additional studies, including a monotherapy approach.

Kim Hee-su, vice president at Moderna Korea, said, "In addition to the combination therapy co-developed with MSD, we are looking at the potential for intismeran autogene as a monotherapy," and added, "Preclinical studies are underway, and we expect to enter full-scale clinical trials around the end of next year."

The intismeran autogene and Keytruda combination therapy, whose clinical results were released in the previous month, met its primary endpoint of suppressing cancer recurrence and metastasis in a phase 3 trial in high-risk melanoma patients. This is the first time an mRNA-based cancer vaccine has met primary endpoints in a phase 3 trial.

Intismeran autogene is made as a patient-specific therapy by analyzing mutations unique to cancer cells from a patient's tumor tissue and selecting neoantigens likely to elicit an immune response.

Currently, MSD is leading the development of combination therapy, including late-stage trials.

In Korea, MSD has completed enrollment of melanoma patients for late-stage trials and is conducting the study.

Building on these clinical results, Moderna plans to broaden the use of mRNA in cancer treatment beyond personalized cancer vaccines.

A representative area is "in vivo CAR-T," a next-generation CAR-T technology that kills cancer cells directly in the body with a single injection. By delivering RNA to specific immune cells to generate CAR-T cells inside the patient, it is considered a next-generation technology that could significantly change the manufacturing process of existing cell therapies.

Kim said, "If mRNA is applied to in vivo CAR-T, it could change the complex manufacturing steps of existing cell therapies," adding, "If we can reduce the process of harvesting a patient's cells, manipulating and culturing them externally, and reinfusing them, and instead induce immune cell function directly in the body, this could evolve into a new treatment approach."

The company is also developing mRNA therapies that target antigens commonly found in specific cancer patient groups. Its core candidate, "mRNA-4359," is in phase 2 as both a Keytruda combination and a monotherapy in melanoma and Non-small cell lung cancer (NSCLC) patients. In phase 1/2 results released in April, it showed a meaningful antitumor response as a first-line treatment for advanced or metastatic melanoma.

While expanding the scope of its mRNA platform in oncology, Moderna is also seeking new growth drivers in infectious disease vaccines. A key next program is the norovirus vaccine.

Norovirus is a major infectious disease that causes vomiting and diarrhea, especially in winter, but vaccine development is considered difficult due to the virus's diversity and frequent mutations. Several corporations have attempted to develop vaccines in the past but fell short in clinical trials. Moderna is currently conducting late-stage clinical trials for its norovirus vaccine.

Moderna emphasizes that for its core business, the COVID-19 vaccine, it must maintain a stable vaccination base focused on older adults and high-risk groups.

As perceptions of COVID-19 as a cold-like illness spread recently, vaccination rates remain lower than for influenza. According to the Korea Disease Control and Prevention Agency, the budget for procuring next year's COVID-19 vaccines has decreased by about 10% from this year, and the procurement volume has also fallen by about 500,000 doses.

Kim said, "COVID-19 remains a significant respiratory infectious disease that can lead to hospitalization and death among older adults, so regular vaccination is needed for high-risk groups, including older adults and those with weakened immunity," adding, "As the older population grows, we must guarantee sufficient vaccination opportunities for high-risk groups when needed."

Fuente: CHOSUN BIZ. Disponible en <https://n9.cl/7f1bc>

Indonesia Develops mRNA-Based Dengue Vaccine to Fight Four Virus Serotypes

Sep 7. The development of health technology in Indonesia requires an ecosystem that is able to bring research results from the laboratory to become products that can be used by the community.

One of the candidates being developed is a tetravalent dengue vaccine based on messenger RNA (mRNA) technology.

The effort is part of a collaboration between the University of Indonesia (UI), the National Research and Innovation Agency (BRIN), the Education Fund Management Agency (LPDP), PT Etana Biotechnologies Indonesia (Etana), and Tsinghua University.

In the Product Group Workshop and Signing of the 2026 Innovation Cooperation Agreement at UI, Depok, Thursday, August 27, Director of Corporate Relation & Strategic Affairs Etana, Andreas Donny Prakasa, said that biotechnology innovation is not enough to stop at the success of research.

According to him, one of the biggest challenges in the development of biotechnology products is the valley of death, which is the phase when research results show potential, but are not ready to be developed into commercial products.

The stages leading to a health product that can be used by the community require a long process. Research results need to go through scale-up development, validation, compliance with Good Manufacturing Practice (GMP) standards, preclinical and clinical testing, as well as regulatory processes and market preparation.

"The industry needs to be involved from the early stages of research so that market needs, production scale, regulations, and economics are considered. This is where the teaching factory plays a strategic role, as a place where research results are prepared to be upgraded from laboratory scale to industrial standards," said Donny.

The research results of interest are mRNA-based tetravalent dengue vaccine candidates. The technology was developed considering the diversity of dengue viruses circulating in Indonesia.

Representative of the UI dengue vaccine research team, Prof. Dra. Beti Ernawati Dewi, explained that the vaccine candidate was designed to cover four dengue serotypes, namely DENV-1 to DENV-4.

The development was carried out by utilizing in silico mutation analysis as well as artificial intelligence approaches. These approaches are used to help design vaccine candidates that match the characteristics of local dengue strains.

"The development of this mRNA-based dengue vaccine is part of an effort to bring innovations that meet Indonesia's needs, by utilizing the diversity of dengue strains circulating in the country," said Prof. Beti.

Based on preliminary testing, the candidate showed neutralisation activity against all four dengue serotypes. Several vaccine constructs have also been reported to show better results than wild type and the commercial comparator Dengvaxia.

However, the results of the initial research do not mean that the vaccine is ready for widespread use. The vaccine candidate still needs a series of research and testing stages to ensure its safety, effectiveness, quality, and feasibility before it can enter the stage of use in the community.

Apart from technological capabilities and funding, the regulatory aspect is an important part of the health innovation journey from research to product.

Representative of the Food and Drug Supervisory Agency (BPOM), Jeffeta Pradeko Putra, explained the BPOM GROW program (Green Research and Opportunities With BPOM). This initiative is designed to provide assistance to researchers in regulatory aspects, including the process leading to the production and registration of research products.

"BPOM is committed to supporting the downstream of research from the beginning. Through

collaboration between academics, businesses, and governments, we facilitate regulatory assistance to distribution permits so that Indonesian researchers' innovation products meet safety and quality standards, and are ready to provide real benefits to the community," said Jeffeta.

Assistance from the initial stage is considered important because the development of biopharmaceutical products has complex safety and quality requirements. By understanding the regulatory needs from the start of the research, it is expected that technology development can run more directed.

The development of vaccines and biopharmaceutical products requires time and large resources. Therefore, the success of downstream processing does not only depend on one party.

The strengthening of teaching factory and laboratory facilities of universities needs to be linked to the Technology Readiness Level (TKT) or Technology Readiness Level (TRL). The mapping helps determine the position of an innovation as well as the stages that need to be taken before the technology can be further developed.

Collaboration also needs to include funding, technology evaluation, testing, regulatory compliance, and commercialization readiness.

In the context of health products, the Pentahelix approach is considered relevant because it brings together five elements, namely academics, industry, government, community, and media.

Through the 2026 Product Group Workshop which took place on 27-28 August 2026, Etana together with UI and BPOM encouraged the strengthening of the research downstream ecosystem. A number of focuses include mapping TKT/TRL from the early stages, continuity of funding from research to commercialization, and increasing industry involvement in assessing the potential for developing research results.

Forums that bring together researchers, industry, and regulators on a regular basis are also expected to shorten the distance between innovations in the laboratory and public health needs.

For the development of dengue vaccines, this kind of ecosystem is important so that innovations that arise from research in the country do not stop as prototypes, but have a clear path to the testing stage, meeting standards, and ultimately can provide benefits to the community.

Fuente: VOI. Disponible en <https://n9.cl/jxaeo>

¿Cómo han cambiado las vacunas la lucha contra las enfermedades infecciosas?

8 sep. Las enfermedades que antes causaban grandes epidemias ahora están bajo control gracias a las vacunas.

Durante décadas, las vacunas han contribuido a cambiar drásticamente la carga de muchas enfermedades infecciosas que antes causaban grandes epidemias en todo el mundo .

Polio

Antes de que la vacuna contra la polio estuviera ampliamente disponible, la enfermedad causaba cientos de miles de casos de parálisis cada año en todo el mundo, principalmente en niños.

Según la Organización Mundial de la Salud (OMS), el número de casos de poliomielitis causados por el virus ha disminuido en más del 99 % desde 1988 gracias a los programas de vacunación y a los

esfuerzos de erradicación de la poliomielitis en todo el mundo. Muchas zonas del planeta han sido certificadas como libres del virus de la poliomielitis salvaje.

En Vietnam, la poliomielitis fue erradicada oficialmente en el año 2000. Mantener altas tasas de vacunación y realizar vigilancia epidemiológica son factores cruciales para proteger este logro.

Sarampión

El sarampión es una de las enfermedades infecciosas más contagiosas. Antes de que las vacunas estuvieran ampliamente disponibles, la mayoría de los niños contraían sarampión en algún momento. Algunos casos podían ser graves, con complicaciones como neumonía, encefalitis o incluso la muerte.

La OMS y UNICEF (Fondo de las Naciones Unidas para la Infancia) estiman que las vacunas contra el sarampión han ayudado a prevenir decenas de millones de muertes en todo el mundo desde el año 2000. Sin embargo, los brotes de sarampión siguen siendo un riesgo debido a la disminución de las tasas de vacunación.

Esto demuestra que las vacunas no solo protegen a las personas vacunadas individualmente, sino que también ayudan a limitar la propagación del virus en la comunidad.

Tos ferina y difteria

Antes de la vacunación generalizada, la tos ferina era una de las principales causas de enfermedad grave y muerte en niños pequeños, especialmente en lactantes. La enfermedad podía provocar complicaciones como neumonía, convulsiones, hipoxia y daño cerebral.

La difteria fue en su día una peligrosa enfermedad infecciosa que podía provocar obstrucción de las vías respiratorias. Las toxinas producidas por la bacteria de la difteria también podían dañar el corazón y el sistema nervioso.

Nuevos desafíos en la era de las vacunas

A pesar de los numerosos logros, la lucha contra las enfermedades infecciosas aún no ha terminado.

La aparición y propagación de nuevos patógenos, el cambio climático, la urbanización y el intercambio internacional pueden alterar los patrones de circulación de algunas enfermedades infecciosas, creando nuevos desafíos para la salud pública.

Además, la desinformación sobre las vacunas en las redes sociales puede provocar que algunas personas duden o retrasen la vacunación. Cuando disminuyen las tasas de vacunación, aumenta el riesgo de brotes de enfermedades prevenibles mediante vacunación.

Por lo tanto, mantener altas tasas de vacunación, garantizar que las personas tengan acceso a las vacunas según lo programado, fortalecer la vigilancia epidemiológica y proporcionar información científica y transparente sobre las vacunas son soluciones cruciales para proteger los logros ya alcanzados.

Las vacunas no son la única solución para prevenir las enfermedades infecciosas, pero sí una de las herramientas de salud pública más eficaces. Mantener una cobertura de vacunación completa no solo protege a las personas, sino que también contribuye a reducir la circulación de patógenos, limitar los brotes y proteger a las personas vulnerables de la comunidad.

Fuente: VIETNAM.VN. Disponible en <https://n9.cl/lyk6vo>

Gavi welcomes prequalification of multi-dose RSV maternal vaccine to protect infants

Sep 9. Gavi, the Vaccine Alliance welcomes the World Health Organization's (WHO) prequalification of a multi-dose vial presentation of an RSV maternal vaccine, a significant milestone, that paves the way for introduction of this new protective vaccine in lower income countries, with Gavi support.



Respiratory syncytial virus (RSV) is the leading infectious disease cause of severe pneumonia in young children globally and the second leading cause of infant mortality after malaria. Each year, RSV is responsible for an estimated 33 million lower respiratory tract infections, 3.6 million hospitalisations and more than 100,000 deaths among children under five. More than 97% of RSV-related deaths occur in low- and middle-income countries, with the greatest burden falling on Africa.

Maternal immunisation offers a powerful opportunity to protect infants during their most vulnerable first months of life, when the risk of severe RSV disease is highest. By vaccinating pregnant women, protective antibodies can be transferred to babies before birth, helping shield them from severe illness, hospitalisation and death.

Commenting on the development, Emily Kobayashi the Director of Vaccine Programmes, at Gavi, the Vaccine Alliance, said:

"The WHO prequalification of a multi-dose RSV maternal vaccine marks an important step towards ensuring that all children, regardless of where they are born, are protected at their very first breath against one of the world's leading causes of infant hospitalisation and death. This multi-dose presentation now creates the opportunity for Gavi-supported countries to deliver this protection through routine maternal immunisation programmes for the first time."

The latest prequalification milestone is also an important signal for the broader RSV market; expansion of the range of presentations and products available helps create a more sustainable market and improves the long-term availability of affordable RSV prevention tools for countries with the highest disease burden.

The Alliance continues to work closely with partners and key stakeholders to support country decision-making and successful vaccine introductions.

Fuente: Gavi. Disponible en <https://n9.cl/ykinh>

Freezer-free RNA vaccine breakthrough could transform the global fight against emerging diseases

Sep 9. The race to develop vaccines faster, distribute them more widely and prepare for the next pandemic has taken an important step forward. Indian biotechnology company Immunoscrypt Life Science has secured up to US\$8.9 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance clinical testing of a next-generation RNA vaccine platform that could eliminate one of the biggest challenges facing modern vaccination programmes: the cold chain.

The investment is significant not only for India's rapidly expanding biotechnology sector but also for global public health.

If successful, the technology could help deliver RNA vaccines to remote and low-resource communities that currently lack the ultra-low temperature storage infrastructure required by many conventional mRNA vaccines. At a time when public health authorities are increasingly concerned about emerging infectious diseases, so-called “Disease X” threats and the possibility of future pandemics, advances that improve vaccine accessibility may prove just as important as advances in vaccine efficacy.

Messenger RNA (mRNA) vaccines became one of the defining scientific successes of the COVID-19 pandemic. Companies such as Pfizer-BioNTech and Moderna demonstrated that RNA-based vaccines



could be designed, manufactured and deployed far more rapidly than many traditional vaccine technologies. The advantages of RNA vaccines are well established. Unlike conventional vaccine approaches that may require growing pathogens or producing large quantities of proteins, RNA platforms can be adapted relatively quickly once the genetic sequence of a new pathogen becomes available.

This speed forms the foundation of CEPI's ambitious 100 Days Mission, a global initiative supported by G7 and G20 nations, including India, that aims to develop safe and effective vaccines against future epidemic threats within 100 days of identifying a new pathogen.

Yet the COVID-19 response also highlighted a major weakness of existing RNA vaccine technologies. Many formulations require storage and transportation at extremely low temperatures. Maintaining such cold-chain systems is expensive, technically challenging and often impractical in rural regions and lower-income countries. The result is a paradox. Some of the world's most advanced vaccine technologies remain difficult to deploy in the places where they may be needed most.

A different approach to RNA vaccines

Immunoscript's proprietary CLNE™ self-amplifying RNA (saRNA) platform seeks to overcome this obstacle. Traditional mRNA vaccines typically encapsulate RNA molecules within lipid nanoparticles. The CLNE platform instead binds RNA directly to the outer surface of nanoemulsion droplets, creating a system that can be dried into a powder and stored under conventional refrigeration conditions of 2°C to 8°C.

This distinction is important for outbreak preparedness. A vaccine that can be transported through routine healthcare supply chains rather than specialised cryogenic systems could substantially improve global access. In an emergency, millions of doses could potentially be distributed more rapidly across regions where cold-chain infrastructure remains limited.

According to CEPI Chief Executive Officer Dr. Richard Hatchett, equitable vaccine access remains a priority for global preparedness efforts. The organisation views thermostable RNA vaccines as a potentially important tool in overcoming one of the major barriers to broader deployment of RNA vaccine technologies during outbreaks.

The importance of such technologies extends well beyond COVID-19. The global health community continues to monitor a wide range of emerging infectious disease threats. Recent years have seen outbreaks involving Mpox, Ebola virus disease, Nipah virus and other pathogens with epidemic potential. CEPI's portfolio includes programmes addressing multiple emerging diseases while simultaneously investing in platform technologies designed to accelerate future vaccine development. The challenge facing public health agencies is that it is impossible to predict with certainty which pathogen will trigger the next major outbreak. This is where platform technologies become increasingly valuable. Instead of building a new vaccine production process from scratch for every threat, advanced RNA systems may provide a flexible foundation that can be adapted rapidly once a pathogen has been identified and sequenced. The goal is not merely faster response but a fundamentally different model of pandemic preparedness.

Why self-amplifying RNA matters

The CLNE platform incorporates another notable feature: self-amplifying RNA. Unlike conventional mRNA vaccines, self-amplifying RNA technologies effectively instruct cells to generate additional copies of the vaccine RNA after administration. In practical terms, this means smaller quantities of starting material may produce a robust immune response.

From a public health perspective, this offers several advantages. First, manufacturing capacity can potentially be extended during emergencies, enabling larger numbers of vaccine doses to be produced from the same manufacturing infrastructure. Second, lower production requirements may reduce overall costs. Third, the technology could improve preparedness for large-scale outbreak scenarios where demand surges rapidly. Researchers have increasingly identified self-amplifying RNA as one of the most promising next-generation vaccine technologies currently under development.

The new CEPI funding will support an early-stage clinical study evaluating both the safety of the CLNE platform and the immune responses generated by a vaccine candidate targeting rabies. Rabies serves as a useful prototype disease because it remains a significant public health concern in many parts of the world while also providing an opportunity to demonstrate the platform's potential beyond COVID-19 applications.

Researchers plan to use artificial intelligence tools to optimise dose selection during the study, illustrating how digital technologies are increasingly being integrated into vaccine development programmes. This combination of RNA science, computational biology and advanced manufacturing reflects broader trends across modern biotechnology.

India's growing biotechnology influence

The development also highlights India's expanding role within the global biotechnology and vaccine ecosystem. India is already one of the world's most important vaccine manufacturing centres, supplying large quantities of vaccines to domestic and international markets. Increasing investment in advanced platform technologies may further strengthen the country's position as a global innovation hub.

Immunoscript itself represents part of a broader evolution of the Indian life sciences sector towards cutting-edge genomic medicine, advanced therapeutics and precision healthcare technologies. The company describes its mission as using biological engineering, artificial intelligence and translational science to address global healthcare challenges.

For India, success in next-generation RNA technologies could deliver both economic and strategic benefits while contributing to international health security.

Another aspect of the project is that its potential extends beyond future pandemics. Although much attention is focused on Disease X scenarios, thermostable RNA platforms may also support vaccine development against existing diseases that continue to impose major burdens on public health systems around the world. In theory, technologies that simplify manufacturing, distribution and storage could expand access not only during emergencies but also during routine immunisation programmes. The broader implication is that innovations developed for pandemic preparedness may ultimately improve everyday healthcare delivery.

Fuente: DIGITAL JOURNAL. Disponible en <https://n9.cl/gqkxm>

Three of Sanofi's next-generation vaccines will be manufactured in Vietnam

Sep 11. According to Mr. Ngo Chi Dung, Chairman of the Board and General Director of VNVC, within the framework of the recent Vietnam-France Business Forum held in France, VNVC and Sanofi reached an agreement to produce next-generation vaccines at the VNVC Vaccine and Biological Products Factory, making Vietnam the first country in Southeast Asia with the capacity to produce these vaccines.

Accordingly, three types of vaccines are prioritized for production at the VNVC Vaccine and Biological Products Factory: the 6-in-1 vaccine with acellular pertussis component, the seasonal influenza vaccine, and the meningococcal vaccine. These are essential vaccines with high demand in Vietnam, preventing many dangerous diseases for various age groups, from young children and teenagers to adults and the elderly.

These new generation vaccines are also identified as strategic technology products according to a Government Decision. Therefore, promoting domestic production is crucial for the development of Vietnam's modern vaccine and pharmaceutical industry, increasing its ability to proactively meet the breakthrough development needs of the healthcare sector, and gradually enhancing Vietnam's position in the global biotechnology value chain.

According to Mr. Ngo Chi Dung, the project is being implemented with investment items according to international standards in the field of pharmaceutical and vaccine production. According to the plan, the factory is expected to be completed in 2027, begin production in 2028, and commercialize from 2029, with the goal of supplying tens of millions of vaccine doses annually to the Vietnamese market, expanding to the region and participating in the global supply chain.

Mr. Ngo Chi Dung shared: "VNVC hopes the project will continue to receive support to ensure its implementation progress and to bring vaccines into production in Vietnam as soon as possible. The success of the project will create a foundation for Sanofi vaccines produced in Vietnam to reach countries in Southeast Asia and participate in the global vaccine supply chain."

"Three next-generation vaccines from Sanofi (France) will be prioritized for production in Vietnam, making Vietnam the first country in Southeast Asia with the capacity to manufacture these products, contributing to increased self-sufficiency in domestic vaccine supply."

The collaboration between Sanofi and VNVC marks a milestone in the comprehensive strategic partnership between Vietnam and France in the healthcare and pharmaceutical sectors. This event contributes to concretizing the major directions outlined in Politburo Resolutions 57, 68, and 72 on breakthroughs in science and technology development, promoting the role of the private sector, specifically in disease prevention, healthcare, and improving public health.

Stephen Alix, Director of International Markets, Vaccines Division at Sanofi, stated that Sanofi highly values Vietnam's orientations in promoting science and technology, innovation, developing high-tech industries, and strengthening the self-reliance of the healthcare system. Through this project, Sanofi hopes to contribute to development goals and help build an increasingly modern biotechnology ecosystem in Vietnam.

Reportedly, the VNVC Vaccine and Biological Products Factory in Tay Ninh has an initial investment of over 2,500 billion VND, covers an area of over 26,000 m², and has a designed capacity of approximately 120 million vaccine doses per year. The factory is being invested in to meet international standards such as WHO-GMP, EU-GMP, and FDA-cGMP, while also developing research capabilities, technology adoption, production, and testing of high-tech vaccines and biological products in Vietnam. VNVC has signed a contract with Syntegon Group (Germany) to invest in a high-capacity vaccine production line system, applying automation and advanced sterile technology.



Representatives from Sanofi and VNVC exchanged a Joint Statement on cooperation in the production of three important next-generation vaccines for children and adults in Vietnam. Photo: VNVC

Fuente: VIETNAM.VN. Disponible en <https://n9.cl/dcb40>

New 14-Valent Pneumococcal Vaccine Shows Strong Safety and Immune Response in Indian Infants

Sep 12. Pneumococcal disease remains one of the most formidable vaccine-preventable threats to young children worldwide, and a newly reported phase IV trial from India offers encouraging evidence that a next-generation pneumococcal conjugate vaccine can meet the moment. The study, published in *BMC Infectious Diseases*, evaluated PNEUBEVAX 14, a 14-valent pneumococcal conjugate vaccine manufactured by Biological E Limited and known by the shorthand BE-PCV14. The vaccine has already earned prequalification from the World Health Organization, a distinction that signals it meets international



standards of quality, safety, and efficacy, and that opens the door to procurement by UNICEF and other global immunization programs. What sets this vaccine apart from the products that have dominated childhood immunization schedules for the past decade is its expanded serotype coverage, which includes two emerging pneumococcal strains, 22F and 33F, that are not covered by the widely used 13-valent vaccine Prevenar 13.

The trial was designed as a prospective, open-label, multicenter, active-controlled study conducted across 31 clinical sites in India, enrolling healthy infants who had never received a pneumococcal conjugate vaccine. Participants aged 6 to 8 weeks at enrollment received three primary doses of either BE-PCV14 or Prevenar 13, followed by a booster dose administered at 12 to 15 months of age, a regimen commonly described as a 3p plus 1 schedule. The investigators, led by Subhash Thuluva of Biological E Limited in Hyderabad, measured serotype-specific immunoglobulin G antibodies against all 14 vaccine serotypes as well as the cross-protective serotype 6A, assessed 28 days after the booster dose. The primary immunological benchmarks were seroresponse rates, defined as the proportion of children achieving serotype-specific IgG concentrations of at least 0.35 micrograms per milliliter, a threshold long used as a correlate of protection against invasive pneumococcal disease, along with geometric mean concentrations of antibody.

The immunogenicity analysis included 559 children who received BE-PCV14 and 147 who received PCV13, providing a substantial evidence base for the comparison. The results were striking in their consistency: after the booster dose, seroresponse rates with BE-PCV14 reached at least 92.8 percent for every one of the 14 vaccine serotypes, and climbed to 96.2 percent for serotype 6A, which is not itself in the vaccine but is known to elicit cross-protection through immunological relatedness to vaccine serotype 6B. For the serotypes shared between the two vaccines, the immune responses elicited by BE-PCV14 were comparable to those generated by Prevenar 13, and post hoc statistical analyses formally demonstrated non-inferiority for all 14 serotypes by both seroresponse and antibody concentration criteria.

The non-inferiority assessment deserves particular attention because of its methodological rigor. The investigators pre-specified that BE-PCV14 would be considered non-inferior to PCV13 for a given serotype if the lower bound of the 95 percent confidence interval for the difference in seroresponse rates exceeded minus 10 percent, and if the lower bound of the confidence interval for the ratio of geometric mean concentrations exceeded 0.5. These are the kinds of thresholds that regulators and vaccine advisory bodies use to judge whether a new product can reasonably substitute for an established one. BE-PCV14 cleared both hurdles for all 14 serotypes, a result that, in the words of the trial team, establishes the vaccine as a credible alternative within existing infant immunization schedules rather than an entirely new paradigm requiring altered dosing strategies.

Perhaps the most consequential finding involves serotypes 22F and 33F, the two additional strains incorporated into BE-PCV14 that are absent from PCV13. The vaccine induced strong antibody responses to both, with booster-induced increases in antibody concentration ranging from 2.4-fold to 5.3-fold across serotypes when compared with pre-booster levels. This matters because pneumococcal serotype replacement is a well-documented phenomenon: when a vaccine eliminates the strains it targets, other strains that were previously less common can expand to fill the ecological vacuum. Serotypes 22F and 33F have been increasingly recognized as causes of invasive pneumococcal disease in countries that have deployed PCV13 at scale, and their inclusion in a new vaccine represents a forward-looking strategy intended to stay ahead of shifting disease epidemiology rather than merely replicate existing coverage.

Safety data from the trial were equally reassuring. Adverse events occurred at similarly low frequencies in both vaccine groups and were predominantly mild local reactions, such as injection-site tenderness or redness, or transient fever. Only two serious adverse events were recorded among BE-PCV14 recipients, and the investigators judged neither to be related to vaccination. The safety profile through 28 days after the booster dose, therefore, mirrors the well-characterized tolerability of licensed pneumococcal conjugate vaccines, an essential consideration for a product intended for universal infant immunization in resource-constrained settings where health systems may have limited capacity to manage vaccine-associated complications.

The trial, registered prospectively with the Clinical Trials Registry of India under identifier CTRI/2023/09/057894 and approved by India's Central Drugs Standard Control Organisation, was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines, with written informed consent obtained from the parents or legally authorized representatives of all participants. Ethics committees overseeing each of the 31 participating sites granted approval, including the Institutional Ethics Committee of the All India Institute of Medical Sciences. The study, funded entirely by Biological E Limited, carries the inherent limitation that many of the authors are or were employees of the sponsoring company, though the trial's active-controlled design against a licensed comparator and its prespecified statistical criteria provide meaningful safeguards against bias in the immunogenicity conclusions.

The public health significance of this work extends well beyond India's borders. *Streptococcus pneumoniae* is responsible for hundreds of thousands of deaths among children under five each year, with the overwhelming majority occurring in low- and middle-income countries where access to effective vaccines has historically lagged behind wealthy nations. Pneumococcal conjugate vaccines have traditionally been among the most expensive components of childhood immunization schedules,

and the introduction of a WHO-prequalified vaccine manufactured in a middle-income country carries the potential to lower prices, expand supply, and reduce dependence on a small number of multinational manufacturers. For India, which runs one of the largest immunization programs in the world through its Universal Immunization Programme, a domestically produced 14-valent vaccine that slots into the standard 3-plus-1 schedule offers both strategic and epidemiological advantages.

The trial's findings also speak to a broader evolution in pneumococcal vaccine science. The 0.35 micrograms per milliliter IgG threshold used in this study is a population-level benchmark derived from efficacy trials of earlier conjugate vaccines, and while it does not guarantee individual protection, it remains the standard immunological bridge for licensure and comparison of new formulations. The demonstrated booster response, with antibody concentrations rising severalfold after the toddler dose, indicates that BE-PCV14 successfully exploits the immunological memory established during the primary series, an attribute that underpins the durability of protection in the second year of life, when the burden of invasive pneumococcal disease and pneumonia peaks in unvaccinated populations.

As pneumococcal disease patterns continue to shift under the selective pressure of global vaccination, the arrival of a well-tolerated, immunogenic 14-valent conjugate vaccine that extends coverage to emerging serotypes while matching the performance of the established 13-valent standard represents a meaningful advance. The authors conclude that PNEUBEVAX 14, when used as a booster in a 3-plus-1 schedule, is well tolerated and elicits robust responses comparable to PCV13 for shared serotypes while effectively broadening coverage to 15 serotypes when cross-protection against 6A is counted. For immunization programs weighing how to future-proof their pneumococcal strategies, this trial provides a substantial and encouraging body of evidence that broader serotype coverage need not come at the cost of safety or immunogenicity.

Fuente: Bioengineer.org. Disponible en <https://n9.cl/bw3jsp>



VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:



Síguenos en redes sociales



@vaccimonitor



@finlayediciones

EBSCO
Information Services



DOAJ
DIRECTORY OF
OPEN ACCESS
JOURNALS



reDalyC.org



HINARI
Research in Health

latindex
Sistema Regional de Información en Línea para
Revistas Científicas de América Latina, el Caribe,
España y Portugal

SeCiMed

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2026/09/01"[Date - Publication] : "2026/09/12"[Date - Publication])) 613 records

[Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.](#)

Mazur NI, Caballero MT, Nunes MC. *Lancet*. 2024 Sep 21;404(10458):1143-1156. doi: 10.1016/S0140-6736(24)01716-1. Epub 2024 Sep 9. PMID: 39265587

[Amyloid- \$\beta\$ -targeting immunotherapies for Alzheimer's disease.](#)

Jin Y, Du Q, Song M, Kang R, Zhou J, Zhang H, Ding Y. *J Control Release*. 2024 Nov;375:346-365. doi: 10.1016/j.jconrel.2024.09.012. Epub 2024 Sep 18. PMID: 39271059

[Transforming vaccinology.](#)

Rappuoli R, Alter G, Pulendran B. *Cell*. 2024 Sep 19;187(19):5171-5194. doi: 10.1016/j.cell.2024.07.021. PMID: 39303685

[pr-independent biogenesis of infectious mature Zika virus particles.](#)

Dowd KA, Schroeder M, Sanchez E, Brumbaugh B, Foreman BM, Burgomaster KE, Shi W, Wang L, Caputo N, Gordon DN, Schwartz CL, Hansen BT, Aleshnick M, Kong WP, Morabito KM, Hickman HD, Graham BS, Fischer ER, Pierson TC. *bioRxiv [Preprint]*. 2024 Sep 12:2024.09.12.612520. doi: 10.1101/2024.09.12.612520. PMID: 39372759

[Apoptotic Vesicles: Therapeutic Mechanisms and Critical Issues.](#)

Ou Q, Huang W, Wang B, Niu L, Li Z, Mao X, Shi S. *J Dent Res*. 2024 Oct;103(11):1057-1065. doi: 10.1177/00220345241265676. Epub 2024 Sep 13. PMID: 39272215

[Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.](#)

García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JR, López A, Ascaso-Del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J, Carcas AJ, Díez-Fuertes F; CombiVacS Study Group. *iScience*. 2024 Aug 14;27(9):110728. doi: 10.1016/j.isci.2024.110728. eCollection 2024 Sep 20. PMID: 39286494

[The greatest Dengue epidemic in Brazil: Surveillance, Prevention, and Control.](#)

Gurgel-Gonçalves R, Oliveira WK, Croda J. *Rev Soc Bras Med Trop*. 2024 Sep 20;57:e002032024. doi: 10.1590/0037-8682-0113-2024. eCollection 2024. PMID: 39319953

[Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer.](#)

de Graaf JF, Pesic T, Spitzer FS, Oosterhuis K, Camps MGM, Zoutendijk I, Teunisse B, Zhu W, Arakelian T, Zondag GC, Arens R, van Bergen J, Ossendorp F. *Mol Ther Oncol*. 2024 Jun 15;32(3):200835. doi: 10.1016/j.omton.2024.200835. eCollection 2024 Sep 19. PMID: 39040850

[mRNA vaccines: a new era in vaccine development.](#)

Chandra S, Wilson JC, Good D, Wei MQ. *Oncol Res*. 2024 Sep 18;32(10):1543-1564. doi: 10.32604/or.2024.043987. eCollection 2024. PMID: 39308511

[ChatGPT to the rescue?](#)

Thorp HH. *Science*. 2024 Sep 13;385(6714):1143. doi: 10.1126/science.adt0007. Epub 2024 Sep 12. PMID: 39265007

[Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects.](#)

Liu Y, Huang Y, He G, Guo C, Dong J, Wu L. *Int J Mol Sci*. 2024 Sep 22;25(18):10166. doi: 10.3390/ijms251810166. PMID: 39337651

[mRNA-based HIV-1 vaccines.](#)

Ahmed S, Herschhorn A. *Clin Microbiol Rev*. 2024 Sep 12;37(3):e0004124. doi: 10.1128/cmr.00041-24. Epub 2024 Jul 17. PMID: 39016564

[Longitudinal Multi-omic Immune Profiling Reveals Age-Related Immune Cell Dynamics in Healthy Adults.](#)

Gong Q, Sharma M, Kuan EL, Glass MC, Chander A, Singh M, Graybuck LT, Thomson ZJ, LaFrance CM, Zaim SR, Peng T, Okada LY, Genge PC, Henderson KE, Dornisch EM, Layton ED, Wittig PJ, Heubeck AT, Mukuka NM, Reading J, Roll CR, Hernandez V, Parthasarathy V, Stuckey TJ, Musgrove B, Swanson E, Lord C, Weiss MDA, Phalen CG, Mettey RR, Lee KJ, Johanneson JB, Kawelo EK, Garber J, Krishnan U, Smithmyer M, Wherry EJ, Vella L, Henrickson SE, Kopp MS, Savage AK, Becker LA, Meijer P, Coffey EM, Goronzy JJ, Speake C, Bumol TF, Goldrath AW, Torgerson TR, Li XJ, Skene PJ, Buckner JH, Gustafson CE. *bioRxiv [Preprint]*. 2024 Sep 14:2024.09.10.612119. doi: 10.1101/2024.09.10.612119. **Update in:** [Nature](#). 2025 Dec;648(8094):696-706. doi: 10.1038/s41586-025-09686-5. PMID: 39314416

[A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.](#)

Cui L, Watanabe S, Miyanaga K, Kiga K, Sasahara T, Aiba Y, Tan XE, Veerananarayanan S, Thitiananpakorn K, Nguyen HM, Wannigama DL. *Antibiotics (Basel)*. 2024 Sep 11;13(9):870. doi: 10.3390/antibiotics13090870. PMID: 39335043

[Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response.](#)

Bhagchandani SH, Yang L, Lam JH, Maiorino L, Ben-Akiva E, Rodrigues KA, Romanov A, Suh H, Aung A, Wu S, Wadhera A, Chakraborty AK, Irvine DJ. *Sci Immunol*. 2024 Sep 20;9(99):eadl3755. doi: 10.1126/sciimmunol.adl3755. Epub 2024 Sep 20. PMID: 39303017

[Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.](#)

Pecenka C, Sparrow E, Feikin DR, Srikantiah P, Darko DM, Karikari-Boateng E, Baral R, Vizzotti C, Rearte A, Jalang'o R, Fleming JA, Martínón-Torres F, Karron RA. *Lancet*. 2024 Sep 21;404(10458):1157-1170. doi: 10.1016/S0140-6736(24)01699-4. Epub 2024 Sep 9. PMID: 39265588

[Ferritin nanoparticle-based Nipah virus glycoprotein vaccines elicit potent protective immune responses in mice and hamsters.](#)

Chen S, Zhang X, Yao Y, Wang S, Li K, Zhang B, Ye T, Chen L, Wu Y, Li E, Xu B, Zhang P, Chuai X, Ran Y, Gong R, Zhang H, Chiu S. *Viol Sin*. 2024 Dec;39(6):909-916. doi: 10.1016/j.virs.2024.09.005. Epub 2024 Sep 16. PMID: 39293542

[Inherent symmetry and flexibility in hepatitis B virus subviral particles.](#)

Wang Q, Wang T, Cao L, Mu A, Fu S, Wang P, Gao Y, Ji W, Liu Z, Du Z, Guddat LW, Zhang W, Li S, Li X, Lou Z, Wang X, Hu Z, Rao Z. *Science*. 2024 Sep 13;385(6714):1217-1224. doi: 10.1126/science.adp1453. Epub 2024 Sep 12. PMID: 39264996

[LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice.](#)

Chen J, Hu Y, Chen Y, Zhou Z, Shen Y, Wang Y, Liu Z, Li X, Su Z, Wu J. *J Control Release*. 2024 Nov;375:513-523. doi: 10.1016/j.jconrel.2024.09.020. Epub 2024 Sep 20. PMID: 39278354

[The next Nobel Prize in chemistry or in physiology or medicine.](#)

Kadoch C, Sheltzer JM, Yin H. *Cell Chem Biol*. 2024 Sep 19;31(9):1566-1567. doi: 10.1016/j.chembiol.2024.08.013. PMID: 39303696

[Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity.](#)

Dvorscek AR, McKenzie CI, Stäheli VC, Ding Z, White J, Fabb SA, Lim L, O'Donnell K, Pitt C, Christ D, Hill DL, Pouton CW, Burnett DL, Brink R, Robinson MJ, Tarlinton DM, Quast I. *Immunity*. 2024 Oct 8;57(10):2433-2452.e7. doi: 10.1016/j.immuni.2024.08.017. Epub 2024 Sep 20. PMID: 39305904

[Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.](#)

Weber WC, Streblow DN, Coffey LL. *BioDrugs*. 2024 Nov;38(6):727-742. doi: 10.1007/s40259-024-00677-y. Epub 2024 Sep 18. PMID: 39292392

[Synergistic integration of mRNA-LNP with CAR-engineered immune cells: Pioneering progress in immunotherapy.](#)

Chen Z, Shu J, Hu Y, Mei H. *Mol Ther*. 2024 Nov 6;32(11):3772-3792. doi: 10.1016/j.ymthe.2024.09.019. Epub 2024 Sep 17. PMID: 39295145

[Influenza vaccine for 2024-2025.](#)

[No authors listed] *Med Lett Drugs Ther*. 2024 Sep 16;66(1711):145-150. doi: 10.58347/tml.2024.1711a. PMID: 39250341

[Vaccination against dengue fever for travellers.](#)

Eperon G, Veit O, Antonini P, Fehr J, Haller S, Hatz C, Landry P, Neumayr A, Niederer-Lohrer A, Schlagenhauf P, De Vallière S, Staehelin C; Swiss Expert Committee on Travel Medicine (ECTM). *Swiss Med Wkly.* 2024 Sep 19;154:3858. doi: 10.57187/s.3858.PMID: 39463237

[Immunotherapy and delivery systems for melanoma.](#)

Liu H, Gou X, Tan Y, Fan Q, Chen J. *Hum Vaccin Immunother.* 2024 Dec 31;20(1):2394252. doi: 10.1080/21645515.2024.2394252. Epub 2024 Sep 17.PMID: 39286868

[Engineering a SARS-CoV-2 Vaccine Targeting the Receptor-Binding Domain Cryptic-Face via Immunofocusing.](#)

Bruun TUJ, Do J, Weidenbacher PA, Utz A, Kim PS. *ACS Cent Sci.* 2024 Sep 17;10(10):1871-1884. doi: 10.1021/acscentsci.4c00722. eCollection 2024 Oct 23.PMID: 39463836

[Development of novel multi-protein chimeric immunogens that protect against infection with the Lyme disease agent, *Borrelia burgdorferi*.](#)

O'Bier NS, Camire AC, Patel DT, Billingsley JS, Hodges KR, Marconi RT. *mBio.* 2024 Oct 16;15(10):e0215924. doi: 10.1128/mbio.02159-24. Epub 2024 Sep 17.PMID: 39287439

[Mathematical modeling of infectious diseases and the impact of vaccination strategies.](#)

Bolatova D, Kadyrov S, Kashkynbayev A. *Math Biosci Eng.* 2024 Sep 19;21(9):7103-7123. doi: 10.3934/mbe.2024314.PMID: 39483076

[Immune-modulative nano-gel-nano system for patient-favorable cancer therapy.](#)

Kim SH, Han RT, Han HS, Kim YM. *Bioact Mater.* 2024 Sep 17;43:67-81. doi: 10.1016/j.bioactmat.2024.08.047. eCollection 2025 Jan.PMID: 39328776

[Mpox mRNA-1769 Vaccine Inhibits Orthopoxvirus Replication at Intranasal, Intrarectal, and Cutaneous Sites of Inoculation.](#)

Cotter CA, Ignacio MA, Americo JL, Earl PL, Mucker EM, Hooper JW, Frey TR, Carfi A, Freyn AW, Moss B. *bioRxiv [Preprint].* 2024 Sep 20:2024.09.19.613928. doi: 10.1101/2024.09.19.613928. **Update in:** [NPJ Vaccines.](#) 2024 Dec 24;9(1):256. doi: 10.1038/s41541-024-01052-2.PMID: 39372733

[Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.](#)

Otsuki T, Akada S, Anami A, Kosaka K, Munjal I, Baber J, Shoji Y, Aizawa M, Swanson KA, Gurtman A. *Vaccine.* 2024 Sep 17;42(22):126041. doi: 10.1016/j.vaccine.2024.06.009. Epub 2024 Jun 8.PMID: 38853036

[Glucosylated Nanovaccines for Dendritic Cell-Targeted Antigen Delivery and Amplified Cancer Immunotherapy.](#)

Liu J, Cui Y, Cabral H, Tong A, Yue Q, Zhao L, Sun X, Mi P. *ACS Nano.* 2024 Sep 17;18(37):25826-25840. doi: 10.1021/acsnano.4c09053. Epub 2024 Aug 28.PMID: 39196858

[Safety of quadrivalent recombinant influenza **vaccine** in pregnant persons and their infants.](#)

Hsiao A, Yee A, Izikson R, Fireman B, Hansen J, Lewis N, Gandhi-Banga S, Selmani A, Talanova O, Kabler H, Inamdar A, Klein NP. *AJOG Glob Rep.* 2024 Sep 20;4(4):100395. doi: 10.1016/j.xagr.2024.100395. eCollection 2024 Nov. PMID: 39512761

[VaxBot-HPV: A GPT-based Chatbot for Answering HPV **Vaccine**-related Questions.](#)

Tao C, Li Y, Li J, Li M, Yu E, Amith M, Tang L, Savas L, Cui L. *Res Sq [Preprint].* 2024 Sep 11:rs.3.rs-4876692. doi: 10.21203/rs.3.rs-4876692/v1. **Update in:** *JAMIA Open.* 2025 Feb 19;8(1):ooaf005. doi: 10.1093/jamiaopen/ooaf005. PMID: 39315262

[Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.](#)

Meaney-Delman D, Carroll S, Polen K, Jatlaoui TC, Meyer S, Oliver S, Gee J, Shimabukuro T, Razzaghi H, Riley L, Galang RR, Tong V, Gilboa S, Ellington S, Cohn A. *Vaccine.* 2024 Sep 17;42 Suppl 3(Suppl 3):125644. doi: 10.1016/j.vaccine.2024.01.069. Epub 2024 Feb 29. PMID: 38423818

[Adverse events following immunization \(AEFI\) with fractional one-fifth and one-half doses of yellow fever **vaccine** compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.](#)

Casey RM, Najjengo MS, Lubega I, Sekiziyivu AB, Twinomuhwezi-Oyet E, Nakato WN, Sciarratta CN, Chu SY, Doshi RH, Kambugu A, Gidudu JF. *Vaccine.* 2024 Sep 17;42(22):126197. doi: 10.1016/j.vaccine.2024.126197. Epub 2024 Aug 15. PMID: 39153293

[Programming Bordetella pertussis lipid A to promote adjuvanticity.](#)

Fathy Mohamed Y, Fernandez RC. *Microb Cell Fact.* 2024 Sep 14;23(1):250. doi: 10.1186/s12934-024-02518-7. PMID: 39272136

[Building the U.S. COVID-19 **vaccine** effectiveness program: Past successes and future directions.](#)

Link-Gelles R, Britton A, Fleming-Dutra KE; CDC COVID-19 Vaccine Effectiveness Team. *Vaccine.* 2024 Sep 17;42 Suppl 3(Suppl 3):125492. doi: 10.1016/j.vaccine.2023.12.002. Epub 2023 Dec 20. PMID: 38129285

[**Vaccine** hesitancy in Scandinavia.](#)

Sherwood-Martin H. *Lancet Infect Dis.* 2024 Nov;24(11):1197. doi: 10.1016/S1473-3099(24)00620-0. Epub 2024 Sep 20. PMID: 39312913

[Shedding Light on the COVID-19 Pandemic: Placental Expression of Cell Biomarkers in Negative, Vaccinated, and Positive Pregnant Women.](#)

Condac C, Lozneau L, Matasariu DR, Ursache A, Bujor IE, Niță ME, Boiculese VL, Bîrluțiu V. *J Clin Med.* 2024 Sep 19;13(18):5546. doi: 10.3390/jcm13185546. PMID: 39337033

[Vaccination with O-linked Mannans Protects against Systemic Candidiasis through Innate Lymphocyte Populations.](#)

Taira CL, Dos Santos Dias L, Lichtenberger S, Whitehead AJ, Kischkel B, Netea MG, Klein BS, Wüthrich M. *J Immunol.* 2024 Sep 15;213(6):843-852. doi: 10.4049/jimmunol.2400065. PMID: 39109925

[RH5: rationally-designed malaria **vaccine** antigen improving efficacy.](#)

Takashima E, Tsuboi T. Trends Parasitol. 2024 Oct;40(10):870-872. doi: 10.1016/j.pt.2024.09.001. Epub 2024 Sep 13. PMID: 39277508

[COVID-19 **vaccine** refusal is driven by deliberate ignorance and cognitive distortions.](#)

Fuławka K, Hertwig R, Pachur T. NPJ Vaccines. 2024 Sep 14;9(1):167. doi: 10.1038/s41541-024-00951-8. PMID: 39271718

[Design of a novel EmTSP-3 and EmTIP based multi-epitope **vaccine** against Echinococcus multilocularis infection.](#)

Fan Y, He Y, Li Y, Yin Z, Shi J, Tian T, Shang K, Shi H, Zhang F, Wen H. Front Immunol. 2024 Sep 16;15:1425603. doi: 10.3389/fimmu.2024.1425603. eCollection 2024. PMID: 39351224

[A methamphetamine **vaccine** using short monoamine and diamine peptide linkers and poly-mannose.](#)

Hossain MK, Davidson M, Feehan J, Matsoukas JM, Nurgali K, Apostolopoulos V. Bioorg Med Chem. 2024 Nov 1;113:117930. doi: 10.1016/j.bmc.2024.117930. Epub 2024 Sep 19. PMID: 39306972

[Monitoring and reporting the US COVID-19 vaccination effort.](#)

Scharf LG, Adeniyi K, Augustini E, Boyd D, Corvin L, Kalach RE, Fast H, Fath J, Harris L, Henderson D, Hicks-Thomson J, Jones-Jack N, Kellerman A, Khan AN, McGarvey SS, McGehee JE, E Miner C, Moore LB, Murthy BP, Myerburg S, Neuhaus E, Nguyen K, Parker M, Pierce-Richards S, Samchok D, Shaw LK, Spoto S, Srinivasan A, Stearle C, Thomas J, Winarsky M, Zell E. Vaccine. 2024 Sep 17;42 Suppl 3(Suppl 3):125495. doi: 10.1016/j.vaccine.2023.12.005. Epub 2023 Dec 14. PMID: 38097453

[COMPARING **vaccine** manufacturing technologies recombinant DNA vs in vitro transcribed \(IVT\) mRNA.](#)

Davidopoulou C, Kouvelas D, Ouranidis A. Sci Rep. 2024 Sep 18;14(1):21742. doi: 10.1038/s41598-024-67797-x. PMID: 39289418

[Low booster uptake in cancer patients despite health benefits.](#)

Figueiredo JC, Levy J, Choi SY, Xu AM, Merin NM, Hamid O, Lemos T, Nguyen N, Nadri M, Gonzalez A, Mahov S, Darrah JM, Gong J, Paquette RL, Mita AC, Vescio RA, Salvy SJ, Mehmi I, Hendifar AE, Natale R, Tourtellotte WG, Ramanujan VK, Huynh CA, Sobhani K, Reckamp KL, Merchant AA. iScience. 2024 Jul 26;27(9):110596. doi: 10.1016/j.isci.2024.110596. eCollection 2024 Sep 20. PMID: 39286512

[A decavalent composite mRNA **vaccine** against both influenza and COVID-19.](#)

Wang Y, Ma Q, Li M, Mai Q, Ma L, Zhang H, Zhong H, Mai K, Cheng N, Feng P, Guan P, Wu S, Zhang L, Dai J, Zhang B, Pan W, Yang Z. mBio. 2024 Sep 11;15(9):e0066824. doi: 10.1128/mbio.00668-24. Epub 2024 Aug 6. PMID: 39105586

[An intranasal cationic liposomal polysaccharide **vaccine** elicits humoral immune responses against Streptococcus pneumoniae.](#)

Wei P, Romanò C, Li C, Clergeaud G, Andresen TL, Henriksen JR, Hansen AE, Clausen MH. *Commun Biol*. 2024 Sep 17;7(1):1158. doi: 10.1038/s42003-024-06806-1. PMID: 39284859

[Viral diseases and the environment relationship.](#)

Gonçalves do Amaral C, Pinto André E, Maffud Cilli E, Gomes da Costa V, Ricardo S Sanches P. *Environ Pollut*. 2024 Dec 1;362:124845. doi: 10.1016/j.envpol.2024.124845. Epub 2024 Sep 13. PMID: 39265774

[A case of *Mycoplasma pneumoniae*-induced rash and mucositis with recent influenza vaccination.](#)

Agarwal V, Gamble G, Amphlett A, Patel NP. *Skin Health Dis*. 2024 Sep 16;4(6):e459. doi: 10.1002/ski2.459. eCollection 2024 Dec. PMID: 39624758

[Antibody Persistence and Risk of COVID-19 Infection: Insights from Modeling.](#)

Coudeville L, Konate E, Simon T, de Lamballerie X, Patterson S, El Guerche-Séblain C, Launay O; AP-PH COVIBOOST Vaccine Trial Group. *Vaccines (Basel)*. 2024 Sep 21;12(9):1079. doi: 10.3390/vaccines12091079. PMID: 39340109

[Evaluation of **vaccine** efficacy with 2B/T epitope conjugated porcine IgG-Fc recombinants against foot-and-mouth disease virus.](#)

Song BM, Lee GH, Kang SM, Tark D. *J Vet Med Sci*. 2024 Sep 20;86(9):999-1007. doi: 10.1292/jvms.23-0480. Epub 2024 Jul 29. PMID: 39069487

[Pan-beta-coronavirus subunit **vaccine** prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.](#)

Wang G, Verma AK, Guan X, Bu F, Odle AE, Li F, Liu B, Perlman S, Du L. *J Virol*. 2024 Sep 17;98(9):e0037624. doi: 10.1128/jvi.00376-24. Epub 2024 Aug 27. PMID: 39189731

[Vaccination practices and knowledge among adults with hemoglobinopathies in Greece: a nationwide survey.](#)

Delicou S, Manganas K, Xydaki A, Evliati L, Myrilla I, Rubatis L, Kostaridou S. *Ther Adv Vaccines Immunother*. 2024 Sep 17;12:25151355241278869. doi: 10.1177/25151355241278869. eCollection 2024. PMID: 39314901

[CircRNA based multivalent neuraminidase **vaccine** induces broad protection against influenza viruses in mice.](#)

Yue X, Zhong C, Cao R, Liu S, Qin Z, Liu L, Zhai Y, Luo W, Lian Y, Zhang M, Lu H, Wang Y, Xu M, Liu S, Lv K, Sun Y, Zhu X, Mai H, Liao J, Yang J, Deng L, Liu Y, Sun C, Zheng KW, Shu Y, Chen YQ. *NPJ Vaccines*. 2024 Sep 16;9(1):170. doi: 10.1038/s41541-024-00963-4. PMID: 39285168

[SARS-CoV-2 natural infection, but not **vaccine**-induced immunity, elicits cross-reactive immunity to OC43.](#)

Garziano M, Cano Fiestas M, Vanetti C, Strizzi S, Murno ML, Clerici M, Biasin M. *Heliyon*. 2024 Sep 21;10(19):e37928. doi: 10.1016/j.heliyon.2024.e37928. eCollection 2024 Oct 15. PMID: 39391514

[Role of community engagement in advancing **vaccine** equity.](#)

Smith S, Marquez E, Haboush-Deloye A, Tu T, Goodie A, Perez D. *Front Public Health*. 2024 Sep 20;12:1435231. doi: 10.3389/fpubh.2024.1435231. eCollection 2024.PMID: 39371205

[Vaccine Potency and Structure of Yeast-Produced Polio Type 2 Stabilized Virus-like Particles.](#)

Hong Q, Wang S, Wang X, Han W, Chen T, Liu Y, Cheng F, Qin S, Zhao S, Liu Q, Cong Y, Huang Z. *Vaccines (Basel)*. 2024 Sep 20;12(9):1077. doi: 10.3390/vaccines12091077.PMID: 39340107

[Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development.](#)

Yang D, Li X, Li J, Liu Z, Li T, Liao P, Luo X, Liu Z, Ming W, Liao G. *J Med Chem*. 2024 Oct 10;67(19):17640-17656. doi: 10.1021/acs.jmedchem.4c01631. Epub 2024 Sep 20.PMID: 39302195

[Knowledge, attitude, and acceptance of COVID-19 vaccine in pregnant women.](#)

Kuptarak A, Phupong V. *Ther Adv Vaccines Immunother*. 2024 Sep 21;12:25151355241278832. doi: 10.1177/25151355241278832. eCollection 2024.PMID: 39345730

[Replication of the Venezuelan Equine Encephalitis Vaccine from a Synthetic PCR Fragment.](#)

Mathew C, Tucker C, Tretyakova I, Pushko P. *Pharmaceutics*. 2024 Sep 17;16(9):1217. doi: 10.3390/pharmaceutics16091217.PMID: 39339253

[Epidemiology and genetic characterization of influenza viruses circulating in Bhutan in 2022.](#)

Dorji K, Klungthong C, Dorji T, Wangchuk T, Yuden P, Pelki T, Ghishing TD, Gyemiry G, Gyeltshen S, Chinnawirotpisan P, Manasatienkij W, Wangchuk S, Farmer A. *PLoS One*. 2024 Sep 17;19(9):e0304849. doi: 10.1371/journal.pone.0304849. eCollection 2024.PMID: 39288111

[Recombinant ferritin-based nanoparticles as neoantigen carriers significantly inhibit tumor growth and metastasis.](#)

Zheng W, Li S, Shi Z, Su K, Ding Y, Zhang L, Tang Q, Han J, Zhao H, Wang F, Zhang H, Hong Z. *J Nanobiotechnology*. 2024 Sep 14;22(1):562. doi: 10.1186/s12951-024-02837-2.PMID: 39272180

[Development and immunogenicity evaluation of a quadruple-gene-deleted pseudorabies virus strain.](#)

Li H, Zhang R, Qu J, Kang Y, Zhang J, Guo R, Li J, Zhang X, Han L, Xie H, Wang X. *Front Microbiol*. 2024 Sep 20;15:1479794. doi: 10.3389/fmicb.2024.1479794. eCollection 2024.PMID: 39372271

[Measures of how well a vaccine works.](#)

Mishra S, Navarro C, Kwong JC. *BMJ*. 2024 Sep 12;386:q1982. doi: 10.1136/bmj.q1982.PMID: 39266246

[Evaluation of effectiveness and safety of Subolesin anti-tick vaccine in Ugandan multi-site field trial.](#)

Kabi F, Contreras M, Semakula J, Sánchez-Sánchez M, Muñoz-Hernández C, Mugerwa S, Kasaija P, Kirunda H, de la Fuente G, Fernández-Melgar R, Rafael M, Fernández de Mera IG, Matovu M, Kyakuwa I, Dhikusooka M, Nsereko G, Boma P, Bugeza J, Moses M, Namukasa A, Obonyo P, Ssekabunga N, Adyero OE, Rutaisire J, Gortazar C, de la Fuente J. *NPJ Vaccines*. 2024 Sep 18;9(1):174. doi: 10.1038/s41541-024-00966-1.PMID: 39294184

[Malaria **Vaccine** Candidate Could Prevent Infection During Pregnancy.](#)

Anderer S.JAMA. 2024 Sep 13. doi: 10.1001/jama.2024.18197. Online ahead of print.PMID: 39269721

[Engineered Carrier-Free Nanosystem-Induced In Situ Therapeutic Vaccines for Potent Cancer Immunotherapy.](#)

Zhang M, Zhao Y, Lv B, Jiang H, Li Z, Cao J.ACS Appl Mater Interfaces. 2024 Sep 11;16(36):47270-47283. doi: 10.1021/acsami.4c09925. Epub 2024 Aug 27.PMID: 39189605

[Schistosomiasis in the Military-A Narrative Review.](#)

Costescu Strachinaru DI, Nyandwaro JN, Stoefs A, Dooms E, Vanbrabant P, François PM, Strachinaru M, Van Esbroeck M, Bottieau E, Soentjens P.Trop Med Infect Dis. 2024 Sep 19;9(9):221. doi: 10.3390/tropicalmed9090221.PMID: 39330910

[Subsequent Vaccination against SARS-CoV-2 after **Vaccine**-Induced Immune Thrombotic Thrombocytopenia.](#)

Uzun G, Ringelmann T, Hammer S, Zlamal J, Luz B, Wolf ME, Henkes H, Bakchoul T, Althaus K.J Clin Med. 2024 Sep 14;13(18):5462. doi: 10.3390/jcm13185462.PMID: 39336949

[**Vaccine** hesitancy among parents of children in their first two years of life.](#)

Magyar R, Voithl PK, Voithl JJM, Diesner-Treiber SC.Front Public Health. 2024 Sep 19;12:1438737. doi: 10.3389/fpubh.2024.1438737. eCollection 2024.PMID: 39363987

[A novel pan-proteome array for high-throughput profiling of the humoral response to *Treponema pallidum*.](#)

Campo JJ, Romeis E, Oberai A, Pablo JV, Hung C, Teng AA, Shandling AD, Phan A, Haynes AM, Giacani L.LiScience. 2024 Jul 31;27(9):110618. doi: 10.1016/j.isci.2024.110618. eCollection 2024 Sep 20.PMID: 39262771

[\[A large epidemiological study on human papillomavirus **vaccine** post-vaccination symptoms and healthy vaccinee bias\].](#)

Suzuki S.Nihon Koshu Eisei Zasshi. 2024 Nov 27;71(11):667-672. doi: 10.11236/jph.24-053. Epub 2024 Sep 13.PMID: 39284722

[Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination.](#)

Tang R, Guo L, Wei T, Chen T, Yang H, Ye H, Lin F, Zeng Y, Yu H, Cai Z, Liu X.Elife. 2024 Sep 13;13:RP98579. doi: 10.7554/eLife.98579.PMID: 39269893

[The changing face of cerebral venous sinus thrombosis-emerging new causes and treatments.](#)

Dix C, Hunt BJ.J Thromb Haemost. 2024 Dec;22(12):3346-3354. doi: 10.1016/j.jtha.2024.08.012. Epub 2024 Sep 12.PMID: 39260741

[Deep Intracolonial Analysis for the Development of Vaccines against Drug-Resistant *Klebsiella pneumoniae* Lineages.](#)

Tajuelo A, Gato E, Oteo-Iglesias J, Pérez-Vázquez M, McConnell MJ, Martín-Galiano AJ, Pérez A. *Int J Mol Sci.* 2024 Sep 11;25(18):9837. doi: 10.3390/ijms25189837.PMID: 39337325

[Plasmid DNA Delivery into the Skin via Electroporation with a Depot-Type Electrode.](#)

Yoshida Y, Aoki M, Nagase K, Marubashi K, Kojima H, Itakura S, Komatsu S, Sugibayashi K, Todo H. *Pharmaceutics.* 2024 Sep 18;16(9):1219. doi: 10.3390/pharmaceutics16091219.PMID: 39339255

[Designing a multi-epitope subunit **vaccine** against Orf virus using molecular docking and molecular dynamics.](#)

Pang F, Long Q, Liang S. *Virulence.* 2024 Dec;15(1):2398171. doi: 10.1080/21505594.2024.2398171. Epub 2024 Sep 11.PMID: 39258802

[In vitro induction of anti-lung cancer immune response by the A549 lung cancer stem cell lysate-sensitized dendritic cell **vaccine**.](#)

Chen L, Rao W, Chen Y, Xie J. *Oncol Lett.* 2024 Sep 13;28(5):550. doi: 10.3892/ol.2024.14683. eCollection 2024 Nov.PMID: 39328277

[Evaluation of **Vaccine** Strategies among Healthcare Workers during COVID-19 Omicron Outbreak in Taiwan.](#)

Lin MR, Huang CG, Chiu CH, Chen CJ. *Vaccines (Basel).* 2024 Sep 17;12(9):1057. doi: 10.3390/vaccines12091057.PMID: 39340088

[Label-Free Quantitative Proteomics Analysis of COVID-19 Vaccines by Nano LC-HRMS.](#)

Zhao H, Li W, Liu J, Li X, Ji H, Hu M, Li M. *Vaccines (Basel).* 2024 Sep 15;12(9):1055. doi: 10.3390/vaccines12091055.PMID: 39340085

[Positive **vaccine** beliefs linked to reduced mental stress in healthcare professionals during COVID-19: a retrospective study.](#)

Lin YY, Cho SF, Hsieh YL, Chuang YS, Hsu CE, Liu YC, Sung CC, Huang YH, Ku W, Hsieh MH, Huang YC, Tu HP, Wang CL, Ho CK. *Front Psychiatry.* 2024 Sep 18;15:1402194. doi: 10.3389/fpsy.2024.1402194. eCollection 2024.PMID: 39359859

[Robust and persistent B-cell responses following SARS-CoV-2 **vaccine** determine protection from SARS-CoV-2 infection.](#)

Byrne J, Gu L, Garcia-Leon A, Gaillard CM, Saini G, Alalwan D, Tomás-Cortázar J, Kenny G, Donohue S, Reynolds B, O'Gorman T, Landay A, Doran P, Stemler J, Koehler P, Cox RJ, Olesen OF, Lelievre JD, O'Broin C, Savinelli S, Feeney ER, O'Halloran JA, Cotter A, Horgan M, Kelly C, Sadlier C, de Barra E, Cornely OA, Gautier V, Mallon PW. *Front Immunol.* 2024 Sep 17;15:1445653. doi: 10.3389/fimmu.2024.1445653. eCollection 2024.PMID: 39355249

[COL6A6 Peptide **Vaccine** Alleviates Atherosclerosis through Inducing Immune Response and Regulating Lipid Metabolism in Apoe\(-/-\) Mice.](#)

Tang D, Liu Y, Duan R, Lin R, Li Z, Liu X, Huang J, Zhao M. *Cells.* 2024 Sep 21;13(18):1589. doi: 10.3390/cells13181589.PMID: 39329770

[Construction and in vitro characterisation of virus-vectored immunocontraceptive candidates derived from felid alphaherpesvirus 1.](#)

Cottingham E, Johnstone T, Vaz PK, Hartley CA, Devlin JM. *Vaccine*. 2024 Sep 17;42(22):125999. doi: 10.1016/j.vaccine.2024.05.047. Epub 2024 May 31. PMID: 38824082

[Syphilis vaccine development: Aligning vaccine design with manufacturing requirements.](#)

Waugh S, Cameron CE. *Hum Vaccin Immunother*. 2024 Dec 31;20(1):2399915. doi: 10.1080/21645515.2024.2399915. Epub 2024 Sep 11. PMID: 39262177

[Comparative 60-day effectiveness of bivalent versus monovalent mRNA vaccines in Shelby County: a population-level analysis.](#)

Plaxco AP, Kmet J, Smeltzer MP, Jiang Y, Taylor M, Nolan VG. *Ther Adv Vaccines Immunother*. 2024 Sep 19;12:25151355241278852. doi: 10.1177/25151355241278852. eCollection 2024. PMID: 39314902

[CD8 positive T-cells decrease neurogenesis and induce anxiety-like behaviour following hepatitis B vaccination.](#)

Zhou T, Gao Y, Wang Z, Dai C, Lei M, Liew A, Yan S, Yao Z, Hu D, Qi F. *Brain Commun*. 2024 Sep 16;6(5):fcae315. doi: 10.1093/braincomms/fcae315. eCollection 2024. PMID: 39386089

[Awareness of HPV and HPV vaccine among college students in China.](#)

Li M, Zhang F, Shi Y, Shi K, Li X, Bai H. *Front Public Health*. 2024 Sep 18;12:1451320. doi: 10.3389/fpubh.2024.1451320. eCollection 2024. PMID: 39360252

[COBRA N2 NA vaccines induce protective immune responses against influenza viral infection.](#)

Zhang X, Skarupka AL, Shi H, Ross TM. *Hum Vaccin Immunother*. 2024 Dec 31;20(1):2403175. doi: 10.1080/21645515.2024.2403175. Epub 2024 Sep 18. PMID: 39291424

[Understanding the rationales and information environments for early, late, and nonadopters of the COVID-19 vaccine.](#)

Singh L, Bao L, Bode L, Budak C, Pasek J, Raghunathan T, Traugott M, Wang Y, Wycoff N. *NPJ Vaccines*. 2024 Sep 14;9(1):168. doi: 10.1038/s41541-024-00962-5. PMID: 39271667

[Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany.](#)

Huang M, Weaver JP, Elbasha E, Weiss T, Bannietts N, Feemster K, White M, Kelly MS. *Vaccines (Basel)*. 2024 Sep 12;12(9):1045. doi: 10.3390/vaccines12091045. PMID: 39340075

[Integrating youth participatory action research and health communication to inform youth and young adult covid-19 vaccine communication research.](#)

Kikut-Stein A, Givan K, Fishman J, Blanco-Liz A, Alvarez-Sanchez D, Fletcher J, Gambrell R, Hernandez A, Richardson C, Shaw A, von Oiste JJ. *Health Educ Res*. 2024 Sep 13;39(5):411-425. doi: 10.1093/her/cyae026. PMID: 39113324

[Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity.](#)

Lensch V, Gabba A, Hincapie R, Bhagchandani SH, Basak A, Alam MM, Noble J, Irvine DJ, Shalek AK, Johnson JA, Finn MG, Kiessling LL. *ACS Nano*. 2024 Oct 1;18(39):26770-26783. doi: 10.1021/acsnano.4c07360. Epub 2024 Sep 16. PMID: 39283240

[Changes in Phenotypic and Molecular Features of Naïve and Central Memory T Helper Cell Subsets following SARS-CoV-2 Vaccination.](#)

Mosavie M, Rynne J, Fish M, Smith P, Jennings A, Singh S, Millar J, Harvala H, Mora A, Kaloyirou F, Griffiths A, Hopkins V, Washington C, Estcourt LJ, Roberts D, Shankar-Hari M. *Vaccines (Basel)*. 2024 Sep 11;12(9):1040. doi: 10.3390/vaccines12091040. PMID: 39340069

[A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion **vaccine** in elderly people aged 60 years and older.](#)

Kou Z, Li X, Liu T, Fan B, An W, An W, Dang M, Zhang K, Tang J, Zhu N, Pan R. *Trop Dis Travel Med Vaccines*. 2024 Sep 15;10(1):18. doi: 10.1186/s40794-024-00228-x. PMID: 39277739

[Adolescent Self-Consent for the HPV **Vaccine** and the Effects on **Vaccine** Rates.](#)

Thompson AD, Spratling R. *J Pediatr Health Care*. 2024 Nov-Dec;38(6):932-935. doi: 10.1016/j.pedhc.2024.07.006. Epub 2024 Sep 22. PMID: 39306783

[Next generation yellow fever **vaccine** induces an equivalent immune and transcriptomic profile to the current **vaccine**: observations from a phase I randomised clinical trial.](#)

Pagnon A, Carre C, Aguirre M, Chautard E, Gimenez S, Raynal F, Feroldi E, Scott P, Modjarrad K, Vangelisti M, Mantel N. *EBioMedicine*. 2024 Oct;108:105332. doi: 10.1016/j.ebiom.2024.105332. Epub 2024 Sep 17. PMID: 39293214

[Editorial: **Vaccine** clinical development in Latin America: achievements, challenges, and future perspectives.](#)

Ulloa-Gutierrez R, DeAntonio R. *Front Med (Lausanne)*. 2024 Sep 12;11:1478343. doi: 10.3389/fmed.2024.1478343. eCollection 2024. PMID: 39328320

[Using a dual immunoinformatics and bioinformatics approach to design a novel and effective multi-epitope **vaccine** against human torovirus disease.](#)

Ahmad S, Ali SS, Iqbal A, Ali S, Hussain Z, Khan I, Khan H. *Comput Biol Chem*. 2024 Dec;113:108213. doi: 10.1016/j.compbiolchem.2024.108213. Epub 2024 Sep 19. PMID: 39326336

[Emulating target trials of postexposure vaccines using observational data.](#)

Boyer C, Lipsitch M. *Am J Epidemiol*. 2024 Sep 12:kwae350. doi: 10.1093/aje/kwae350. Online ahead of print. PMID: 39270677

[Challenges and opportunities during the COVID-19 vaccination efforts in long-term care.](#)

Stone ND, Parker Fiebelkorn A, Guo A, Mothershed E, Moccia L, Bell J, Yassanye D, Hall E, Duggar C, Srinivasan A, Meyer SA, Link-Gelles R. *Vaccine*. 2024 Sep 17;42 Suppl 3:125554. doi: 10.1016/j.vaccine.2023.12.064. Epub 2024 Jan 5. PMID: 38184394

[Protective Effects of 23-Valent Pneumococcal Polysaccharide Vaccination Against Mortality: The VENUS Study.](#)

Murata F, Maeda M, Fukuda H. *Open Forum Infect Dis*. 2024 Sep 11;11(9):ofae530. doi: 10.1093/ofid/ofae530. eCollection 2024 Sep. PMID: 39329110

[The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina.](#)

Quiroga R, Gastellu S, Fernández B, Ottaviani R, Zuccoli JR, Vallecorsa PD, Aliaga J, Barberia L. *Vaccine*. 2024 Sep 17;42(22):126037. doi: 10.1016/j.vaccine.2024.06.005. Epub 2024 Jun 13. PMID: 38871572

[Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.](#)

Abad N, Bonner KE, Kolis J, Brookmeyer KA, Voegeli C, Lee JT, Singleton JA, Quartarone R, Black C, Yee D, Ramakrishnan A, Rodriguez L, Clay K, Hummer S, Holmes K, Manns BJ, Donovan J, Humbert-Rico T, Flores SA, Griswold S, Meyer S, Cohn A. *Vaccine*. 2024 Sep 17;42 Suppl 3:125604. doi: 10.1016/j.vaccine.2024.01.029. Epub 2024 Jan 23. PMID: 38267329

[A Newcastle disease live virus vaccine is safe and efficacious at various storage conditions.](#)

Huma I, Azeem S, Naz S, Yaqub T, Mushtaq MH, Azam M. *Vet Ital*. 2024 Sep 18;59(3). doi: 10.12834/VetIt.2980.19377.1. PMID: 39298117

[Anticipatory in silico vaccine designing based on specific antigenic epitopes from Streptococcus mutans against diabetic pathogenesis.](#)

Murugan G, Kothandan G, Padmanaban R. *In Silico Pharmacol*. 2024 Sep 18;12(2):86. doi: 10.1007/s40203-024-00260-x. eCollection 2024. PMID: 39310673

[Construction of Recombinant Marek's Disease Virus Co-Expressing VP1 and VP2 of Chicken Infectious Anemia Virus.](#)

Li K, Liu Y, Liu C, Zhang Y, Cui H, Qi X, Zhang J, Xu J, Wang S, Chen Y, Duan Y, Gao Y, Wang X. *Vaccines (Basel)*. 2024 Sep 13;12(9):1047. doi: 10.3390/vaccines12091047. PMID: 39340077

[Development of COVID-19 vaccine policy - United States, 2020-2023.](#)

Oliver SE, Wallace M, Twentyman E, Moulia DL, Godfrey M, Link-Gelles R, Meyer S, Fleming-Dutra KE, Hall E, Wolicki J, MacNeil J, Bell BP, Lee GM, Daley MF, Cohn A, Wharton M. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125512. doi: 10.1016/j.vaccine.2023.12.022. Epub 2023 Dec 29. PMID: 38158297

[Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines.](#)

Kristyanto H, Slaets L, Braams E, Scheys I, Heesbeen R, Cárdenas V, Shukarev G, Scheper G, Sadoff J, Lühn K, Schuitemaker H, Struyf F, Hendriks J. *J Thromb Haemost*. 2024 Dec;22(12):3532-3541. doi: 10.1016/j.jtha.2024.08.019. Epub 2024 Sep 13. PMID: 39278600

[Progress with the Second Dose Measles **Vaccine** Introduction and Coverage in the WHO African Region.](#)

Masresha BG, Shibeshi ME, Grant GB, Hatcher C, Wiysonge CS. *Vaccines* (Basel). 2024 Sep 18;12(9):1069. doi: 10.3390/vaccines12091069.PMID: 39340099

[Lifestyle score is associated with cellular immune profiles in healthy Tanzanian adults.](#)

Pyuza JJ, van Dorst MMAR, Stam K, Wammes L, König M, Kullaya VI, Kruize Y, Huisman W, Andongolile N, Ngowi A, Shao ER, Mremi A, Hogendoorn PCW, Msuya SE, Jochems SP, de Steenhuijsen Piters WAA, Yazdanbakhsh M. *Brain Behav Immun Health*. 2024 Sep 20;41:100863. doi: 10.1016/j.bbih.2024.100863. eCollection 2024 Nov.PMID: 39398291

[Breaking Latent Infection: How ORF37/38-Deletion Mutants Offer New Hope against EHV-1 Neuropathogenicity.](#)

Hu Y, Zhang SY, Sun WC, Feng YR, Gong HR, Ran DL, Zhang BZ, Liu JH. *Viruses*. 2024 Sep 16;16(9):1472. doi: 10.3390/v16091472.PMID: 39339948

[Understanding Barriers to Establishing Public JYNNEOS Mpox Vaccination Clinics in New Hampshire: Mpox **vaccine** clinic NH.](#)

Kang H, Mahatanan R, Lee D, Locke S, Talbot EA, Chan BP. *Disaster Med Public Health Prep*. 2024 Sep 18;18:e121. doi: 10.1017/dmp.2024.99.PMID: 39291325

[Fc-empowered exosomes with superior epithelial layer transmission and lung distribution ability for pulmonary vaccination.](#)

Meng F, Xing H, Li J, Liu Y, Tang L, Chen Z, Jia X, Yin Z, Yi J, Lu M, Gao X, Zheng A. *Bioact Mater*. 2024 Sep 12;42:573-586. doi: 10.1016/j.bioactmat.2024.08.015. eCollection 2024 Dec.PMID: 39308551

[Adjuvant-dependent impacts on **vaccine**-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic *Neisseria*.](#)

Islam EA, Fegan JE, Zeppa JJ, Ahn SK, Ng D, Currie EG, Lam J, Moraes TF, Gray-Owen SD. *bioRxiv* [Preprint]. 2024 Sep 12:2024.09.07.611809. doi: 10.1101/2024.09.07.611809. **Update in:** [Vaccine](#). 2025 Feb 27;48:126709. doi: 10.1016/j.vaccine.2025.126709.PMID: 39314293

[An effective **vaccine** against influenza A virus based on the matrix protein 2 \(M2\).](#)

Zuckermann FA, Grinkova YV, Husmann RJ, Pires-Alves M, Storms S, Chen WY, Sligar SG. *Vet Microbiol*. 2024 Nov;298:110245. doi: 10.1016/j.vetmic.2024.110245. Epub 2024 Sep 14.PMID: 39293153

[Immune Response after Vaccination against Tick-Borne Encephalitis Virus \(TBEV\) in Horses.](#)

Kälin D, Becsek A, Stürmer H, Bachofen C, Siegrist D, Jonsdottir HR, Schoster A. *Vaccines* (Basel). 2024 Sep 19;12(9):1074. doi: 10.3390/vaccines12091074.PMID: 39340104

[A multidimensional approach to understanding **vaccine** hesitancy among first generation college students.](#)

Gold JM, Amuta AO, Cisneros YL. *J Am Coll Health*. 2025 Oct;73(8):3239-3244. doi: 10.1080/07448481.2024.2394795. Epub 2024 Sep 16.PMID: 39283303

[SMS-Based Active Surveillance of Adverse Events following Immunization in Children: The VigiVax Study.](#)

Gonella LA, Moretti F, Capuano A, De Sarro C, Ferrara L, Geninatti E, Guarnieri G, Hysolako X, Lalli M, Leoni O, Mangano AMP, Marani Toro P, Mecchia V, Merlano MC, Palleria C, Potenza AM, Rossi P, Rossi M, Sanità F, Sapigni E, Scavone C, Sommaro C, Tuccori M, Zanoni G, Moretti U, VigiVax Working Group. *Vaccines (Basel)*. 2024 Sep 20;12(9):1076. doi: 10.3390/vaccines12091076.PMID: 39340106

[Rational Design of Lipid Nanoparticles for Enhanced mRNA Vaccine Delivery via Machine Learning.](#)

Bae SH, Choi H, Lee J, Kang MH, Ahn SH, Lee YS, Choi H, Jo S, Lee Y, Park HJ, Lee S, Yoon S, Roh G, Cho S, Cho Y, Ha D, Lee SY, Choi EJ, Oh A, Kim J, Lee S, Hong J, Lee N, Lee M, Park J, Jeong DH, Lee K, Nam JH. *Small*. 2025 Feb;21(8):e2405618. doi: 10.1002/sml.202405618. Epub 2024 Sep 12.PMID: 39264000

[piSTING: A Pocket-Independent Agonist Based on Multivalency-Driven STING Oligomerization.](#)

Zhuo SH, Wang TY, Zhao L, Su JY, Hu JJ, Zhao YF, Li YM. *Angew Chem Int Ed Engl*. 2024 Sep 16;63(38):e202407037. doi: 10.1002/anie.202407037. Epub 2024 Jul 3.PMID: 38767062

[A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.](#)

Feng J, Du Y, Chen L, Su W, Wei H, Liu A, Jiang X, Guo J, Dai C, Xu Y, Peng T. *Vaccine*. 2024 Sep 17;42(22):126008. doi: 10.1016/j.vaccine.2024.05.056. Epub 2024 Jun 3.PMID: 38834431

[Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies.](#)

Malebo K, Woodward J, Ximba P, Mkhize Q, Cingo S, Moyo-Gwete T, Moore PL, Williamson AL, Chapman R. *Vaccines (Basel)*. 2024 Sep 18;12(9):1063. doi: 10.3390/vaccines12091063.PMID: 39340093

[The Role of the Basophil Activation Test in the Diagnosis of Drug-Induced Anaphylaxis.](#)

Czarnobilska M, Bulanda M, Czarnobilska E, Dyga W, Mazur M. *Diagnostics (Basel)*. 2024 Sep 13;14(18):2036. doi: 10.3390/diagnostics14182036.PMID: 39335714

[Molecular Dynamics Simulation of Lipid Nanoparticles Encapsulating mRNA.](#)

Zhang Z, Cheng D, Luo W, Hu D, Yang T, Hu K, Liang L, Liu W, Hu J. *Molecules*. 2024 Sep 17;29(18):4409. doi: 10.3390/molecules29184409.PMID: 39339404

[Cost-benefit analysis of human adenovirus vaccine development in a Korean military setting.](#)

Eom J, Kim Y, Kim D, Lee E, Kwon SH, Jo MW, Jung J, Park H, Park B. *Vaccine*. 2024 Sep 17;42(22):126006. doi: 10.1016/j.vaccine.2024.05.054. Epub 2024 May 27.PMID: 38806354

[U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023.](#)

Duggar C, Santoli JM, Noblit C, Moore LB, El Kalach R, Bridges CB. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125703. doi: 10.1016/j.vaccine.2024.02.020. Epub 2024 Feb 15.PMID: 38360476

[Strategy against super-resistant bacteria: Curdlan-induced trained immunity combined with multi-epitope subunit **vaccine**.](#)

Li H, Niu L, Wang J, Chang Q, Zhang S, Wang J, Zeng J, Gao M, Ge J. *Int J Biol Macromol*. 2024 Sep 14;280(Pt 1):135663. doi: 10.1016/j.ijbiomac.2024.135663. Online ahead of print. PMID: 39284466

[Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.](#)

Krause KD, D'Avanzo PA, Karr AG, Rhem C, Halkitis PN. *Vaccine*. 2024 Dec 2;42(26):126320. doi: 10.1016/j.vaccine.2024.126320. Epub 2024 Sep 14. PMID: 39277945

[Seroconversion in liver and intestine transplant patients after one, two or three doses of adenoviral vector vaccines against SARS-CoV-2. Single center experience in Argentina.](#)

Silvina Y, Renata C, Gastón R, Compagnucci Malena F, Lorena T, Laura D, Valeria D, Gabriel G, Guillermo D, Martin R, Virginia Gentilini M. *Hum Immunol*. 2024 Nov;85(6):111091. doi: 10.1016/j.humimm.2024.111091. Epub 2024 Sep 11. PMID: 39265411

[Oral cholera **vaccine** coverage in Goma, Democratic Republic of the Congo, 2022, following 2019-2020 targeted preventative mass campaigns.](#)

Briskin E, Bateyi Mustafa SH, Mahamba R, Kabunga D, Kubuya J, Porten K; Epicentre-MSF DRC cholera working group; Akilimali L, Okitayemba Welo P, Broban A. *Vaccine X*. 2024 Sep 12;20:100555. doi: 10.1016/j.jvacx.2024.100555. eCollection 2024 Oct. PMID: 39315336

[An immunoinformatics approach for a potential NY-ESO-1 and WT1 based multi-epitope **vaccine** designing against triple-negative breast cancer.](#)

Khanam A, Hridoy HM, Alam MS, Sultana A, Hasan I. *Heliyon*. 2024 Aug 28;10(17):e36935. doi: 10.1016/j.heliyon.2024.e36935. eCollection 2024 Sep 15. PMID: 39286192

[Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 **vaccine**.](#)

Mvula M, Mtonga F, Mandolo J, Jowati C, Kalirani A, Chigamba P, Lisimba E, Mitole N, Chibwana MG, Jambo KC. *BMC Infect Dis*. 2024 Sep 12;24(1):959. doi: 10.1186/s12879-024-09891-z. PMID: 39266969

[Kinetics of humoral and cellular immune responses 5 months post-COVID-19 booster dose by immune response groups at the peak immunity phase: An observational historical cohort study using the Fukushima vaccination community survey.](#)

Kobashi Y, Kawamura T, Shimazu Y, Kaneko Y, Nishikawa Y, Sugiyama A, Tani Y, Nakayama A, Yoshida M, Zho T, Yamamoto C, Saito H, Takita M, Wakui M, Kodama T, Tsubokura M. *Vaccine X*. 2024 Sep 12;20:100553. doi: 10.1016/j.jvacx.2024.100553. eCollection 2024 Oct. PMID: 39309610

[Mitochondrial Hyperactivity and Reactive Oxygen Species Drive Innate Immunity to the Yellow Fever Virus-17D Live-Attenuated **Vaccine**.](#)

Muccilli SG, Schwarz B, Jessop F, Shannon JG, Bohrsen E, Shue B, Hong SH, Hsu T, Ashbrook AW, Guarnieri JW, Lack J, Wallace DC, Bosio CM, MacDonald MR, Rice CM, Yewdell JW, Best SM. *bioRxiv*

[Preprint]. 2024 Sep 15:2024.09.04.611167. doi: 10.1101/2024.09.04.611167. **Update in:** [PLoS Pathog. 2025 Apr 21;21\(4\):e1012561. doi: 10.1371/journal.ppat.1012561.PMID: 39282299](#)

[Rapid Decline of Mpox Antibody Responses Following MVA-BN Vaccination.](#)

Collier AY, McMahan K, Jacob-Dolan C, Liu J, Borducchi EN, Moss B, Barouch DH. medRxiv [Preprint]. 2024 Sep 11:2024.09.10.24313399. doi: 10.1101/2024.09.10.24313399. **Update in:** [JAMA. 2024 Nov 19;332\(19\):1669-1672. doi: 10.1001/jama.2024.20951.PMID: 39314978](#)

[Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents.](#)

Tsang TK, Sullivan SG, Meng Y, Lai FTT, Fan M, Huang X, Lin Y, Peng L, Zhang C, Yang B, Ainslie KEC, Cowling BJ. BMC Med. 2024 Sep 12;22(1):384. doi: 10.1186/s12916-024-03597-4. PMID: 39267060

[Reassuring humoral and cellular immune responses to SARS-CoV-2 vaccination in participants with systemic sclerosis.](#)

Benoit JM, Breznik JA, Huynh A, Cowbrough B, Baker B, Heessels L, Lodhi S, Yan E, Bhakta H, Clare R, Nazy I, Bramson JL, Larché MJ, Bowdish DM. Immunol Lett. 2024 Dec;270:106929. doi: 10.1016/j.imlet.2024.106929. Epub 2024 Sep 19. PMID: 39305938

[Virulence and Immune Evasion Strategies of FMDV: Implications for Vaccine Design.](#)

Medina GN, Diaz San Segundo F. Vaccines (Basel). 2024 Sep 19;12(9):1071. doi: 10.3390/vaccines12091071. PMID: 39340101

[Mpox Epidemiology and Vaccine Effectiveness, England, 2023.](#)

Charles H, Thorley K, Turner C, Bennet KF, Andrews N, Bertran M, Mandal S, Amirthalingam G, Ramsay ME, Mohammed H, Sinka K. Emerg Infect Dis. 2024 Oct;30(10):2145-2148. doi: 10.3201/eid3010.240292. Epub 2024 Sep 11. PMID: 39259828

[Pre- and post-Ad26.COV2-S booster dose antibody levels predict COVID-19 disease risk.](#)

Roels S, Bruckner M, Sadoff J, Cárdenas V, Tang C, Hagedoorn S, Heerwegh D, Stieh DJ, Le Gars M. Vaccine. 2024 Sep 17;42(22):126159. doi: 10.1016/j.vaccine.2024.126159. Epub 2024 Aug 8. PMID: 39121698

[Isotype-aware inference of B cell clonal lineage trees from single-cell sequencing data.](#)

Weber LL, Reiman D, Roddur MS, Qi Y, El-Kebir M, Khan AA. Cell Genom. 2024 Sep 11;4(9):100637. doi: 10.1016/j.xgen.2024.100637. Epub 2024 Aug 28. PMID: 39208795

[Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.](#)

Wang Q, Mellis IA, Guo Y, Gherasim C, Valdez R, Gordon A, Ho DD, Liu L. Cell Rep Med. 2024 Sep 17;5(9):101701. doi: 10.1016/j.xcrm.2024.101701. Epub 2024 Aug 28. PMID: 39208800

[Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with Comirnaty®: A randomized, observer-blind, controlled, phase 1 study.](#)

Sow SO, Tapia MD, Haidara FC, Diallo F, Han X, Chen J, Shi L, Yang Q, Yu B, Hu Y, Yuan L, Liu G, Grappi S, Monti M, Viviani S, Ji M, Zhou C. *Int J Infect Dis.* 2024 Nov;148:107237. doi: 10.1016/j.ijid.2024.107237. Epub 2024 Sep 11. PMID: 39270925

[Digitally Enabled Generic Analytical Framework Accelerating the Pace of Liquid Chromatography Method Development for Vaccine Adjuvant Formulations.](#)

Hemida M, Barrientos RC, Kinsey C, Kuster N, Bhavsar M, Beck AG, Wang H, Singh A, Aggarwal P, Arcinas A, Mukherjee M, Appiah-Amponsah E, Regalado EL. *ACS Pharmacol Transl Sci.* 2024 Sep 11;7(10):3108-3118. doi: 10.1021/acsptsci.4c00306. eCollection 2024 Oct 11. PMID: 39421659

[Health impact of rotavirus vaccination in China.](#)

Oluwaseun S, Yang C, Si Tu SJ, Yin J, Song Y, Sun Q, Kanibir N, Hartwig S, Carias C. *Hum Vaccin Immunother.* 2024 Dec 31;20(1):2386750. doi: 10.1080/21645515.2024.2386750. Epub 2024 Sep 13. PMID: 39269780

[Edward Jenner: A Beacon of Hope in the Age of Disease.](#)

Balaji L, Ravella Venkatasubramanyam N, Umapathy N, Easwaran S, Prabhakaran N. *Cureus.* 2024 Sep 15;16(9):e69472. doi: 10.7759/cureus.69472. eCollection 2024 Sep. PMID: 39411642

[An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis.](#)

Sefat KMSR, Kumar M, Kehl S, Kulkarni R, Leekha A, Paniagua MM, Ackart DF, Jones N, Spencer C, Podell BK, Ouellet H, Varadarajan N. *Vaccine.* 2024 Sep 17;42(22):125909. doi: 10.1016/j.vaccine.2024.04.055. Epub 2024 May 3. PMID: 38704256

[A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination.](#)

Severa M, Ricci D, Etna MP, Facchini M, Puzelli S, Fedele G, Iorio E, Cairo G, Castrechini S, Ungari V, Iannetta M, Leone P, Chirico M, Pisanu ME, Bottazzi B, Benedetti L, Sali M, Bartolomucci R, Balducci S, Garlanda C, Stefanelli P, Spadea A, Palamara AT, Coccia EM. *Vaccines (Basel).* 2024 Sep 13;12(9):1050. doi: 10.3390/vaccines12091050. PMID: 39340080

[Environmental surveillance of a circulating vaccine-derived poliovirus type 2 outbreak in Israel between 2022 and 2023: a genomic epidemiology study.](#)

Zuckerman NS, Bucris E, Morad-Eliyahu H, Weiss L, Vasserman R, Fratty IS, Aguvaev I, Cohen-Said Z, Matar R, Erster O, Shulman LM, Yishai R, Hecht-Sagie L, Alroy-Preis S, Mendelson E, Lustig Y, Sofer D, Bar-Or I, Weil M. *Lancet Microbe.* 2024 Oct;5(10):100893. doi: 10.1016/S2666-5247(24)00116-2. Epub 2024 Sep 13. PMID: 39284332

[Evaluation of the Effect of mRNA and Inactivated SARS-CoV-2 Vaccines on the Levels of Cytokines IL-2, IFN-γ, and Anti-RBD Spike SARS-CoV-2 Antibodies in People Living with HIV \(PLHIV\).](#)

Amanah A, Ariyanto IA, Bela B, Pramanagara R, Sudarmono P. *Biomedicines*. 2024 Sep 18;12(9):2115. doi: 10.3390/biomedicines12092115. PMID: 39335628

[Comparison of viraemia and nasal shedding after PRRSV-1 challenge following vaccination with three commercially available PRRS modified live virus vaccines.](#)

Hancox L, Balasch M, Angulo J, Scott-Baird E, Mah CK. *Res Vet Sci*. 2024 Nov;180:105416. doi: 10.1016/j.rvsc.2024.105416. Epub 2024 Sep 13. PMID: 39293105

[Hybrid nanoparticle-mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines.](#)

Li J, Wu T, Wang W, Gong Y, Lu M, Zhang M, Lu W, Zhou Y, Yang Y. *Sci Adv*. 2024 Sep 20;10(38):eadn3002. doi: 10.1126/sciadv.adn3002. Epub 2024 Sep 18. PMID: 39292792

[Development of a maturity assessment tool to evaluate and strengthen National Immunization Technical Advisory Groups \(NITAGs\).](#)

Dryer E, Shefer A, Desai S, Rodewald L, Bastías M, El Omeiri N, Ndiaye S, Cook K, Henaff L, Kennedy E. *Vaccine*. 2024 Sep 17;42(22):126005. doi: 10.1016/j.vaccine.2024.05.053. Epub 2024 May 27. PMID: 38802292

[Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine \(SYS6006\) in minks, cats, blue foxes, and raccoon dogs.](#)

Huo H, Wang J, Li C, Xiao S, Wang H, Ge J, Zhong G, Wen Z, Wang C, Lang Q, Chen L, Wang Z, Wang J, Wang X, He X, Guan Y, Shuai L, Bu Z. *Front Cell Infect Microbiol*. 2024 Sep 19;14:1468775. doi: 10.3389/fcimb.2024.1468775. eCollection 2024. PMID: 39364147

[Trends and factors associated with receipt of human papillomavirus \(HPV\) vaccine in private, public, and alternative settings in the United States.](#)

White MC, Osazuwa-Peters OL, Aboulella DK, Barnes JM, Cannon TY, Watts TL, Adjei Boakye E, Osazuwa-Peters N. *Vaccine*. 2024 Sep 17;42(22):126036. doi: 10.1016/j.vaccine.2024.06.004. Epub 2024 Jun 13. PMID: 38876838

[Haji vaccination strategies: Preparedness for risk mitigation.](#)

Alshamrani M, Farahat F, Alzunitan M, Hasan MA, Alsherbini N, Albarrak A, Johani SMA, Shibl A, Al-Tawfiq JA, Zumla A, Memish ZA. *J Infect Public Health*. 2024 Nov;17(11):102547. doi: 10.1016/j.jiph.2024.102547. Epub 2024 Sep 17. PMID: 39353398

[Comprehensive Spatial-Temporal and Risk Factor Insights for Optimizing Livestock Anthrax Vaccination Strategies in Karnataka, India.](#)

Anandakumar J, Suresh KP, Patil AV, Jagadeesh CA, Bylaiah S, Patil SS, Hemadri D. *Vaccines (Basel)*. 2024 Sep 22;12(9):1081. doi: 10.3390/vaccines12091081. PMID: 39340111

[Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023.](#)

Laemmle-Ruff I, Fryk JJ, Shenton P, Clothier HJ, Parsons S, Iles L, White C, Murray M, Buttery J, Crawford NW. *Vaccine*. 2024 Dec 2;42(26):126368. doi: 10.1016/j.vaccine.2024.126368. Epub 2024 Sep 20. PMID: 39305837

[A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants.](#)

Hao T, Li Y, Liu P, Wang X, Xu K, Lei W, Li Y, Zhang R, Li X, Zhao X, Xu K, Lu X, Bi Y, Song H, Wu G, Zhu B, Gao GF. *PLoS Pathog*. 2024 Sep 20;20(9):e1012508. doi: 10.1371/journal.ppat.1012508. eCollection 2024 Sep. PMID: 39303003

[Rational optimization of glycoprotein E \(gE\)-encoding mRNA for improved Varicella-zoster virus mRNA vaccine development.](#)

Huang L, Zhang S, Zhao T, Cai T, Bu L, Di Z, Zhang Y, Yang C, Yang Y, Lin A. *Emerg Microbes Infect*. 2024 Dec;13(1):2392661. doi: 10.1080/22221751.2024.2392661. Epub 2024 Sep 12. PMID: 39137287

[COVID-19 Vaccine Safety Technical \(VaST\) Work Group: Enhancing vaccine safety monitoring during the pandemic.](#)

Markowitz LE, Hopkins RH Jr, Broder KR, Lee GM, Edwards KM, Daley MF, Jackson LA, Nelson JC, Riley LE, McNally VV, Schechter R, Whitley-Williams PN, Cunningham F, Clark M, Ryan M, Farizo KM, Wong HL, Kelman J, Beresnev T, Marshall V, Shay DK, Gee J, Woo J, McNeil MM, Su JR, Shimabukuro TT, Wharton M, Keipp Talbot H. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125549. doi: 10.1016/j.vaccine.2023.12.059. Epub 2024 Feb 9. PMID: 38341293

[Decision Regret and Vaccine Hesitancy among Nursing Students and Registered Nurses in Italy: Insights from Structural Equation Modeling.](#)

Brera AS, Arrigoni C, Belloni S, Conte G, Magon A, Arcidiacono MA, Pasek M, Shabat G, Bonavina L, Caruso R. *Vaccines (Basel)*. 2024 Sep 14;12(9):1054. doi: 10.3390/vaccines12091054. PMID: 39340084

[Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge.](#)

Park HS, Matsuoka Y, Santos C, Luongo C, Liu X, Yang L, Kaiser JA, Duncan EF, Johnson RF, Teng IT, Kwong PD, Buchholz UJ, Le Nouën C. *bioRxiv [Preprint]*. 2024 Sep 13:2024.09.12.612598. doi: 10.1101/2024.09.12.612598. **Update in:** *PLoS Pathog*. 2025 Apr 21;21(4):e1012585. doi: 10.1371/journal.ppat.1012585. PMID: 39372768

[Determining factors associated with vaccination coverage in the first year of life in Brazil \(2013-2022\).](#)

Lui L, Réquia WJ, Dos Santos F, Albert CE, da Cruz Vieira L, McGrath S. *Vaccine*. 2024 Dec 2;42(26):126382. doi: 10.1016/j.vaccine.2024.126382. Epub 2024 Sep 21. PMID: 39307022

[Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines.](#)

Amhis N, Carignan J, Tai LH. *Mol Ther Oncol*. 2024 Jun 8;32(3):200825. doi: 10.1016/j.omton.2024.200825. eCollection 2024 Sep 19. PMID: 39006944

[Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.](#)

Dahl BA, Tritter B, Butryn D, Dahlke M, Browning S, Gelting R, Fleming M, Ortiz N, Labrador J, Novak R, Fitter D, Bell E, McGuire M, Rosenbaum R, Pulwer R, Wun J, McCaffrey A, Chowdhury M, Parks N, Cunningham M, Mounts A, Curry D, Richardson D, Grant G. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125827. doi: 10.1016/j.vaccine.2024.03.054. Epub 2024 Mar 23. PMID: 38523004

[Protocol for analyzing BCG-induced trained immunity in murine bone marrow-derived macrophages.](#)

Xu JC, Hu Z, Fan XY. *STAR Protoc*. 2024 Sep 20;5(3):103267. doi: 10.1016/j.xpro.2024.103267. Epub 2024 Aug 17. PMID: 39154346

[Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins.](#)

Thimmiraju SR, Villar MJ, Kimata JT, Strych U, Bottazzi ME, Hotez PJ, Pollet J. *Viruses*. 2024 Sep 20;16(9):1492. doi: 10.3390/v16091492. PMID: 39339968

[Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters.](#)

Tamming L, Duque D, Bavananthasivam J, Tran A, Lansdell C, Frahm G, Wu J, Fekete EEF, Creskey M, Thulasi Raman SN, Laryea E, Zhang W, Pfeifle A, Gravel C, Stalker A, Hashem AM, Chen W, Stuible M, Durocher Y, Safronetz D, Cao J, Wang L, Sauve S, Rosu-Myles M, Zhang X, Johnston MJW, Li X. *Mol Ther Methods Clin Dev*. 2024 Aug 19;32(3):101325. doi: 10.1016/j.omtm.2024.101325. eCollection 2024 Sep 12. PMID: 39309757

[Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.](#)

Mu Z, Whitley J, Martik D, Sutherland L, Newman A, Barr M, Parks R, Wiehe K, Cain DW, Hodges KZ, Venkatayogi S, Lee EM, Smith L, Mansouri K, Edwards RJ, Wang Y, Rountree W, Alameh M-G, Tam Y, Barbosa C, Tomai M, Lewis MG, Santrai S, Maughan M, Tian M, Alt FW, Weissman D, Saunders KO, Haynes BF. *J Virol*. 2024 Sep 17;98(9):e0013724. doi: 10.1128/jvi.00137-24. Epub 2024 Aug 13. PMID: 39136461

[Circular RNAs: Novel Players in Cancer Mechanisms and Therapeutic Strategies.](#)

Kim J. *Int J Mol Sci*. 2024 Sep 20;25(18):10121. doi: 10.3390/ijms251810121. PMID: 39337606

[Pediatric Oncology Providers' HPV Vaccine Knowledge, Attitude, Self-Efficacy, and Practice after Communication Training: A Comparison with a National Survey.](#)

Teixeira RA, Grimes A, Embry L, Aguilar C, Shay LA. *Vaccines (Basel)*. 2024 Sep 17;12(9):1060. doi: 10.3390/vaccines12091060. PMID: 39340090

[The BCG vaccine and SARS-CoV-2: Could there be a beneficial relationship?](#)

Peña-Bates C, Lascurain R, Ortiz-Navarrete V, Chavez-Galan L. *Heliyon*. 2024 Sep 19;10(18):e38085. doi: 10.1016/j.heliyon.2024.e38085. eCollection 2024 Sep 30. PMID: 39347386

[Respect for history: an important dimension of contemporary obstetrics and gynecology.](#)

Oyelese Y, Grünebaum A, Chervenak F.J *Perinat Med*. 2024 Sep 16;52(9):914-926. doi: 10.1515/jpm-2024-0348. Print 2024 Nov 26. PMID: 39272109

[\[Establishment of a Coronavirus Disease 2019 **Vaccine** Distribution and Supply System\].](#)

Kim JA, Kim Y, Sohn J, Park J. *Jugan Geongang Gwa Jilbyeong*. 2024 Oct 24;17(41):1750-1763. doi: 10.56786/PHWR.2024.17.41.4. Epub 2024 Sep 11. PMID: 41334103

[Meningococcal **vaccine** Bexsero elicits a robust cellular immune response that targets but is not consistently protective against *Neisseria gonorrhoeae* during murine vaginal infection.](#)

Zeppa JJ, Fegan JE, Maiello P, Islam EA, Lee IS, Pham C, Caruso LL, Gray-Owen SD. *bioRxiv* [Preprint]. 2024 Sep 13:2024.09.08.611931. doi: 10.1101/2024.09.08.611931. **Update in:** [mSphere](#). 2025 May 27;10(5):e0094024. doi: 10.1128/msphere.00940-24. PMID: 39314429

[Evaluating Nanoparticulate **Vaccine** Formulations for Effective Antigen Presentation and T-Cell Proliferation Using an In Vitro Overlay Assay.](#)

Pasupuleti D, Bagwe P, Ferguson A, Uddin MN, D'Souza MJ, Zughaier SM. *Vaccines (Basel)*. 2024 Sep 13;12(9):1049. doi: 10.3390/vaccines12091049. PMID: 39340079

[Human Papillomavirus \(HPV\) vaccination coverage among French adolescents: A claims data study.](#)

de Pouvourville G, Guyot E, Farge G, Belhassen M, Bérard M, Jacoud F, Bensimon L, Baldauf JJ. *Vaccine*. 2024 Sep 17;42(22):126039. doi: 10.1016/j.vaccine.2024.06.007. Epub 2024 Jun 8. PMID: 38852035

[HIV **Vaccine** Development at a Crossroads: New B and T Cell Approaches.](#)

Govindan R, Stephenson KE. *Vaccines (Basel)*. 2024 Sep 12;12(9):1043. doi: 10.3390/vaccines12091043. PMID: 39340073

[COVID-19 **vaccine** uptake inequality among older adults: A multidimensional demographic analysis.](#)

Karimi SM, Parh MYA, Shakib SH, Zarei H, Aranha V, Graham A, Allen T, Khan SM, Moghadami M, Antimisiaris D, McKinney WP, Little B, Chen Y, Ingram T. *Am J Infect Control*. 2025 Jan;53(1):115-125. doi: 10.1016/j.ajic.2024.09.007. Epub 2024 Sep 12. PMID: 39277037

[Caregiver acceptance of human papillomavirus **vaccine** for their female children in Chileka, Blantyre, Malawi.](#)

Bwanali AN, Liundi P, Lubanga AF, Mpinganjira SL, Gadama LA. *Vaccine X*. 2024 Sep 18;20:100557. doi: 10.1016/j.jvax.2024.100557. eCollection 2024 Oct. PMID: 39381544

[VacSol-ML\(ESKAPE\)\(: Machine learning empowering **vaccine** antigen prediction for ESKAPE pathogens.](#)

Nasir S, Anwer F, Ishaq Z, Saeed MT, Ali A. *Vaccine*. 2024 Sep 17;42(22):126204. doi: 10.1016/j.vaccine.2024.126204. Epub 2024 Aug 9. PMID: 39126830

[Advances and prospects of RNA delivery nanoplatforms for cancer therapy.](#)

Attia MS, Kijanka G, Nguyen NT, Zhang J, An H. *Acta Pharm Sin B*. 2025 Jan;15(1):52-96. doi: 10.1016/j.apsb.2024.09.009. Epub 2024 Sep 14. PMID: 40041887

[Effect of **vaccine** dose intervals: Considering immunity levels, **vaccine** efficacy, and strain variants for disease control strategy.](#)

Ghosh S, Banerjee M, Chattopadhyay AK. *PLoS One*. 2024 Sep 19;19(9):e0310152. doi: 10.1371/journal.pone.0310152. eCollection 2024. PMID: 39298500

[Effectiveness of inactivated COVID-19 vaccines in preventing COVID-19-related hospitalization during the Omicron BF.7-predominant epidemic wave in Beijing, China: a cohort study.](#)

Zhao D, Sun Y, Li J, Li X, Ma Y, Cao Z, Zhang J, Ma J, Li J, Wang Q, Suo L, Zhang D, Yang P. *BMC Infect Dis*. 2024 Sep 17;24(1):991. doi: 10.1186/s12879-024-09889-7. PMID: 39289630

[Use of 21-Valent Pneumococcal Conjugate **Vaccine** Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.](#)

Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, Schechter R, Poehling KA, Long SS, Loehr J, Cohen AL. *MMWR Morb Mortal Wkly Rep*. 2024 Sep 12;73(36):793-798. doi: 10.15585/mmwr.mm7336a3. PMID: 39264843

[\[Progress of researches on toxoplasmosis vaccines based on the CRISPR/Cas9 technology\].](#)

Wu Y, Zhang X, Li J, Xie J, Wang L, Sun H. *Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi*. 2024 Sep 20;36(5):542-547. doi: 10.16250/j.32.1374.2024026. PMID: 39623998

[Serotypes and Genotypes of *Streptococcus pneumoniae* in an Unvaccinated Population in Suzhou, China.](#)

Huo X, Tan Z, Qian H, Qin Y, Dong C, Li C, Kong X, Hong J. *Infect Drug Resist*. 2024 Sep 16;17:4001-4009. doi: 10.2147/IDR.S454042. eCollection 2024. PMID: 39309071

[Longevity of serologic responses following a single dose of typhoid conjugate **vaccine** among children living with HIV in Pakistan: A prospective cohort study.](#)

Batool R, Yousafzai MT, Mir F, Muhammad S, Shaikh SA, Memon S, Qamar FN. *Vaccine*. 2024 Sep 17;42(22):126009. doi: 10.1016/j.vaccine.2024.05.057. Epub 2024 May 29. PMID: 38811267

[Use of Haemophilus influenzae Type b-Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.](#)

Collins JP, Loehr J, Chen WH, Clark M, Pinell-McNamara V, McNamara LA. *MMWR Morb Mortal Wkly Rep*. 2024 Sep 12;73(36):799-802. doi: 10.15585/mmwr.mm7336a4. PMID: 39264849

[A real-world study of BBIBP-CorV **vaccine** effectiveness in a Sri Lanka rural province.](#)

Wijekoon L, Wickramasinghe N, Rathnasekara T, Somathilake T, Sarathchandra C, Senanayake H, Weerawansa P, Ganegama R, Zhang Y, Yang Y, Ma R, Zhang Y, Xie D, Li Z, Liu X, Qin S, Siribaddana

S.Heliyon. 2024 Sep 14;10(18):e37662. doi: 10.1016/j.heliyon.2024.e37662. eCollection 2024 Sep 30.PMID: 39323840

[First Experimental Application of DNA-Layered Salmonid Alphavirus-Based Replicon **Vaccine** in Non-Salmonid Fish: Induced Early Semi-Specific Protection against Spring Viraemia of Carp Virus \(SVCV\) in Common Carp \(*Cyprinus carpio*\).](#)

Abonyi F, Eszterbauer E, Baska F, Hardy T, Doszpoly A. *Animals (Basel)*. 2024 Sep 18;14(18):2698. doi: 10.3390/ani14182698.PMID: 39335287

[Using cluster analysis to explore COVID-19 **vaccine** booster hesitancy by levels of medical mistrust in fully vaccinated US adults.](#)

Paulus K, Bauerle Bass S, Cabey W, Singley K, Luck C, Hoadley A, Kerstetter M, Rotaru AM, Knight E, Murali S, Verma S, Wilson-Shabazz I, Gardiner H. *Ann Med*. 2024 Dec;56(1):2401122. doi: 10.1080/07853890.2024.2401122. Epub 2024 Sep 11.PMID: 39258584

[Making sense of a pandemic: reasoning about COVID-19 in the intellectual dark web.](#)

Doody S. *Front Sociol*. 2024 Sep 16;9:1374042. doi: 10.3389/fsoc.2024.1374042. eCollection 2024.PMID: 39351293

[Anti-SARS-CoV-2 Nucleocapsid Antibody Positivity Three Years after COVID-19.](#)

Kang CK, Kim Y, Jo HJ, Lee CM, Kim NJ, Lee CH, Choe PG, Park WB, Oh MD. *Jpn J Infect Dis*. 2024 Sep 19;77(5):285-288. doi: 10.7883/yoken.JJID.2024.011. Epub 2024 Apr 30.PMID: 38684427

[Anti-SARS-CoV-2 Nucleocapsid Antibody Positivity Three Years after COVID-19.](#)

Kang CK, Kim Y, Jo HJ, Lee CM, Kim NJ, Lee CH, Choe PG, Park WB, Oh MD. *Jpn J Infect Dis*. 2024 Sep 19;77(5):285-288. doi: 10.7883/yoken.JJID.2024.011. Epub 2024 Apr 30.PMID: 38684427

[Local and systemic side effects of COVID-19 **vaccine** in Tunisian cancer patients: A prospective single center study.](#)

Ben Kridis W, Boudawara O, Khanfir A. *J Oncol Pharm Pract*. 2026 Jan;32(1):38-42. doi: 10.1177/10781552241285034. Epub 2024 Sep 17.PMID: 39285730

[Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months.](#)

Wanlapakorn N, Sarawanangkoor N, Srimuan D, Thatsanathorn T, Klinfueng S, Poovorawan Y. *Vaccine X*. 2024 Sep 20;20:100561. doi: 10.1016/j.jvacx.2024.100561. eCollection 2024 Oct.PMID: 39385752

[Influenza and COVID-19 **Vaccine** Uptake Among Individuals With Versus Without Diagnosed Psychiatric Disorders.](#)

Owen-Smith A, Stewart C, Coleman KJ, Cromwell L, Barton L, Simon G. *Psychiatr Serv*. 2025 Feb 1;76(2):169-176. doi: 10.1176/appi.ps.20230638. Epub 2024 Sep 11.PMID: 39257313

[Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023.](#)

Mahasing C, Suphanchaimat R, Teekasap P, Nittayasoot N, Wongsanuphat S, Thammawijaya P. *PLoS One*. 2024 Sep 17;19(9):e0310427. doi: 10.1371/journal.pone.0310427. eCollection 2024. PMID: 39288199

[Elevated body mass index is not significantly associated with reduced influenza **vaccine** effectiveness.](#)

King JP, Nguyen HQ, Kiniry EL, Phillips CH, Gaglani M, Martin ET, Geffel KM, Nowalk MP, Chung JR, Flannery B, Belongia EA. *Sci Rep*. 2024 Sep 13;14(1):21466. doi: 10.1038/s41598-024-72081-z. PMID: 39271784

[High-resolution kinetics and cellular determinants of SARS-CoV-2 antibody response over two years after COVID-19 vaccination.](#)

Rubio R, Macià D, Barrios D, Vidal M, Jiménez A, Molinos-Albert LM, Díaz N, Canyelles M, Lara-Escandell M, Planchais C, Santamaria P, Carolis C, Izquierdo L, Aguilar R, Moncunill G, Dobaño C. *Microbes Infect*. 2025 Feb;27(2):105423. doi: 10.1016/j.micinf.2024.105423. Epub 2024 Sep 17. PMID: 39299570

[Construction and evaluation of a *Salmonella Paratyphi A* **vaccine** candidate based on a *poxA* gene mutation.](#)

You Y, Zhao X, Jie J, Xie Y, Hao Z, He Q, Zhou Y. *Gene*. 2025 Jan 15;933:148952. doi: 10.1016/j.gene.2024.148952. Epub 2024 Sep 18. PMID: 39299530

[DNA-Engineered Degradable Invisibility Cloaking for Tumor-Targeting Nanoparticles.](#)

Zhao Y, Hou J, Guo L, Zhu S, Hou X, Cao S, Zhou M, Shi J, Li J, Liu K, Zhang H, Wang L, Fan C, Zhu Y. *J Am Chem Soc*. 2024 Sep 11;146(36):25253-25262. doi: 10.1021/jacs.4c09479. Epub 2024 Aug 28. PMID: 39196310

[Hybrid Immunity against SARS-CoV-2 Variants: A Narrative Review of the Literature.](#)

Tsagkli P, Geropeppa M, Papadatou I, Spoulou V. *Vaccines (Basel)*. 2024 Sep 14;12(9):1051. doi: 10.3390/vaccines12091051. PMID: 39340081

[Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond.](#)

Chang JY, Balch C, Oh HS. *Viruses*. 2024 Sep 17;16(9):1476. doi: 10.3390/v16091476. PMID: 39339952

[Characterization of bi-segmented and tri-segmented recombinant Pichinde virus particles.](#)

Murphy H, Huang Q, Jensen J, Weber N, Mendonça L, Ly H, Liang Y. *J Virol*. 2024 Oct 22;98(10):e0079924. doi: 10.1128/jvi.00799-24. Epub 2024 Sep 12. PMID: 39264155

[Human papillomavirus type-specific distribution in cervical intraepithelial neoplasia and cancer in The Gambia prior to HPV immunization programme: a baseline for monitoring the quadrivalent **vaccine**.](#)

Bah H, Ceasay F, Leigh O, Bah HT, Savage AT, Kimmitt PT. *Infect Agent Cancer*. 2024 Sep 12;19(1):44. doi: 10.1186/s13027-024-00601-7. PMID: 39267099

[Rational design of a DNA-launched live attenuated **vaccine** against human enterovirus 71.](#)

Zhang RR, He MJ, Zhou C, Xu YP, Tang W, Cao TS, Wang ZJ, Wu M, Ming T, Huang YJ, Sun MX, Zhao H, Deng YQ, Li XF, Wang B, Ye Q, Qin CF. *Virol Sin.* 2024 Oct;39(5):812-820. doi: 10.1016/j.virs.2024.09.008. Epub 2024 Sep 19. PMID: 39306193

[Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public-private partnership with pharmacies.](#)

Jones-Jack N, El Kalach R, Yassanye D, Link-Gelles R, Olorukooba A, deMartino AK, Elam M, Romerhausen D, Vazquez M, Duggar C, Kim C, Patel A, Guo A, Gharpure R, Tippins A, Moore L. *Vaccine.* 2024 Sep 17;42 Suppl 3(Suppl 3):125667. doi: 10.1016/j.vaccine.2024.01.092. Epub 2024 Feb 1. PMID: 38302337

[Designing of a chimeric multiepitope **vaccine** against bancroftian lymphatic filariasis through immunoinformatics approaches.](#)

Parvin R, Habib Ullah Masum M, Ferdous J, Mahdeen AA, Shafiqul Islam Khan M. *PLoS One.* 2024 Sep 19;19(9):e0310398. doi: 10.1371/journal.pone.0310398. eCollection 2024. PMID: 39298468

[Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community.](#)

Benedict Kpozehouen E, Raina Macintyre C, Tan TC. *Vaccine.* 2024 Sep 17;42(22):126003. doi: 10.1016/j.vaccine.2024.05.051. Epub 2024 May 24. PMID: 38789372

[Shared challenges to the control of complex intracellular neglected pathogens.](#)

Perez RL, Chase J, Tanner R. *Front Public Health.* 2024 Sep 11;12:1423420. doi: 10.3389/fpubh.2024.1423420. eCollection 2024. PMID: 39324165

[Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein **vaccine** in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.](#)

van Heesbeen R, Bastian AR, Omoruyi E, Rosen J, Comeaux CA, Callendret B, Heijnen E. *Vaccine.* 2024 Dec 2;42(26):126273. doi: 10.1016/j.vaccine.2024.126273. Epub 2024 Sep 13. PMID: 39276619

[Prime-boost immunization with inactivated human adenovirus type 55 combined with an adjuvant enhances neutralizing antibody responses in mice.](#)

Seo SH, Choi JA, Jung DI, Park Y, Yang E, Jung S, Kwon T, Kwon SH, Song M. *Virol J.* 2024 Sep 16;21(1):220. doi: 10.1186/s12985-024-02491-y. PMID: 39285440

[Epidemiological Profile and Awareness Regarding Animal Bite Management in an Urban Area.](#)

Mallikarjuna S, Jeshanah MS. *Cureus.* 2024 Sep 11;16(9):e69159. doi: 10.7759/cureus.69159. eCollection 2024 Sep. PMID: 39398839

[Using **Vaccine** Safety Data to Demonstrate the Potential of Pooled Data Analysis.](#)

Hawken S, Wilson LA, Wilson K. *Vaccines (Basel).* 2024 Sep 14;12(9):1052. doi: 10.3390/vaccines12091052. PMID: 39340082

[N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation.](#)

Monroe J, Eyler DE, Mitchell L, Deb I, Bojanowski A, Srinivas P, Dunham CM, Roy B, Frank AT, Koutmou KS. *Nat Commun*. 2024 Sep 16;15(1):8119. doi: 10.1038/s41467-024-51301-0. PMID: 39284850

[Unlocking Immunity: Innovative prostate cancer **vaccine** strategies.](#)

Gu Q, Qi A, Wang N, Zhou Z, Zhou X. *Int Immunopharmacol*. 2024 Dec 5;142(Pt A):113137. doi: 10.1016/j.intimp.2024.113137. Epub 2024 Sep 14. PMID: 39276448

[Effectiveness of modified vaccinia Ankara-Bavarian Nordic **vaccine** against mpox infection: emulation of a target trial.](#)

Navarro C, Lau C, Buchan SA, Burchell AN, Nasreen S, Friedman L, Okpokoro E, Austin PC, Tan DHS, Gubbay JB, Kwong JC, Mishra S; Canadian Immunization Research Network Provincial Collaborative Network Investigators. *BMJ*. 2024 Sep 11;386:e078243. doi: 10.1136/bmj-2023-078243. PMID: 39260880

[Timely **vaccine** strain selection and genomic surveillance improves evolutionary forecast accuracy of seasonal influenza A/H3N2.](#)

Huddleston J, Bedford T. *medRxiv [Preprint]*. 2024 Sep 13:2024.09.11.24313489. doi: 10.1101/2024.09.11.24313489. **Update in:** [Elife](#). 2025 Dec 04;14:RP104282. doi: 10.7554/eLife.104282. PMID: 39314963

[Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.](#)

Treharne A, Patel Murthy B, Zell ER, Jones-Jack N, Loper O, Bakshi A, Nalla A, Kuramoto S, Cheng I, Dykstra A, Robison SG, Youngers EH, Schauer S, Gibbs Scharf L, Harris L. *Vaccine*. 2024 Sep 17;42(22):125997. doi: 10.1016/j.vaccine.2024.05.045. Epub 2024 May 25. PMID: 38797629

[Prevalence, spatial variation and determinants of zero-dose children in Ethiopia: Spatial and multilevel analyses.](#)

Tamir TT, Zegeye AF, Mekonen EG, Tekeba B, Ali MS, Gonete AT, Kassie AT, Workneh BS, Wassie M, Alemu TG. *Public Health*. 2024 Nov;236:365-372. doi: 10.1016/j.puhe.2024.09.011. Epub 2024 Sep 19. PMID: 39303624

[CC180 clade dynamics do not universally explain *Streptococcus pneumoniae* serotype 3 persistence post-**vaccine**: a global comparative population genomics study.](#)

Stanley S, Silva-Costa C, Gomes-Silva J, Melo-Cristino J, Malley R, Ramirez M. *medRxiv [Preprint]*. 2024 Sep 18:2024.08.29.24312665. doi: 10.1101/2024.08.29.24312665. **Update in:** [EBioMedicine](#). 2025 Jul;117:105781. doi: 10.1016/j.ebiom.2025.105781. PMID: 39252931

[A spike-based mRNA **vaccine** that induces durable and broad protection against porcine deltacoronavirus in piglets.](#)

Li J, Xiao L, Chen Z, Fan L, Wang W, Guo R, He Z, Hu H, Jiang J, Zhao L, Zhong T, Fan B, Zhu X, Li B. *J Virol*. 2024 Sep 17;98(9):e0053524. doi: 10.1128/jvi.00535-24. Epub 2024 Aug 19. PMID: 39158273

[Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA **Vaccine** in Humans.](#)

Kent SJ, Li S, Amarasena TH, Reynaldi A, Lee WS, Leeming MG, O'Connor DH, Nguyen J, Kent HE, Caruso F, Juno JA, Wheatley AK, Davenport MP, Ju Y. *ACS Nano*. 2024 Oct 1;18(39):27077-27089. doi: 10.1021/acsnano.4c11652. Epub 2024 Sep 19. PMID: 39298422

[A Preliminary Study to Evaluate the Immune Response to a Booster Dose of the Adult Tetanus-Diphtheria **Vaccine** \(Td\) Available in Iran.](#)

Noorian S, Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M, Montazeri H, Baghaei M, Niazi MJ. *Iran J Pharm Res*. 2024 Sep 11;23(1):e146572. doi: 10.5812/ijpr-146572. eCollection 2024 Jan-Dec. PMID: 39830669

[The Effectiveness of Interventions Targeting Adolescents in HPV Vaccination-A Scoping Review.](#)

Iova CF, Daina LG, Daina MD, Ghitea TC. *Medicina (Kaunas)*. 2024 Sep 22;60(9):1550. doi: 10.3390/medicina60091550. PMID: 39336591

[The Role of Health Belief Model Constructs and Content Creator Characteristics in Social Media Engagement: Insights from COVID-19 **Vaccine** Tweets.](#)

Jia X, Ahn S, Seelig MI, Morgan SE. *Healthcare (Basel)*. 2024 Sep 14;12(18):1845. doi: 10.3390/healthcare12181845. PMID: 39337186

[The Evolution of Vaccines Development across *Salmonella* Serovars among Animal Hosts: A Systematic Review.](#)

Siddique A, Wang Z, Zhou H, Huang L, Jia C, Wang B, Ed-Dra A, Teng L, Li Y, Yue M. *Vaccines (Basel)*. 2024 Sep 18;12(9):1067. doi: 10.3390/vaccines12091067. PMID: 39340097

[Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza **vaccine** adjuvanted with gram-positive matrix \(GEM\) particles \(FluGEM\): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.](#)

van der Plas JL, Haijema BJ, Leenhouts K, Paul Zoetewij J, Burggraaf J, Kamerling IMC. *Vaccine*. 2024 Sep 17;42(22):125836. doi: 10.1016/j.vaccine.2024.03.063. Epub 2024 May 20. PMID: 38772837

[Prevalence and Trends of Not Receiving a Dose of DPT-Containing **Vaccine** Among Children 12-35 Months: An Analysis of 81 Low- And Middle-Income Countries.](#)

Karlsson O, Rajpal S, Johri M, Kim R, Subramanian SV. *J Epidemiol Glob Health*. 2024 Dec;14(4):1490-1503. doi: 10.1007/s44197-024-00294-6. Epub 2024 Sep 19. PMID: 39298110

[T cell inducing **vaccine** against cytomegalovirus immediate early 1 \(IE1\) protein provides high level cross strain protection against congenital CMV.](#)

Choi KY, El-Hamdi N, McGregor A. *Vaccine*. 2024 Dec 2;42(26):126357. doi: 10.1016/j.vaccine.2024.126357. Epub 2024 Sep 18. PMID: 39298998

[Potential Association between Shift Work and Serologic Response to Hepatitis B Vaccination among Manufacturing Workers in Republic of Korea.](#)

Kim SH, Chae CH. *Vaccines (Basel)*. 2024 Sep 11;12(9):1041. doi: 10.3390/vaccines12091041. PMID: 39340070

[Strategies to strengthen COVID-19 **vaccine** uptake and improve **vaccine** equity in U.S. Territories and Freely Associated States during the first six months of **vaccine** rollout.](#)

Tippins A, Acevedo JC, Palomeque FS, Coy KC, Chadd P, Stowell D, Ademokun O, Apaisam C, Basilius M, Brostrom R, Collazo IOG, Encarnacion J, Gerena IC, Hancock T, Hunte-Ceasar T, Judicpa P, Leon-Guerrero M, Martinez M, Masunu Y, Pangelinan H, Parian E, Pedro D. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125956. doi: 10.1016/j.vaccine.2024.05.005. Epub 2024 May 7. PMID: 38719692

[PathMHC: a workflow to selectively target pathogen-derived MHC peptides in discovery immunopeptidomics experiments for **vaccine** target identification.](#)

Leddy O, Yuki Y, Carrington M, Bryson BD, White FM. *bioRxiv* [Preprint]. 2024 Sep 11:2024.09.11.612454. doi: 10.1101/2024.09.11.612454. PMID: 39314426

[Neutralizing Antibodies against 10 SARS-CoV-2 Variants at Two Years Post-COVISHIELD Vaccination with Special Reference to Omicron Subvariants and Booster Administration.](#)

Patil R, Palkar S, Mishra A, Arankalle V. *Vaccines* (Basel). 2024 Sep 11;12(9):1039. doi: 10.3390/vaccines12091039. PMID: 39340071

[Impact of the COVID-19 Pandemic on Measles Vaccination Coverage and Estimated Catch-up Efforts for Serbia.](#)

Burgess C, Lisul B, Pawaskar M, Petigara T, Murtagh J, Kanazir M, Loncarevic G, Carias C. *Pediatr Infect Dis J*. 2024 Oct 1;43(10):1011-1017. doi: 10.1097/INF.0000000000004487. Epub 2024 Sep 16. PMID: 39105529

[WHO acts to boost access to mpox **vaccine**.](#)

Wise J. *BMJ*. 2024 Sep 19;386:q2024. doi: 10.1136/bmj.q2024. PMID: 39299741

[Systematic analysis of traditional Chinese medicine prescriptions provides new insights into drug combination therapy for pox.](#)

Wu J, Guo D. *J Ethnopharmacol*. 2025 Jan 30;337(Pt 1):118842. doi: 10.1016/j.jep.2024.118842. Epub 2024 Sep 19. PMID: 39306210

[Developing films to support **vaccine**-hesitant, ethnically diverse parents' decision-making about the human papillomavirus \(HPV\) **vaccine**: a codesign study.](#)

Fisher H, Denford S, Chantler T, Audrey S, Finn A, Hajinur H, Hickman M, Mounier-Jack S, Roderick M, Tucker L, Yates J, Mohamed A. *BMJ Open*. 2024 Sep 12;14(9):e079539. doi: 10.1136/bmjopen-2023-079539. PMID: 39266324

[Identifying Rab2 Protein as a Key Interactor of Centrin1 Essential for *Leishmania donovani* Growth.](#)

Roshanara, Tandon R, Baig MS, Das S, Srivastava R, Puri N, Nakhasi HL, Selvapandiyani A. *ACS Infect Dis*. 2024 Sep 13;10(9):3273-3288. doi: 10.1021/acsinfecdis.4c00351. Epub 2024 Aug 7. PMID: 39110117

[Cost-effectiveness analysis of the 20-valent pneumococcal conjugate **vaccine** for the pediatric population in South Korea.](#)

Kang DW, June Choe Y, Lee JY, Suk IA, Kim YS, Kim HY, Byun BK, Park SK. *Vaccine*. 2024 Sep 17;42(22):126000. doi: 10.1016/j.vaccine.2024.05.048. Epub 2024 Jun 5. PMID: 38845302

[Characterization of *Streptococcus agalactiae* 1a isolated from farmed Nile tilapia \(*Oreochromis niloticus*\) in North America, Central America, and Southeast Asia.](#)

Fyrand K, Xu C, Evensen Ø. *Fish Shellfish Immunol*. 2024 Nov;154:109919. doi: 10.1016/j.fsi.2024.109919. Epub 2024 Sep 22. PMID: 39317296

[Different Antigen-Specific CD4⁺ and CD8⁺ T-Cell Response against HCMV Proteins in Pregnant Women with Primary Infection and in Control Subjects with Remote Infection.](#)

Zavaglio F, d'Angelo P, Fornara C, Zelini P, Comolli G, Furione M, Arossa A, Spinillo A, Lilleri D, Baldanti F. *J Clin Med*. 2024 Sep 13;13(18):5448. doi: 10.3390/jcm13185448. PMID: 39336935

[Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza **vaccine**: A post hoc analysis of the DANFLU-1 randomized clinical trial.](#)

Christensen J, Johansen ND, Janstrup KH, Modin D, Skaarup KG, Nealon J, Samson S, Loiacono M, Harris R, Larsen CS, Jensen AMR, Landler NE, Claggett BL, Solomon SD, Gislason GH, Køber L, Landray MJ, Sivapalan P, Jensen JUS, Biering-Sørensen T. *J Infect*. 2024 Nov;89(5):106276. doi: 10.1016/j.jinf.2024.106276. Epub 2024 Sep 18. PMID: 39303788

[Heterogeneity of SARS-CoV-2 immune responses after the nationwide Omicron wave in China.](#)

Wu J, Jiang M, Li J, Hu X, Long Q, Song S, Ye H, He Y, Ma X, Yu W, Chen X, Zhao L, Wu F, Chen X, Zheng J, Wang M, Zheng B, Yang S, Bu L, Chen Q, Li K, Zheng Y, Gao Z. *Microbiol Spectr*. 2024 Nov 5;12(11):e0111724. doi: 10.1128/spectrum.01117-24. Epub 2024 Sep 17. PMID: 39287459

[Simplified scalable synthesis of a water-soluble toll-like receptor 2 agonistic lipopeptide adjuvant for use with protein-based viral vaccines.](#)

Brar DS, Kaur A, Patil MT, Honda-Okubo Y, Petrovsky N, Salunke DB. *Bioorg Chem*. 2024 Dec;153:107835. doi: 10.1016/j.bioorg.2024.107835. Epub 2024 Sep 22. PMID: 39342891

[Estimates of **vaccine** effectiveness of the updated monovalent XBB.1.5 COVID-19 **vaccine** against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023.](#)

Lee JA, Jang H, Ahn SM, Seong JE, Kim YK, Sohn Y, Jung SI, Jeong HW, Kim SW, Lee JS, Baek JH, Lee SJ, Kwon GY, Shin J, Jeong H, Kim C, Choi JY. *Int J Infect Dis*. 2024 Nov;148:107249. doi: 10.1016/j.ijid.2024.107249. Epub 2024 Sep 20. PMID: 39307179

[Salmonella pathogenesis-based In-silico design and immunoinformatic analysis of multi-epitope **vaccine** constructs in broiler veterinary medicine.](#)

Mora-Ochoa YI, Ramirez-Cando LJ. *Vet J*. 2024 Dec;308:106240. doi: 10.1016/j.tvjl.2024.106240. Epub 2024 Sep 12. PMID: 39276848

[Discovery of three novel neutralizing antibody epitopes on the human astrovirus capsid spike and mechanistic insights into virus neutralization.](#)

Lanning S, Aguilar-Hernández N, Serrão VHB, López T, O'Rourke SM, Lentz A, Ricemeyer L, Espinosa R, López S, Arias CF, DuBois RM. *bioRxiv* [Preprint]. 2024 Sep 14;2024.09.14.613010. doi: 10.1101/2024.09.14.613010. **Update in:** *J Virol.* 2025 Feb 25;99(2):e0161924. doi: 10.1128/jvi.01619-24. PMID: 39314284

[Tonsil explants as a human in vitro model to study **vaccine** responses.](#)

Bonaiti E, Muraro MG, Robert PA, Jakscha J, Dirnhofer S, Martin I, Berger CT. *Front Immunol.* 2024 Sep 17;15:1425455. doi: 10.3389/fimmu.2024.1425455. eCollection 2024. PMID: 39355250

[Short-Term Immunogenicity of Licensed Subunit RSV Vaccines in Residents of Long-Term Care Facilities \(LTCF\) Compared to Community-Dwelling Older Adults.](#)

Falsey AR, Branche AR, Peasley M, Cole M, Petrone KK, Obrecht S, Steinmetz K, Smith T, Owen A, Anderson CS, Overby C, Peterson DR, Walsh EE. *J Am Med Dir Assoc.* 2024 Nov;25(11):105281. doi: 10.1016/j.jamda.2024.105281. Epub 2024 Sep 21. PMID: 39317337

[COVID-19 breakthrough infections in vaccinated individuals at BPKIHS, Nepal.](#)

Karmacharya A, Rai K, Siwakoti S, Khanal B, Bhattarai NR. *BMC Infect Dis.* 2024 Sep 19;24(1):1003. doi: 10.1186/s12879-024-09902-z. PMID: 39300352

[UK paediatricians' attitudes towards the chicken pox **vaccine**: The SPOTTY study.](#)

O'Mahony E, Sherman SM, Marlow R, Bedford H, Fitzgerald F. *Vaccine.* 2024 Sep 17;42(22):126199. doi: 10.1016/j.vaccine.2024.126199. Epub 2024 Aug 8. PMID: 39121697

[Exploring COVID-19 **vaccine** uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.](#)

Beitari S, Yi S, Sharma S, Yung R, Conway B. *Vaccine.* 2024 Sep 17;42(22):125904. doi: 10.1016/j.vaccine.2024.04.050. Epub 2024 Apr 17. PMID: 38637213

[The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer.](#)

Yu EM, Patel I, Hwang MW, Polani F, Aragon-Ching JB. *Clin Med Insights Oncol.* 2024 Sep 19;18:11795549241277181. doi: 10.1177/11795549241277181. eCollection 2024. PMID: 39323979

[Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens.](#)

Yao D, Patel RS, Lam A, Glover Q, Srinivasan C, Herchen A, Ritchie B, Agrawal B. *Int J Mol Sci.* 2024 Sep 11;25(18):9814. doi: 10.3390/ijms25189814. PMID: 39337303

[Immunogenicity of a 30-valent M protein mRNA group A Streptococcus **vaccine**.](#)

Finn MB, Penfound TA, Salehi S, Ogega CO, Dold C, Plante O, Dale JB. *Vaccine.* 2024 Sep 17;42(22):126205. doi: 10.1016/j.vaccine.2024.126205. Epub 2024 Aug 13. PMID: 39141987

[Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals.](#)

Kiso M, Uraki R, Yamayoshi S, Imai M, Kawaoka Y. *iScience*. 2024 Aug 17;27(9):110729. doi: 10.1016/j.isci.2024.110729. eCollection 2024 Sep 20. PMID: 39280602

[Real-world safety data for MVA-BN: Increased frequency of syncope following intradermal administration for immunization against mpox disease.](#)

Weidenthaler H, Vidojkovic S, Martin BK, De Moerlooze L. *Vaccine*. 2024 Sep 17;42(22):126024. doi: 10.1016/j.vaccine.2024.05.072. Epub 2024 Jun 4. PMID: 38839518

[PLGA-Astragalus Polysaccharide Nanovaccines Exert Therapeutic Effect in Colorectal Cancer.](#)

Cao Q, Zhou R, Guo S, Meng K, Yang X, Liu M, Ma B, Su C, Duan X. *Int J Nanomedicine*. 2024 Sep 12;19:9437-9458. doi: 10.2147/IJN.S479334. eCollection 2024. PMID: 39290859

[Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study.](#)

Angelidakis G, Chemaly RF, Sahasrabhojane PV, Morado-Aramburo O, Jiang Y, Bhatti MM, Shpall E, Hosing C, Jain P, Mahadeo KM, Khawaja F, Elhajj P, Wargo JA, Jenq RR, Ajami NJ, Kebriaei P, Ariza-Heredia EJ. *Vaccines (Basel)*. 2024 Sep 19;12(9):1070. doi: 10.3390/vaccines12091070. PMID: 39340100

[A safer cell-based yellow fever live attenuated **vaccine** protects mice against YFV infection.](#)

Guo W, Jiang T, Rao J, Zhang Z, Zhang X, Su J, Yin C, Lu M, Hu X, Shan C. *iScience*. 2024 Sep 17;27(10):110972. doi: 10.1016/j.isci.2024.110972. eCollection 2024 Oct 18. PMID: 39398246

[Single and two-dose typhoid conjugate **vaccine** safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children.](#)

Nampota-Nkomba N, Nyirenda OM, Mapemba V, Masonga R, Patel PD, Misiri T, Mwakiseghile F, Wachepa R, Ndaferankhande JM, Lipenga B, Patel P, Banda H, Oshinsky J, Pasetti MF, Heyderman RS, Jamka LP, Hosangadi D, Datta S, Gordon MA, Neuzil KM, Laurens MB. *Hum Vaccin Immunother*. 2024 Dec 31;20(1):2384760. doi: 10.1080/21645515.2024.2384760. Epub 2024 Sep 12. PMID: 39263923

[Multivalent MVA-vectored **vaccine** elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice.](#)

Escalante GM, Reidel IG, Mutsunguma LZ, Cua S, Tello BA, Rodriguez E, Farelo MA, Zimmerman C, Muniraju M, Li H, Govindan AN, Axthelm MK, Wong SW, Ogembo JG. *Front Immunol*. 2024 Sep 13;15:1445209. doi: 10.3389/fimmu.2024.1445209. eCollection 2024. PMID: 39346922

[COVID-19 **vaccine** uptake in individuals with functional difficulty, disability, and comorbid conditions: insights from a national survey in Bangladesh.](#)

Khanam SJ, Rana MS, Islam MM, Khan MN. *BMC Public Health*. 2024 Sep 17;24(1):2531. doi: 10.1186/s12889-024-20096-6. PMID: 39289678

[Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist alpha-Galactosylceramide Leads to **Vaccine**-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs.](#)

Artiaga BL, Madden D, Kwon T, McDowell C, Keating C, Balaraman V, de Carvahlo Madrid DM, Touchard L, Henningson J, Meade P, Krammer F, Morozov I, Richt JA, Driver JP. *Vaccines* (Basel). 2024 Sep 18;12(9):1068. doi: 10.3390/vaccines12091068.PMID: 39340098

["Build back the confidence": qualitative exploration of community experiences with polio vaccination in the Covid-19 context in Cameroon and Ethiopia.](#)

Lorenzetti L, Alam CMP, Namey E, Monj C, Tsegaye A, Ateeq N, Massom DM, McLain G, Tsanga S, Mcintosh R. *BMC Public Health*. 2024 Sep 18;24(1):2532. doi: 10.1186/s12889-024-19860-5.PMID: 39289677

[Social norms, **vaccine** confidence, and interpersonal communication as predictors of vaccination intentions: Findings from slum areas in Varanasi, India.](#)

Rimal RN, Ganjoo R, Jamison A, Parida M, Tharmarajah S. *Vaccine*. 2024 Sep 17;42(22):126038. doi: 10.1016/j.vaccine.2024.06.006. Epub 2024 Jun 21.PMID: 38909001

[The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of **vaccine** completion in a recovering healthcare system.](#)

Al-Dahir S, Hassan TAL, Moss W, Khalil A, Burnham G, Knoll MD, Hossain SMM, Talaat K. *Vaccine*. 2024 Nov 14;42 Suppl 5:126383. doi: 10.1016/j.vaccine.2024.126383. Epub 2024 Sep 21.PMID: 39307681

[Novel finding of **vaccine**-derived rubella virus-associated granulomata in an adult patient post-allogeneic haematopoietic stem cell transplant.](#)

Durity E, Zheng J, Sanchez E, Donati M, Perry K, Derrick J, Taylor A, Fink C, Holden J, Grant P, Byott M, Rickaby W, Asher N, Walker SL, Thomson K, Bunker C. *Br J Haematol*. 2024 Nov;205(5):2063-2066. doi: 10.1111/bjh.19762. Epub 2024 Sep 15.PMID: 39279194

[Ladders and stairs: how the intervention ladder focuses blame on individuals and obscures systemic failings and interventions.](#)

Paetkau T. *J Med Ethics*. 2024 Sep 20;50(10):684-689. doi: 10.1136/jme-2023-109563.PMID: 38408850

[Influenza **vaccine** uptake among youth with sickle cell disease who are seen in clinic before and after the COVID-19 pandemic.](#)

Walden J, Stanek JR, Young J, Griffith MM, Nahata L, Creary SE. *Vaccine*. 2024 Sep 17;42(22):126212. doi: 10.1016/j.vaccine.2024.126212. Epub 2024 Aug 9.PMID: 39126828

[Rev1deltawzm **vaccine** candidate is safe in young and adult sheep and protects against *Brucella ovis* infection in rams.](#)

Mena-Bueno S, Garrido V, Romero F, Zabalza-Baranguá A, Grilló MJ. *Vaccine*. 2024 Sep 17;42(22):125998. doi: 10.1016/j.vaccine.2024.05.046. Epub 2024 May 27.PMID: 38806353

[Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.](#)

Wee LE, Malek MIBA, Tan J, Chiew C, Lee V, Heng D, Ong B, Lye DC, Tan KB. *Vaccine*. 2024 Dec 2;42(26):126356. doi: 10.1016/j.vaccine.2024.126356. Epub 2024 Sep 18. PMID: 39299002

[Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV-2.](#)

Maxwell JWC, Stockdale S, Stewart EL, Ashley CL, Smith LJ, Steain M, Triccas JA, Byrne SN, Britton WJ, Ashhurst AS, Payne RJ. *ACS Infect Dis*. 2024 Sep 13;10(9):3419-3429. doi: 10.1021/acsinfecdis.4c00544. Epub 2024 Aug 28. PMID: 39196071

[Vaccine for digital images against steganography.](#)

Li X, Wang Z. *Sci Rep*. 2024 Sep 12;14(1):21340. doi: 10.1038/s41598-024-72693-5. PMID: 39266648

[The expanding universe of type I regulatory T cell biology: a new role in cancer immunotherapy.](#)

Nideffer JF, Jagannathan P. *Immunol Cell Biol*. 2024 Nov;102(10):868-870. doi: 10.1111/imcb.12822. Epub 2024 Sep 11. PMID: 39261289

[Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity.](#)

Chalupka A, Riedmann U, Richter L, Chakeri A, El-Khatib Z, Sprenger M, Theiler-Schwetz V, Trummer C, Willeit P, Schennach H, Benka B, Werber D, Høeg TB, Ioannidis JPA, Pilz S. *Open Forum Infect Dis*. 2024 Sep 19;11(10):ofae547. doi: 10.1093/ofid/ofae547. eCollection 2024 Oct. PMID: 39371370

[Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus.](#)

Karabag Yilmaz E, Agbas A, Canpolat N, Gunalp A, Sahin S, Ozbey D, Gulmez R, Saygili SK, Kocazeybek B, Kasapcopur O, Caliskan S. *Lupus Sci Med*. 2024 Sep 20;11(2):e001268. doi: 10.1136/lupus-2024-001268. PMID: 39306341

[A cynomolgus monkey E. coli urinary tract infection model confirms efficacy of new FimH vaccine candidates.](#)

Chorro L, Ciolino T, Torres CL, Illenberger A, Aglione J, Corts P, Lypowy J, Ponce C, La Porte A, Burt D, Volberg GL, Ramaiah L, McGovern K, Hu J, Anderson AS, Silmon de Monerri NC, Kanevsky I, Donald RGK. *Infect Immun*. 2024 Oct 15;92(10):e0016924. doi: 10.1128/iai.00169-24. Epub 2024 Sep 19. PMID: 39297649

[Messaging to Reduce Booster Hesitancy among the Fully Vaccinated.](#)

Qin C, Joslyn S, Han JH, Savelli S, Agrawal N. *Vaccines (Basel)*. 2024 Sep 18;12(9):1066. doi: 10.3390/vaccines12091066. PMID: 39340096

[Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV \(vCP2438\) **vaccine** prime plus bivalent subtype C gp120/MF59 **vaccine** boost \(HVTN 100\): A phase 1-2 randomized double-blind placebo-controlled trial.](#)

Naicker V, Laher F, Bekker LG, Seaton KE, Allen M, De Rosa S, Yates NL, Mkhize NN, Saunders K, Heptinstall J, Malahleha M, Mngadi K, Daniels B, Innes C, Yu C, Modise T, Bekker V, Grunenberg N, Furch B, Miner MD, Phogat S, Diazgranados CA, Gurunathan S, Koutsoukos M, Van Der Meeren O, Roxby AC, Ferrari G, Morris L, Montefiori D, McElrath MJ, Tomaras GD, Moodie Z. PLOS Glob Public Health. 2024 Sep 20;4(9):e0003319. doi: 10.1371/journal.pgph.0003319. eCollection 2024. PMID: 39302924

[Long-term changes in wearable sensor data in people with and without Long Covid.](#)

Radin JM, Vogel JM, Delgado F, Coughlin E, Gadaleta M, Pandit JA, Steinhubl SR. NPJ Digit Med. 2024 Sep 13;7(1):246. doi: 10.1038/s41746-024-01238-x. PMID: 39271927

[Uptake, adverse effect, and associated factors of COVID-19 **vaccine** among those living with human immunodeficiency virus, at Bole sub-city health facility Addis Ababa, Ethiopia.](#)

Seid S, Gebru Gebremeskel T. Hum Vaccin Immunother. 2024 Dec 31;20(1):2389576. doi: 10.1080/21645515.2024.2389576. Epub 2024 Sep 17. PMID: 39286864

[Modeling conjugate **vaccine** and natural induced antibody correlates of protection for pneumococcal colonization and acute otitis media infection in young children.](#)

Pham M, Pichichero M. Vaccine. 2024 Dec 2;42(26):126295. doi: 10.1016/j.vaccine.2024.126295. Epub 2024 Sep 11. PMID: 39265455

[Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate **vaccine**.](#)

Dashti N, Golsaz-Shirazi F, Soltanghoraee H, Zarnani AH, Mohammadi M, Imani D, Jeddi-Tehrani M, Amiri MM, Shokri F. Eur J Microbiol Immunol (Bp). 2024 May 16;14(3):228-242. doi: 10.1556/1886.2024.00045. Print 2024 Sep 11. PMID: 38753442

[Pediatric Coronavirus Disease 2019 **Vaccine** Experiences, Practices, and Attitudes in Rural Primary Care Clinicians.](#)

Higgins DM, Skenadore AM, Perreira C, Furniss A, Brewer SE, Cataldi JR, Nederveld AL, Scherer LD, Severson R, Roth H, O'Leary ST. Acad Pediatr. 2025 Mar;25(2):102578. doi: 10.1016/j.acap.2024.09.002. Epub 2024 Sep 13. PMID: 39278347

[Structure-guided assembly of an influenza spike nanobicelle **vaccine** provides pan H1 intranasal protection.](#)

Myers ML, Gallagher JR, Woolfork DD, Khorrami ND, Park WB, Maldonado-Puga S, Bohrsen E, Schwarz BH, Alves DA, Bock KW, Dearborn AD, Harris AK. bioRxiv [Preprint]. 2024 Sep 16:2024.09.16.613335. doi: 10.1101/2024.09.16.613335. PMID: 39372767

[Risk benefit analysis to evaluate risk of thromboembolic events after mRNA COVID-19 vaccination and COVID-19.](#)

Tran HNQ, Risk M, Nair GB, Zhao L.NPJ Vaccines. 2024 Sep 13;9(1):166. doi: 10.1038/s41541-024-00960-7.PMID: 39271677

[A Comparative Analysis of Computational Strategies in Multi-Epitope **Vaccine** Design Against Human Papillomavirus and Cervical Cancer.](#)

Najafi A, Ataee MH, Farzanehpour M, Esmaeili Guvarchin Ghaleh H.Cell J. 2024 Sep 11;26(7):403-426. doi: 10.22074/cellj.2024.2028622.1568.PMID: 39290119

[\[Fatal case of co-infection with yellow fever virus and SARS-CoV2 during the 2020 Covid-19 pandemic in French Guiana\].](#)

Thomas C, Pichard C, Rousset D, Demar M, Djossou F, Sanna A, Dudognon L, Nacher M, Pujo JM, Michaud C, Gaillet M, Kallel H, Epelboin L.Med Trop Sante Int. 2024 Sep 12;4(3):mts.v4i3.2024.445. doi: 10.48327/mts.v4i3.2024.445. eCollection 2024 Sep 30.PMID: 39931723

[Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study.](#)

Kim Y, Han K, Kim JH.Ophthalmic Epidemiol. 2025 Aug;32(4):403-411. doi: 10.1080/09286586.2024.2399345. Epub 2024 Sep 17.PMID: 39288331

[High abundance of butyrate-producing bacteria in the naso-oro-pharynx of SARS-CoV-2-infected persons in an African population: implications for low disease severity.](#)

Akorli J, Opoku M, Appiah-Twum F, Akpo MS, Ismail RY, Boamah GYK, Obeng-Aboagye E, Adu-Asamoah D, Donkor IO.BMC Infect Dis. 2024 Sep 20;24(1):1020. doi: 10.1186/s12879-024-09948-z.PMID: 39304808

[Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide **vaccine** in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.](#)

Marantos T, Kyriazopoulou E, Angelakis E, Kitsos D, Chondrogianni M, Mpizta G, Papadopoulos A, Giannopoulos S, Voumvourakis K, Tsiodras S.Vaccine. 2024 Sep 17;42(22):126001. doi: 10.1016/j.vaccine.2024.05.049. Epub 2024 May 24.PMID: 38796324

[Intranasal administration of octavalent next-generation influenza **vaccine** elicits protective immune responses against seasonal and pre-pandemic viruses.](#)

Uno N, Ebensen T, Guzman CA, Ross TM.J Virol. 2024 Sep 17;98(9):e0035424. doi: 10.1128/jvi.00354-24. Epub 2024 Aug 22.PMID: 39171925

[Differential effects of social versus monetary incentives on inhibitory control under acute inflammation.](#)

Alvarez GM, Jolink TA, West TN, Cardenas MN, Feldman MJ, Cohen JR, Muscatell KA.Brain Behav Immun. 2025 Jan;123:950-964. doi: 10.1016/j.bbi.2024.09.010. Epub 2024 Sep 16.PMID: 39293694

[Human papilloma virus **vaccine** induced thrombocytopenia accompanied by a wide spectrum of reversible inflammatory responses - a case report.](#)

Holm S, Michelsen AE, Schultz NH, Ueland T, Reikvam H, Holme PA, Aukrust P, Halvorsen B. *Scand J Clin Lab Invest.* 2024 Oct;84(6):425-427. doi: 10.1080/00365513.2024.2400663. Epub 2024 Sep 12. PMID: 39264796

[Efficacy of vaccination during pregnancy in reducing the risk of SARS-CoV-2 infection in infants younger than 12 months. Puglia \(Italy\), 2021-23.](#)

De Virgilio Suglia C, Stefanizzi P, Graziano G, Moscara L, Delle Fontane A, Minelli M, Tafuri S. *Hum Vaccin Immunother.* 2024 Dec 31;20(1):2403831. doi: 10.1080/21645515.2024.2403831. Epub 2024 Sep 17. PMID: 39288786

[Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine \(bOPV\).](#)

Badizadegan ND, Wassilak SGF, Estívariz CF, Wiesen E, Burns CC, Bolu O, Thompson KM. *Pathogens.* 2024 Sep 17;13(9):804. doi: 10.3390/pathogens13090804. PMID: 39338995

[Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019-2020 U.S. influenza season.](#)

Imran M, Mills C, McDermott KW, Dean A, Bogdanov A, McGovern I, Haag M. *Vaccine.* 2024 Dec 2;42(26):126316. doi: 10.1016/j.vaccine.2024.126316. Epub 2024 Sep 19. PMID: 39299000

[Coverage of influenza vaccination and influencing factors among healthcare workers in Shandong Province, China, 2021-2022.](#)

Liu Y, Liu T, Yao M, Wang Q, Li R, Kou Z. *Hum Vaccin Immunother.* 2024 Dec 31;20(1):2402116. doi: 10.1080/21645515.2024.2402116. Epub 2024 Sep 16. PMID: 39279572

[Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?](#)

Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C. *Cells.* 2024 Sep 16;13(18):1558. doi: 10.3390/cells13181558. PMID: 39329742

[Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method study.](#)

Helary A, Botelho-Nevers E, Bonneton M, Khennouf L, Sambourg J, Launay O, Gagneux-Brunon A. *Vaccine.* 2024 Sep 17;42(22):126035. doi: 10.1016/j.vaccine.2024.06.003. Epub 2024 Jun 22. PMID: 38910094

[Antibody responses against influenza A decline with successive years of annual influenza vaccination: results from an Australian Healthcare Worker cohort.](#)

Sullivan S, Khvorov A, Carolan L, Dowson L, Hadiprodjo J, Sánchez-Ovando S, Liu Y, Leung V, Hodgson D, Blyth C, Macnish M, Cheng A, Hagenauer M, Clark J, Dougherty S, Macartney K, Koirala A, Khatami A, Jadhav A, Marshall H, Riley K, Wark P, Delahunty C, Subbarao K, Kucharski A, Fox A. *Res Sq [Preprint].* 2024 Sep 16;rs.3.rs-4854923. doi: 10.21203/rs.3.rs-4854923/v1. **Update in:** [NPJ Vaccines.](#) 2025 Jan 17;10(1):11. doi: 10.1038/s41541-024-01057-x. PMID: 39372918

[A heterogeneous continuous age-structured model of mumps with vaccine.](#)

Azimaqin N, Li Y, Liu X. *Infect Dis Model*. 2024 Sep 13;10(1):75-98. doi: 10.1016/j.idm.2024.09.004. eCollection 2025 Mar. PMID: 39328987

[The impact of **vaccine** hesitancy on psychological impairment among healthcare workers in a Total Worker Health\(\) approach.](#)

Di Prinzio RR, Ceresi B, Arnesano G, Dosi A, Maimone M, Vacca ME, Vinci MR, Camisa V, Santoro A, Raponi M, Tomao P, Vonesch N, Moscato U, Zaffina S, Dalmaso G. *Front Public Health*. 2024 Sep 12;12:1447334. doi: 10.3389/fpubh.2024.1447334. eCollection 2024. PMID: 39328994

[Health and economic impacts of **Vaccae** vaccination incorporating active case finding in India and South Africa: a modelling study.](#)

Yue WL, Zhai PY, Mao JJ, Ma JF, Ren WL, Jiang T, Zhang B, Zhuang X, Feng J, Zang X, Qin G. *BMJ Public Health*. 2024 Sep 20;2(2):e001042. doi: 10.1136/bmjph-2024-001042. eCollection 2024 Dec. PMID: 40018595

[Use of UK faith Centre as a COVID-19 community vaccination clinic: exploring a potential model for community-based health care delivery.](#)

Wehling H, Weston D, Hall C, Mills F, Amlôt R, Dennis A, Forbes L, Armes J, Mohamed M, Buckley S, Dar OA, Mohamed A, Wurie F, Shafi S, Zumla SA, Ala A. *Postgrad Med J*. 2024 Sep 22;100(1188):751-759. doi: 10.1093/postmj/qgae028. PMID: 38702294

[Tuberculosis and T cells: Impact of T cell diversity in tuberculosis infection.](#)

Vats D, Rani G, Arora A, Sharma V, Rathore I, Mubeen SA, Singh A. *Tuberculosis (Edinb)*. 2024 Dec;149:102567. doi: 10.1016/j.tube.2024.102567. Epub 2024 Sep 18. PMID: 39305817

[Advances in *Leishmania* Vaccines: Current Development and Future Prospects.](#)

Ayala A, Llanes A, Leonart R, Restrepo CM. *Pathogens*. 2024 Sep 20;13(9):812. doi: 10.3390/pathogens13090812. PMID: 39339003

[Mixed methods approach to understanding COVID-19 **vaccine** hesitancy among immigrants in the Chicago.](#)

Sharp M, Lozano P, Southworth A, Peters A, Lam H, Randal FT, Quinn M, Kim KE. *Vaccine*. 2024 Sep 17;42(22):125552. doi: 10.1016/j.vaccine.2023.12.062. Epub 2024 Jan 9. PMID: 38199924

[Corrigendum to "The relative **vaccine** effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials" \[J Infect 89 \(2024\) 106187\].](#)

Skaarup KG, Lassen MCH, Modin D, Johansen ND, Loiacono MM, Harris RC, Lee JKH, Dufournet M, Vardeny O, Peikert A, Claggett B, Solomon SD, Jensen JUS, Biering-Sørensen T. *J Infect*. 2024 Nov;89(5):106270. doi: 10.1016/j.jinf.2024.106270. Epub 2024 Sep 12. PMID: 39270534

[Rotavirus-Specific Maternal Serum Antibodies and **Vaccine** Responses to RV3-BB Rotavirus **Vaccine** Administered in a Neonatal or Infant Schedule in Malawi.](#)

Morgan B, Lyons EA, Handley A, Bogdanovic-Sakran N, Pavlic D, Witte D, Mandolo J, Turner A, Jere KC, Justice F, Ong DS, Bonnici R, Boniface K, Donato CM, Mpakiza A, Meyer A, Bar-Zeev N, Iturriza-Gomara M, Cunliffe NA, Danchin M, Bines JE. *Viruses*. 2024 Sep 19;16(9):1488. doi: 10.3390/v16091488. PMID: 39339964

[Safe re-immunization of mRNA-1273 COVID-19 vaccine after BNT162b2 mRNA COVID-19 vaccine-induced nonepisodic angioedema with eosinophilia.](#)

Kampitak T. *Postgrad Med J*. 2024 Sep 22;100(1188):769-770. doi: 10.1093/postmj/qgae060. PMID: 38727579

[Comprehensive analytics of COVID-19 vaccine research: From topic modeling to topic classification.](#)

Rouhani S, Mozaffari F. *Artif Intell Med*. 2024 Nov;157:102980. doi: 10.1016/j.artmed.2024.102980. Epub 2024 Sep 18. PMID: 39332065

[A programmatic update on COVID-19 vaccination in rural communities in the United States.](#)

Piasecki AM, Hall DM, Zajac J, Miller SA, Nilson JR. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125897. doi: 10.1016/j.vaccine.2024.04.043. Epub 2024 Apr 25. PMID: 38670846

[Mechanism of enterovirus VP0 maturation cleavage based on the structure of a stabilised assembly intermediate.](#)

Kingston NJ, Snowden JS, Grehan K, Hall PK, Hietanen EV, Passchier TC, Polyak SJ, Filman DJ, Hogle JM, Rowlands DJ, Stonehouse NJ. *PLoS Pathog*. 2024 Sep 19;20(9):e1012511. doi: 10.1371/journal.ppat.1012511. eCollection 2024 Sep. PMID: 39298524

[Oral administration enhances directly mucosal immune system in intestine of olive flounder \(*Paralichthys olivaceus*\).](#)

Sohn MY, Jeong JM, Kang G, Woo WS, Kim KH, Son HJ, Joo MS, Park CI. *Dev Comp Immunol*. 2025 Jan;162:105262. doi: 10.1016/j.dci.2024.105262. Epub 2024 Sep 11. PMID: 39270949

[Whole-sporozoite malaria vaccines: where we are, where we are going.](#)

Moita D, Prudêncio M. *EMBO Mol Med*. 2024 Oct;16(10):2279-2289. doi: 10.1038/s44321-024-00131-0. Epub 2024 Sep 16. PMID: 39284948

[A Qualitative Analysis of the Functions of Primary Care Nurses in COVID-19 Vaccination.](#)

Lyons R, Mathews M, Ryan D, Hedden L, Lukewich J, Marshall EG, Gill PS, Isenor JE, Martin-Misener R, Wickett J, Bulman D, Dufour E, Meredith L, Spencer S, Vaughan C, Brown JB. *J Adv Nurs*. 2025 May;81(5):2510-2520. doi: 10.1111/jan.16468. Epub 2024 Sep 20. PMID: 39304325

[The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022.](#)

Fiebelkorn AP, Adelsberg S, Anthony R, Ashenafi S, Asif AF, Azzarelli M, Bailey T, Boddie TT, Boyer AP, Bungum NW, Burstin H, Burton JL, Casey DM, Chaumont Menendez C, Courtot B, Cronin K, Dowdell C, Downey LH, Fields M, Fitzsimmons T, Frank A, Gustafson E, Gutierrez-Nkomo M, Harris BL, Hill J, Holmes

K, Huerta Migus L, Jacob Kuttothara J, Johns N, Johnson J, Kelsey A, Kingangi L, Landrum CM, Lee JT, Martinez PD, Medina Martínez G, Nicholls R, Nilson JR, Ohiaeri N, Pegram L, Perkins C, Piasecki AM, Pindyck T, Price S, Rodgers MS, Roney H, Schultz EM, Sobczyk E, Thierry JM, Toledo C, Weiss NE, Wiatr-Rodriguez A, Williams L, Yang C, Yao A, Zajac J. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125551. doi: 10.1016/j.vaccine.2023.12.061. Epub 2024 Jan 18. PMID: 38238113

[Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study.](#)

Wu Y, Wang X, Huang Y, Chen R, Xu Y, Wei W, Qin F, Yuan Z, Su J, Chen X, Liu J, Wen L, Shi M, Qin T, Liao Y, Lu B, Tao X, Wang C, Chen S, Li J, Liu WJ, Ye L, Liang H, Jiang J. *Viruses*. 2024 Sep 18;16(9):1481. doi: 10.3390/v16091481. PMID: 39339957

[Cervical Cancer Screening and Prevention Uptake in Females with Autism Spectrum Disorder.](#)

Chen Y, Powers J, McDougale CJ, Zürcher NR, Thom RP. *J Autism Dev Disord*. 2026 Jan;56(1):1-12. doi: 10.1007/s10803-024-06565-2. Epub 2024 Sep 18. PMID: 39294385

[Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization.](#)

Moghnieh R, Haddad W, Jbeily N, El-Hassan S, Eid S, Baba H, Sily M, Saber Y, Abdallah D, Bizri AR, Sayegh MH. *PLoS One*. 2024 Sep 13;19(9):e0306457. doi: 10.1371/journal.pone.0306457. eCollection 2024. PMID: 39269963

[Differences in PCV13 Recommendation Practices between Pediatric Care Providers and Primary Care Providers in China: A Cross-Sectional Survey of Behavior and Social Drivers.](#)

Dang Y, Wang L, Liu Y, Wang B, Deng H, Ye C, Wang C, Huang Y. *Vaccines (Basel)*. 2024 Sep 22;12(9):1082. doi: 10.3390/vaccines12091082. PMID: 39340112

[Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.](#)

Lustig Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, Margalit I, Asraf K, Doolman R, Chalkias S, Das R, Elfatarany G, Harats D, Kreiss Y, Regev-Yochay G. *Vaccine*. 2024 Sep 17;42(22):126010. doi: 10.1016/j.vaccine.2024.05.058. Epub 2024 May 27. PMID: 38806352

[Galloyl-boosted gold nanorods: Unleashing personalized cancer immunotherapy potential.](#)

Ye J, Yu J, Zhao M, Zhang Y, Wang Z, Li S, Zhang B, Zhang H, Zhou T, Wang Y, Li X, He Z, Liu H, Wang Y. *J Colloid Interface Sci*. 2025 Jan 15;678(Pt C):272-282. doi: 10.1016/j.jcis.2024.09.100. Epub 2024 Sep 11. PMID: 39298978

[Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 \(Wuhan\) produced under the WHO/MPP mRNA Technology Transfer Programme.](#)

Bernadin O, Cochin M, Driouich JS, Laprie C, Steigler P, Boukes G, Fenner C, de Lamballerie X, Nougairède A. *Vaccine*. 2024 Dec 2;42(26):126378. doi: 10.1016/j.vaccine.2024.126378. Epub 2024 Sep 21. PMID: 39307023

[Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1 \$\beta\$ Secretion and T Cell Adjuvanticity.](#)

Weiss AM, Lopez MA 2nd, Rosenberger MG, Kim JY, Shen J, Chen Q, Ung T, Ibeh UM, Knight HR, Rutledge NS, Studnitzer B, Rowan SJ, Esser-Kahn AP. *J Med Chem.* 2024 Sep 12;67(17):14974-14985. doi: 10.1021/acs.jmedchem.4c00516. Epub 2024 Aug 20. PMID: 39162654

[An Iterative Approach to Polish the Nanopore Sequencing Basecalling for Therapeutic RNA Quality Control.](#)

Wang Z, Tu MJ, Liu Z, Wang KK, Fang Y, Hao N, Zhang HH, Que J, Sun X, Yu AM, Ding H. *bioRxiv [Preprint]*. 2024 Sep 18:2024.09.12.612711. doi: 10.1101/2024.09.12.612711. **Update in:** *Commun Biol.* 2025 Oct 1;8(1):1406. doi: 10.1038/s42003-025-08811-4. PMID: 39345479

[COVID-19 Vaccine Safety in Pregnancy, A Nested Case-Control Study in Births From April 2021 to March 2022, England.](#)

Mensah AA, Stowe J, Jardine JE, Kirsebom FCM, Clare T, Kall M, Campbell H, Lopez-Bernal J, Andrews N. *BJOG.* 2024 Dec;131(13):1882-1893. doi: 10.1111/1471-0528.17949. Epub 2024 Sep 16. PMID: 39279662

[A squalene oil emulsified MPL-A and anti-CD200/CD300a antibodies adjuvanted whole-killed Leishmania vaccine provides durable immunity against L. donovani parasites.](#)

Mahapatra B, Singh A, Banerjee A, Sirohi S, Singh S, Dubey VK, Singh RK. *Vaccine.* 2024 Dec 2;42(26):126373. doi: 10.1016/j.vaccine.2024.126373. Epub 2024 Sep 16. PMID: 39288578

[Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.](#)

Ying B, Liang C-Y, Desai P, Scheaffer SM, Elbashir SM, Edwards DK, Thackray LB, Diamond MS. *J Virol.* 2024 Sep 17;98(9):e0057424. doi: 10.1128/jvi.00574-24. Epub 2024 Aug 28. PMID: 39194250

[The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study.](#)

Doherty K, Bonnett L, Agbla SC, Beveridge NER, Decraene V, Fleming KM, Hungerford D, French N. *Vaccine.* 2024 Sep 17;42(22):126002. doi: 10.1016/j.vaccine.2024.05.050. Epub 2024 May 24. PMID: 38796329

[Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized Pickering emulsion.](#)

Song T, Cao F, Huang X, Wu S, Zhou Y, Ngai T, Xia Y, Ma G. *Vaccine.* 2024 Sep 17;42(22):126022. doi: 10.1016/j.vaccine.2024.05.070. Epub 2024 Jun 13. PMID: 38876839

[Newly developed mRNA vaccines induce immune responses in Litopenaeus vannamei shrimps during primary vaccination.](#)

See SA, Bhassu S, Tang SS, Yusoff K. *Dev Comp Immunol.* 2025 Jan;162:105264. doi: 10.1016/j.dci.2024.105264. Epub 2024 Sep 17. PMID: 39299363

[Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle Vaccines.](#)

Rothen DA, Dutta SK, Krenger PS, Pardini A, Vogt AS, Josi R, Lieknina I, Osterhaus ADME, Mohsen MO, Vogel M, Martina B, Tars K, Bachmann MF. *Vaccines* (Basel). 2024 Sep 14;12(9):1053. doi: 10.3390/vaccines12091053.PMID: 39340083

[High **vaccine** effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.](#)

Bejko D, Ernst C, Vergison A, Stranges S, Zeegers MP, Mossong J. *Vaccine*. 2024 Sep 17;42(22):126011. doi: 10.1016/j.vaccine.2024.05.059. Epub 2024 Jun 1.PMID: 38825555

[Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle **vaccine**.](#)

Casazza JP, Hofstetter AR, Costner PJM, Holman LA, Hendel CS, Widge AT, Wu RL, Whalen WR, Cunningham J, Arthur A, Wang X, Ola A, Saunders J, Mendoza F, Novik L, Burgos Florez MC, Ortega-Villa AM, Apte PJ, Strom L, Wang L, Imam M, Basappa M, Naisan M, Castro M, Trost JF, Narpala SR, Vanderven HA, Yamshchikov GV, Berkowitz NM, Gordon IJ, Plummer SH, Wycuff DL, Vazquez S, Gillespie RA, Creanga A, Adams WC, Carlton K, Gall JG, McDermott AB, Serebryannyy LA, Houser KV, Koup RA, Graham BS, Ledgerwood JE, Mascola JR, Pierson TC, Andrews SF, Kanekiyo M, Dropulic LK; VRC 323 study team. *NPJ Vaccines*. 2024 Sep 17;9(1):171. doi: 10.1038/s41541-024-00959-0.PMID: 39289377

[Immunity against **vaccine**-preventable diseases among pregnant employees in Germany. A situation analysis before the introduction of the Measles Protection Act.](#)

Wolfschmidt-Fietkau A, Goertz RS, Goertzen S, Schmid K, Seidling M, Gherman E, Ochmann U, Drexler H. *Vaccine*. 2024 Sep 17;42(22):125996. doi: 10.1016/j.vaccine.2024.05.044. Epub 2024 May 31.PMID: 38824086

[Investigating the predictors of COVID-19 **vaccine** decision-making among parents of children aged 5-11 in the UK.](#)

Davey SA, Hampson C, Christodoulaki ME, Gaffiero D. *Vaccine*. 2024 Sep 17;42(22):126021. doi: 10.1016/j.vaccine.2024.05.069. Epub 2024 Jun 14.PMID: 38876837

[VEGF165b mutant can be used as a protein carrier to form a chimeric tumor **vaccine** with Mucin1 peptide to elicit an anti-tumor response.](#)

Liang C, Geng L, Dong Y, Zhang H. *Mol Immunol*. 2024 Nov;175:31-39. doi: 10.1016/j.molimm.2024.09.009. Epub 2024 Sep 18.PMID: 39298996

[Evaluation of comparative effect between aluminum hydroxide gel and montanide \(ISA 70\) in potency and protection of locally prepared rabbit hemorrhagic disease virus 2 \(RHDV2\) vaccines in rabbits.](#)

Ahmed DAA, Sadiq Y, Eldin MS, Ibrahim RS, Amen O, Abodalal SESA. *BMC Vet Res*. 2024 Sep 11;20(1):407. doi: 10.1186/s12917-024-04239-w.PMID: 39261948

[Overview of U.S. COVID-19 **vaccine** safety surveillance systems.](#)

Gee J, Shimabukuro TT, Su JR, Shay D, Ryan M, Basavaraju SV, Broder KR, Clark M, Buddy Creech C, Cunningham F, Goddard K, Guy H, Edwards KM, Forshee R, Hamburger T, Hause AM, Klein NP, Kracalik I,

Lamer C, Loran DA, McNeil MM, Montgomery J, Moro P, Myers TR, Olson C, Oster ME, Sharma AJ, Schupbach R, Weintraub E, Whitehead B, Anderson S. *Vaccine*. 2024 Sep 17;42 Suppl 3:125748. doi: 10.1016/j.vaccine.2024.02.065. Epub 2024 Apr 16. PMID: 38631952

[Progress Toward Poliomyelitis Eradication - Pakistan, January 2023-June 2024.](#)

Mbaeyi C, Ul Haq A, Safdar RM, Khan Z, Corkum M, Henderson E, Wadood ZM, Alam MM, Franka R. *MMWR Morb Mortal Wkly Rep*. 2024 Sep 12;73(36):788-792. doi: 10.15585/mmwr.mm7336a2. PMID: 39264848

[Efficacy and safety of Abdala COVID-19 subunit **vaccine** in children and adolescents: An open-label, single-arm, phase 2 trial \(MENIQUE\).](#)

Hernández-Bernal F, Noa-Romero E, Quintana-Guerra J, Chávez-Chong CO, Martín-Bauta Y, Alvaré-Alvaré L, Salvato-Dueñas A, Felipe-Mallea D, Porta-Díaz M, Cruz-Sui O, Urrutia-Pérez K, Urrutia-Pérez K, Rodríguez-Reinoso JL, Alonso-Valdés M, Cinza-Estévez Z, Rodríguez-Triana A, Cruz-Gómez Y, Limonta-Fernández M, Rodríguez-Acosta M, Ayala-Ávila M, Muzio-González VL; ABDALA Group of Investigators. *Vaccine*. 2024 Sep 17;42(22):126223. doi: 10.1016/j.vaccine.2024.126223. Epub 2024 Aug 15. PMID: 39151232

[Effectiveness of Lanzhou Lamb Rotavirus **Vaccine** and RotaTeg Against Hospitalized Rotavirus Infections Among Children During 2020-2023 in Guangdong Province, China: A Test-Negative Case-Control Study.](#)

Yi Y, Liu J, Zhang Y, Zeng B, Lin L, Li C, Yang F, Zhang H, Xie R, Huang Z, Kang M, Jiang Y. *Infect Dis Ther*. 2024 Nov;13(11):2301-2317. doi: 10.1007/s40121-024-01040-y. Epub 2024 Sep 16. PMID: 39283583

[Compliance with COVID-19 government guidance and rules by disabled people and people from minoritised ethnic groups: Qualitative findings from the CICADA study.](#)

Rivas C, Anand K, Moore AP. *PLoS One*. 2024 Sep 19;19(9):e0301242. doi: 10.1371/journal.pone.0301242. eCollection 2024. PMID: 39298441

[A cross-sectional study on the understanding and attitudes toward influenza and influenza vaccines among different occupational groups in China.](#)

Zhao X, Hu X, Wang J, Shen M, Zhou K, Han X, Thomas M, Wang K, Wang L, Wang Z. *Hum Vaccin Immunother*. 2024 Dec 31;20(1):2397214. doi: 10.1080/21645515.2024.2397214. Epub 2024 Sep 17. PMID: 39286861

[Design and immunogenicity of an HIV-1 clade C pediatric envelope glycoprotein stabilized by multiple platforms.](#)

Kumar S, Del Moral-Sánchez I, Singh S, Newby ML, Allen JD, Bijl TPL, Vaghani Y, Jing L, Ortlund EA, Crispin M, Patel A, Sanders RW, Luthra K. *bioRxiv [Preprint]*. 2024 Sep 19:2024.09.14.613016. doi: 10.1101/2024.09.14.613016. **Update in:** *Vaccines (Basel)*. 2025 Jan 22;13(2):110. doi: 10.3390/vaccines13020110. PMID: 39345501

[A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for **vaccine** and gene therapy applications.](#)

Bliss CM, Hulin-Curtis SL, Williams M, Marušková M, Davies JA, Statkute E, Baker AT, Stack L, Kerstetter L, Kerr-Jones LE, Milward KF, Russell G, George SJ, Badder LM, Stanton RJ, Coughlan L, Humphreys IR, Parker AL. *Mol Ther Methods Clin Dev.* 2024 Jul 30;32(3):101308. doi: 10.1016/j.omtm.2024.101308. eCollection 2024 Sep 12. PMID: 39206304

[Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.](#)

Brackenridge S, John N, He W, Früh K, Borrow P, McMichael A. *J Virol.* 2024 Sep 17;98(9):e0120624. doi: 10.1128/jvi.01206-24. Epub 2024 Aug 29. PMID: 39207137

[Antigenic peptide-tobacco mosaic virus conjugates as a fungal **vaccine** candidate.](#)

Qian W, Ou J, Jin J, Li K, Ju X, Zhu M, Tian Y, Niu Z. *Colloids Surf B Biointerfaces.* 2025 Jan;245:114251. doi: 10.1016/j.colsurfb.2024.114251. Epub 2024 Sep 16. PMID: 39317042

[Protection Evaluation of a New Attenuated ASFV by Deletion of the *L60L* and *CD2v* Genes against Homologous Challenge.](#)

Yang J, Zhu R, Li N, Zhang Y, Zhou X, Yue H, Li Q, Wang Y, Miao F, Chen T, Zhang F, Zhang S, Qian A, Hu R. *Viruses.* 2024 Sep 14;16(9):1464. doi: 10.3390/v16091464. PMID: 39339941

[Connect, collaborate and tailor: a model of community engagement through infographic design during the COVID-19 pandemic.](#)

Vernon-Wilson E, Tetui M, DeMarco M, Grindrod K, Waite NM. *BMC Public Health.* 2024 Sep 19;24(1):2551. doi: 10.1186/s12889-024-20037-3. PMID: 39300382

[A Qualitative Study of the Views of Ethnic Minority Healthcare Workers Towards COVID-19 Vaccine Education \(CoVE\) to Support Vaccine Promotion and Uptake.](#)

Blake H, Premakumar V, Premakumar A, Fecowycz A, Khulumula SK, Jones W, Somerset S. *New Solut.* 2024 Nov;34(3):198-212. doi: 10.1177/10482911241273914. Epub 2024 Sep 17. PMID: 39289922

[Tracking temporal variations of fatality and symptomology correlated with COVID-19 dominant variants and vaccine effectiveness in the United States.](#)

Lin S, Liu H, Qi Q, Trees I, Gao D, Friedman S, Xue XR, Lawrence D. *Front Public Health.* 2024 Sep 18;12:1419886. doi: 10.3389/fpubh.2024.1419886. eCollection 2024. PMID: 39360263

[COVID-19 Knowledge Among Sexual and Gender Minority Adults in New York City.](#)

Wright CG, Bowling J, Platt J, Carpino T, Low A, Mantell J, Hoos D, Castor D, El-Sadr W, Greenleaf AR. *LGBT Health.* 2025 Feb-Mar;12(2):152-162. doi: 10.1089/lgbt.2023.0277. Epub 2024 Sep 17. PMID: 39288085

[An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023-2024.](#)

Shen AK, Gutu V, Druc A, Ebama M, Belayneh A, Adams B, Valteau M, Paraschiv A. *Vaccine.* 2024 Dec 2;42(26):126322. doi: 10.1016/j.vaccine.2024.126322. Epub 2024 Sep 17. PMID: 39293299

[Association between maternal mRNA covid-19 vaccination in early pregnancy and major congenital anomalies in offspring: population based cohort study with sibling matched analysis.](#)

Jorgensen SCJ, Drover SSM, Fell DB, Austin PC, D'Souza R, Guttman A, Buchan SA, Wilson SE, Nasreen S, Brown KA, Schwartz KL, Tadrus M, Wilson K, Kwong JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. *BMJ Med.* 2024 Sep 16;3(1):e000743. doi: 10.1136/bmjmed-2023-000743. eCollection 2024. PMID: 39574424

[Low-frequency CD8\(+\) T cells induced by SIGN-R1\(+\) macrophage-targeted **vaccine** confer SARS-CoV-2 clearance in mice.](#)

Muraoka D, Moi ML, Muto O, Nakatsukasa T, Deng S, Takashima C, Yamaguchi R, Sawada SI, Hayakawa H, Nguyen TTN, Haseda Y, Soga T, Matsushita H, Ikeda H, Akiyoshi K, Harada N. *NPJ Vaccines.* 2024 Sep 18;9(1):173. doi: 10.1038/s41541-024-00961-6. PMID: 39294173

[Glycoprotein E-Displaying Nanoparticles Induce Robust Neutralizing Antibodies and T-Cell Response against Varicella Zoster Virus.](#)

Wang H, Zhang S, Xue W, Zeng Y, Liu L, Cui L, Liu H, Zhang Y, Chen L, Nie M, Zhang R, Chen Z, Hong C, Zheng Q, Cheng T, Gu Y, Li T, Xia N, Li S. *Int J Mol Sci.* 2024 Sep 12;25(18):9872. doi: 10.3390/ijms25189872. PMID: 39337359

[Ruminant livestock TR V\(D\)J genes and CDR3 repertoire.](#)

Wu F, Deng Y, Yao X, Li J. *Vet Immunol Immunopathol.* 2024 Nov;277:110829. doi: 10.1016/j.vetimm.2024.110829. Epub 2024 Sep 22. PMID: 39316948

[Skin Lesions Caused by HPV-A Comprehensive Review.](#)

Maghiar L, Sandor M, Sachelarie L, Bodog R, Huniadi A. *Biomedicines.* 2024 Sep 13;12(9):2098. doi: 10.3390/biomedicines12092098. PMID: 39335611

[Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated **vaccine**.](#)

Shiu EYC, Cheng SMS, Martín-Sánchez M, Au NYM, Chan KCK, Li JKC, Fung LWC, Luk LLH, Chaothai S, Kwan TC, Ip DKM, Leung GM, Poon LLM, Peiris JSM, Leung NHL, Cowling BJ. *Vaccine.* 2024 Dec 2;42(26):126317. doi: 10.1016/j.vaccine.2024.126317. Epub 2024 Sep 13. PMID: 39276621

[Factors influencing HPV **vaccine** hesitancy among university students in China: A cross-sectional survey utilizing the 3Cs model.](#)

He Y, Zhang X, Li J, Chen Y, Zhang L, Wei Y. *Hum Vaccin Immunother.* 2024 Dec 31;20(1):2400750. doi: 10.1080/21645515.2024.2400750. Epub 2024 Sep 17. PMID: 39288789

[Combo COVID-19 and Flu mRNA **Vaccine** Falls Short of Total Flu Protection.](#)

Anderer S. *JAMA.* 2024 Sep 13. doi: 10.1001/jama.2024.18194. Online ahead of print. PMID: 39269723

[Evaluation of the attributable fraction and burden of HPV-related oropharyngeal cancers in Greece-the ORPHEAS study.](#)

Psyrris A, Psychogios G, Kyrodimos E, Constantinidis J, Agelaki S, Boukovinas I, Lygeros S, Ploiarchopoulou K, Spathis A, Economopoulou P, Litsou E, Dimitriadis I, Athanasopoulos C, Zioga S, Trimis G, Poughias L, Panayiotides I. *ESMO Open*. 2024 Oct;9(10):103724. doi: 10.1016/j.esmoop.2024.103724. Epub 2024 Sep 18. PMID: 39298992

[Research Note: The infectious bursal disease \(Gumboro disease\) vaccination scheme affects the quantitative and qualitative carcass characteristics and the immune response of Ross 308 broiler chickens.](#)

Wegner M, Gesek M, Banaszak M, Adamski M, Wlaźlak S, Biesek J. *Poult Sci*. 2024 Dec;103(12):104344. doi: 10.1016/j.psj.2024.104344. Epub 2024 Sep 18. PMID: 39353328

[Predicting herd immunity achievement: a time-series analysis of vaccination and fatality rates using 1,075 days of COVID-19 data.](#)

Hon BYC, Chan J, Ng KS, Lam SC. *Front Public Health*. 2024 Sep 20;12:1403163. doi: 10.3389/fpubh.2024.1403163. eCollection 2024. PMID: 39371208

[Adeno-Associated Virus 5 Protein Particles Produced by *E. coli* Cell-Free Protein Synthesis.](#)

Deuker D, Asilonu E, Bracewell DG, Frank S. *ACS Synth Biol*. 2024 Sep 20;13(9):2710-2717. doi: 10.1021/acssynbio.4c00403. Epub 2024 Aug 23. PMID: 39178386

[A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants.](#)

Chen J, Huang Z, Xiao J, Du S, Bu Q, Guo H, Ye J, Chen S, Gao J, Li Z, Lan M, Wang S, Zhang T, Zhang J, Wu Y, Zhang Y, Xia N, Yuan Q, Cheng T. *Cell Rep Methods*. 2024 Sep 16;4(9):100856. doi: 10.1016/j.crmeth.2024.100856. Epub 2024 Sep 6. PMID: 39243752

[An Application of an Initial Full Value of **Vaccine** Assessment Methodology to Measles-Rubella MAPs for Use in Low- and Middle-Income Countries.](#)

Ko M, Frivold C, Mvundura M, Soble A, Gregory C, Christiansen H, Hasso-Agopsowicz M, Fu H, Jit M, Hsu S, Mistilis JJ, Scarna T, Earle K, Menozzi-Arnaud M, Giersing B, Jarrahian C, Yakubu A, Malvolti S, Amorij JP. *Vaccines (Basel)*. 2024 Sep 19;12(9):1075. doi: 10.3390/vaccines12091075. PMID: 39340105

[Targeting Polyprotein to Design Potential Multiepitope **Vaccine** against Omsk Hemorrhagic Fever Virus \(OHFV\) by Evaluating Allergenicity, Antigenicity, and Toxicity Using Immunoinformatic Approaches.](#)

Alnuqaydan AM, Eisa AA. *Biology (Basel)*. 2024 Sep 20;13(9):738. doi: 10.3390/biology13090738. PMID: 39336165

[Detection and Molecular Characterization of GI-1 and GI-23 Avian Infectious Bronchitis Virus in Broilers Indicate the Emergence of New Genotypes in Bolivia.](#)

Villanueva-Pérez D, Tataje-Lavanda L, Montalván-Avalos A, Paredes-Inofuente D, Montoya-Ortiz S, Isasi-Rivas G, Fernández MF, Fernández-Sánchez M, Fernández-Díaz M. *Viruses*. 2024 Sep 14;16(9):1463. doi: 10.3390/v16091463. PMID: 39339939

[Vaccine Hesitancy at Nine Community Sites Across the United States, Early in COVID-19 Vaccine Rollout.](#)

Ratnayake A, Hernandez JH, Justman J, Farley JE, Hirsch-Moverman Y, Ho K, Mayer S, Oluyomi A, Sobieszczyk ME, Swaminathan S, Skalland T, Tapsoba JD; CoVPN 5002 Study Team; Kissinger PJ. *J Racial Ethn Health Disparities*. 2025 Dec;12(6):3721-3732. doi: 10.1007/s40615-024-02172-0. Epub 2024 Sep 12. PMID: 39264541

[Low Rates of Immunity among Medical Students and Residents in the Era of the Resurgence of Measles.](#)

Ferrari C, Somma G, Caputi V, Treglia M, Pallocci M, Cenko F, Buonomo E, Carestia M, Di Giampaolo L, Olesen OF, Coppeta L. *Pathogens*. 2024 Sep 11;13(9):784. doi: 10.3390/pathogens13090784. PMID: 39338975

[Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections.](#)

Kaushal A. *J Transl Med*. 2024 Sep 18;22(1):847. doi: 10.1186/s12967-024-05587-9. PMID: 39294611

[A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.](#)

Koneru A, Wells K, Amanda Carnes C, Drumhiller K, Chatham-Stephens K, Melton M, Oliphant H, Hall S, Dennison C, Fiscus M, Vogt T. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125837. doi: 10.1016/j.vaccine.2024.03.064. Epub 2024 Apr 9. PMID: 38594121

[Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy \(HERIZON\).](#)

Tobias J, Maglakelidze M, Andrić Z, Ryspayeva D, Bulat I, Nikolić I, Petrović Z, Chawla T, Nagarkar R, Garner-Spitzer E, Zielinski CC, Chong LMO, Nixon B, Ede NJ, Yavrom S, Kundi M, Wiedermann U. *Clin Cancer Res*. 2024 Sep 13;30(18):4044-4054. doi: 10.1158/1078-0432.CCR-24-0742. PMID: 39028916

[CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19 vaccine requirements and recommendations.](#)

Surtees TC, Granade CJ, Wells C, Banks M, Lucas P, Graitcer SB. *Vaccine*. 2024 Sep 17;42 Suppl 3(Suppl 3):125513. doi: 10.1016/j.vaccine.2023.12.023. Epub 2023 Dec 27. PMID: 38154993

[Changes in the mumps vaccine coverage and incidence of mumps before and after the public subsidization program: A descriptive study using a population-based database in Japan.](#)

Sato S, Ono S, Sasabuchi Y, Uemura K, Yasunaga H. *Am J Infect Control*. 2025 Jan;53(1):82-86. doi: 10.1016/j.ajic.2024.09.011. Epub 2024 Sep 16. PMID: 39293675

[Correction: Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches.](#)

Hashempour A, Khodadad N, Akbarinia S, Ghasabi F, Ghasemi Y, Matin Karbalaee Ali Nazar M, Falahi S. *BMC Infect Dis*. 2024 Sep 20;24(1):1023. doi: 10.1186/s12879-024-09951-4. PMID: 39304818

[Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.](#)

Zheng H, Li C, Zheng X, Jiang HD, Li Y, Yao A, Li X, Wang F, Liu W, Cao X, Qi R, Chen L, Jin L, Zhu F, Li J, Chen F. *Front Immunol.* 2024 Sep 12;15:1461419. doi: 10.3389/fimmu.2024.1461419. eCollection 2024. PMID: 39328415

[Immunization strategies for individuals with sickle cell anemia: A narrative review.](#)

Obeagu EI, Obeagu GU. *Medicine (Baltimore).* 2024 Sep 20;103(38):e39756. doi: 10.1097/MD.00000000000039756. PMID: 39312357

[COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.](#)

Chang JY, Chang M, Huang S, Bosco J, McNairy M, Tukur S, Wu YH, Kunkel-Jure J, Weidler J, Goodman T, Dorr C, Roberts R, Gray B, Zucker J, Sobieszczyk ME, Castor D. *Vaccine.* 2024 Dec 2;42(26):126260. doi: 10.1016/j.vaccine.2024.126260. Epub 2024 Sep 11. PMID: 39265456

[Dynamics of multisystem inflammatory syndrome in children associated to COVID-19 in Chile: Epidemiologic trends during pandemic, before and after children vaccination.](#)

Villena R, Izquierdo G, Wilhelm J, García C, Acuña M, Riquelme P, Alvarado S, Torres JP. *Vaccine.* 2024 Sep 17;42(22):126015. doi: 10.1016/j.vaccine.2024.05.063. Epub 2024 Jun 8. PMID: 38852034

[Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in Philadelphia: Lessons from the VaxUpPhillyFamilies program.](#)

Badlis S, Yu H, Klusaritz H, S L Tan A, Dooley T, Heggs H, Collins S, Raczka G, DeRoche-Brown N, Feuerstein-Simon R, Bauermeister JA, Villarruel AM, Bonett S, Glanz K, Lipman T. *Vaccine.* 2024 Sep 17;42(22):126040. doi: 10.1016/j.vaccine.2024.06.008. Epub 2024 Jun 8. PMID: 38853034

[Establishment and Application of Mismatch Amplification Mutation Assay-PCR for Rapid Detection and Differentiation of Duck Hepatitis A Virus-1 Attenuated Vaccine and Wild Strains.](#)

Yu CD, Choi YR, Park JY, Kim SW, Cha SY, Jang HK, Kang M, Wei B. *Animals (Basel).* 2024 Sep 21;14(18):2733. doi: 10.3390/ani14182733. PMID: 39335322

[Estimating the impact of vaccination: lessons learned in the first phase of the Vaccine Impact Modelling Consortium.](#)

Gaythorpe KAM, Li X, Clapham H, Dansereau E, Fitzjohn R, Hinsley W, Hogan D, Jit M, Mengistu T, Perkins TA, Portnoy A, Vynnycky E, Woodruff K, Ferguson NM, Trotter CL. *Gates Open Res.* 2024 Sep 13;8:97. doi: 10.12688/gatesopenres.15556.1. eCollection 2024. PMID: 39398325

[Immunization Status, Immunization Coverage, and Factors Associated with Immunization Service Utilization Among HIV-Exposed and HIV-Infected Children in India.](#)

Datta M, Yasmin S, Biswas R. *Int J MCH AIDS.* 2024 Sep 20;13:e021. doi: 10.25259/IJMA_18_2024. eCollection 2024. PMID: 39526167

[Correction: TgVax452, an epitope-based candidate **vaccine** targeting Toxoplasma gondii tachyzoite-specific SAG1-related sequence \(SRS\) proteins: immunoinformatics, structural simulations and experimental evidence-based approaches.](#)

Majidiani H, Pourseif MM, Kordi B, Sadeghi MR, Najafi A. BMC Infect Dis. 2024 Sep 13;24(1):969. doi: 10.1186/s12879-024-09881-1. PMID: 39271976

[Advancements, challenges, and future perspectives in developing feline herpesvirus 1 as a **vaccine** vector.](#)

Luo X, Liang R, Liang L, Tang A, Hou S, Ding J, Li Z, Tang X. Front Immunol. 2024 Sep 12;15:1445387. doi: 10.3389/fimmu.2024.1445387. eCollection 2024. PMID: 39328406

[The current status and development forecasts of vaccines for aquaculture and its effects on bacterial and viral diseases.](#)

Mkulo EM, Wang B, Amoah K, Huang Y, Cai J, Jin X, Wang Z. Microb Pathog. 2024 Nov;196:106971. doi: 10.1016/j.micpath.2024.106971. Epub 2024 Sep 20. PMID: 39307198

[Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis.](#)

Wandera EA, Kurokawa N, Mutua MM, Muriithi B, Nyangao J, Khamadi SA, Kathiiko C, Wachira M, Njuguna E, Mwaura B, Golicha RO, Njau J, Morita K, Kaneko S, Komoto S, Tsutsui N, Ichinose Y. Vaccine. 2024 Sep 17;42(22):126210. doi: 10.1016/j.vaccine.2024.126210. Epub 2024 Aug 15. PMID: 39151233

[The roles of rabies virus structural proteins in immune evasion and implications for **vaccine** development.](#)

Wang PH, Xing L. Can J Microbiol. 2024 Nov 1;70(11):461-469. doi: 10.1139/cjm-2024-0023. Epub 2024 Sep 19. PMID: 39297428

[Enhanced production of recombinant coxsackievirus A16 using a serum-free HEK293A suspension culture system for bivalent enterovirus **vaccine** development.](#)

Chen YA, Shen YS, Fang CY, Chan TT, Wu SR, Wang JR, Wu SC, Liu CC. Vaccine X. 2024 Sep 19;20:100559. doi: 10.1016/j.jvax.2024.100559. eCollection 2024 Oct. PMID: 39364390

[COVID-19 update: New Pfizer and Moderna **vaccine** formulations for 2024-2025.](#)

[No authors listed] Med Lett Drugs Ther. 2024 Sep 16;66(1711):151-152. doi: 10.58347/tml.2024.1711c. PMID: 39250343

[A Quadruple Gene-Deleted Live BoHV-1 Subunit RVFV **Vaccine** Vector Reactivates from Latency and Replicates in the TG Neurons of Calves but Is Not Transported to and Shed from Nasal Mucosa.](#)

Pavulraj S, Stout RW, Paulsen DB, Chowdhury SI. Viruses. 2024 Sep 21;16(9):1497. doi: 10.3390/v16091497. PMID: 39339973

[Identification of highly conserved surface-exposed peptides of spike protein for multiepitope **vaccine** design against emerging omicron variants: An immunoinformatic approach.](#)

Sultan Khan M, Shakya M, Kumar Verma C, Mukherjee R. Hum Immunol. 2024 Nov;85(6):111117. doi: 10.1016/j.humimm.2024.111117. Epub 2024 Sep 13. PMID: 39276411

[Pseudorabies Virus Glycoproteins E and B Application in **Vaccine** and Diagnosis Kit Development.](#)

Bude SA, Lu Z, Zhao Z, Zhang Q. Vaccines (Basel). 2024 Sep 20;12(9):1078. doi: 10.3390/vaccines12091078. PMID: 39340108

[Surveillance of adverse events following varicella **vaccine** immunization in Jiangsu province, China from 2017 to 2023.](#)

Zhang L, Fu Y, Wang W, Liu Y, Hu R, Wang Z, Sun X. BMC Infect Dis. 2024 Sep 16;24(1):983. doi: 10.1186/s12879-024-09903-y. PMID: 39285384

[Chimeric adenovirus-based herpes zoster **vaccine** with the tPA signal peptide elicits a robust T-cell immune response.](#)

Jang SO, Lee JH, Chung YJ, Oh HS, Shin M, Kim SO, Hong SP. Virology. 2024 Dec;600:110243. doi: 10.1016/j.virol.2024.110243. Epub 2024 Sep 16. PMID: 39288613

[Coronavirus disease-19 **vaccine** uptake, willingness for vaccination, and associated Factors among chronic follow patients attending in the two comprehensive specialized hospitals of Bahir Dar, Ethiopia.](#)

Tegegne D, Kebede M, Biresaw H, Andargie A, Ewunetu M, Dessie G. BMC Infect Dis. 2024 Sep 13;24(1):976. doi: 10.1186/s12879-024-09882-0. PMID: 39271982

[Perceptions of COVID-19 vaccination and factors influencing COVID-19 **vaccine** acceptance among indigenous peoples in Quebec, Canada: Insights from a facebook posts and comments analysis.](#)

Labbé F, Lapointe M, Dubé E, Fletcher C. Hum Vaccin Immunother. 2024 Dec 31;20(1):2397868. doi: 10.1080/21645515.2024.2397868. Epub 2024 Sep 15. PMID: 39279294

[Safety Profile of COVID-19 Vaccines in HIV Patients Undergoing ART and Their Impact on Immune Recovery and HIV Reservoirs.](#)

Song B, Wang X, Shen L, Cheng J, Tian J, Zhang C, Zhao Z, Zhou Y, Liang R, Zhou Z, Yang X, Suo X, Jiang T, Huang H, Guan Q, Yang Y, Bai B. Infect Dis Immun. 2024 Oct;4(4):178-186. doi: 10.1097/ID9.000000000000138. Epub 2024 Sep 19. PMID: 42326884

[Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.](#)

Yang K, Zeng Y, Wu X, Li J, Guo J. Front Immunol. 2024 Sep 11;15:1392898. doi: 10.3389/fimmu.2024.1392898. eCollection 2024. PMID: 39351240

[Analysis of Beyfortus® \(Nirsevimab\) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention.](#)

Banoun H. Curr Issues Mol Biol. 2024 Sep 18;46(9):10369-10395. doi: 10.3390/cimb46090617. PMID: 39329969

[Sequential immunization with chimeric hemagglutinin \$\Delta\$ NS1 attenuated influenza vaccines induces broad humoral and cellular immunity.](#)

Rathnasinghe R, Chang LA, Pearl R, Jangra S, Aspelund A, Hoag A, Yildiz S, Mena I, Sun W, Loganathan M, Crossland NA, Gertje HP, Tseng AE, Aslam S, Albrecht RA, Palese P, Krammer F, Schotsaert M, Muster T, García-Sastre A. NPJ Vaccines. 2024 Sep 16;9(1):169. doi: 10.1038/s41541-024-00952-7. PMID: 39300090

[Vaccine-induced reduction of COVID-19 clusters in school settings in Japan during the epidemic wave caused by B.1.1.529 \(Omicron\) BA.2, 2022.](#)

Okada Y, Nishiura H. Math Biosci Eng. 2024 Sep 12;21(9):7087-7101. doi: 10.3934/mbe.2024312. PMID: 39483074

[A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine \(HEXASIL \) in Indian toddlers.](#)

Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Kawade A, Lalwani S, Ravi MD, Ramanan PV, Kamath V, Agarwal A, Dogar V, Gautam M, Jaganathan KS, Kumar R, Sharma I, Gairola S. Vaccine. 2024 Dec 2;42(26):126380. doi: 10.1016/j.vaccine.2024.126380. Epub 2024 Sep 19. PMID: 39303376

[Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial.](#)

Snider CJ, Zaman K, Estivariz CF, Aziz AB, Yunus M, Haque W, Hendley WS, Weldon WC, Oberste MS, Pallansch MA, Wassilak SGF, Anand A. Vaccine. 2024 Sep 17;42(22):126216. doi: 10.1016/j.vaccine.2024.126216. Epub 2024 Aug 14. PMID: 39146859

[Protective immune response against Rhodococcus equi: An innate immunity-focused review.](#)

da Silveira BP, Cohen ND, Lawhon SD, Watson RO, Bordin AI. Equine Vet J. 2025 May;57(3):563-586. doi: 10.1111/evj.14214. Epub 2024 Sep 11. PMID: 39258739

[Determinants of measles second dose vaccination dropout among children aged 18-24 months in Ejere woreda, central Ethiopia; unmatched case-control study.](#)

Nurgi K, Ahmed S, Ganfure G, Bekele GG. Front Pediatr. 2024 Sep 18;12:1432762. doi: 10.3389/fped.2024.1432762. eCollection 2024. PMID: 39359739

[Jonas Salk \(1914-1995\): Pioneering the Fight Against Polio and Beyond.](#)

Sahu H, Choudhari SG, Gaidhane A, Chakole S. Cureus. 2024 Sep 18;16(9):e69681. doi: 10.7759/cureus.69681. eCollection 2024 Sep. PMID: 39429327

[Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases.](#)

Sinani G, Sessevmez M, Şenel S. Pharmaceutics. 2024 Sep 13;16(9):1201. doi: 10.3390/pharmaceutics16091201. PMID: 39339237

[Whole-genome sequencing of *Neisseria meningitidis* collected in Chile from pediatric patients during 2016-2019 and coverage **vaccine** prediction.](#)

Arteta-Acosta C, Villena R, Hormazabal JC, Fernández J, Santolaya ME. *Vaccine*. 2024 Dec 2;42(26):126311. doi: 10.1016/j.vaccine.2024.126311. Epub 2024 Sep 13. PMID: 39276620

[Challenges and advancements in the development of vaccines and therapies against Chagas disease.](#)

Pinazo MJ, Malchiodi E, Ioset JR, Bivona A, Gollob KJ, Dutra WO. *Lancet Microbe*. 2024 Oct;5(10):100972. doi: 10.1016/j.lanmic.2024.100972. Epub 2024 Sep 18. PMID: 39303738

[Indirect effectiveness of COVID-19 vaccines in the pre-omicron and omicron periods: A nation-wide test-negative case-control study in Brazil.](#)

Cerqueira-Silva T, Boaventura VS, Pearce N, Barral-Netto M. *Int J Infect Dis*. 2024 Nov;148:107241. doi: 10.1016/j.ijid.2024.107241. Epub 2024 Sep 18. PMID: 39303761

[Isolation and characterization of a novel S1-gene insertion porcine epidemic diarrhea virus with low pathogenicity in newborn piglets.](#)

Su M, Wang Y, Yan J, Xu X, Zheng H, Cheng J, Du X, Liu Y, Ying J, Zhao Y, Wang Z, Duan X, Yang Y, Cheng C, Ye Z, Sun J, Sun D, Song H. *Virulence*. 2024 Dec;15(1):2397512. doi: 10.1080/21505594.2024.2397512. Epub 2024 Sep 16. PMID: 39282989

[A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.](#)

Quiambao BP, Payumo RA, Roa C, Borja-Tabora CF, Emmeline Montellano M, Reyes MRL, Zoleta-De Jesus L, Capeding MR, Solimen DP, Barez MY, Reid C, Chuang A, Tsao E, McClain JB. *Vaccine*. 2024 Sep 17;42(22):126018. doi: 10.1016/j.vaccine.2024.05.066. Epub 2024 Jun 4. PMID: 38834432

[Level of hesitation of parents about childhood vaccines and affecting factors: a cross-sectional study in Turkey.](#)

Bayram Değer V, Yiğitalp G. *BMC Public Health*. 2024 Sep 13;24(1):2494. doi: 10.1186/s12889-024-19961-1. PMID: 39272044

[Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein **vaccine** candidates.](#)

Luo H, Ma Y, Bi J, Li Z, Wang Y, Su Z, Gerstweiler L, Ren Y, Zhang S. *Vaccine*. 2024 Sep 17;42(22):125992. doi: 10.1016/j.vaccine.2024.05.040. Epub 2024 May 28. PMID: 38811268

[Author Correction: A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal **vaccine**.](#)

Kim Y, Bae S, Yu KS, Lee S, Lee C, Kim J, Her H, Oh J. *NPJ Vaccines*. 2024 Sep 19;9(1):175. doi: 10.1038/s41541-024-00965-2. PMID: 39300100

[Uncovering the coronavirus outbreak: present understanding and future research paths.](#)

Roy J, Banerjee A, Mukherjee S, Maji BK. J Basic Clin Physiol Pharmacol. 2024 Sep 18;35(4-5):241-251. doi: 10.1515/jbcpp-2024-0134. eCollection 2024 Jul 1. PMID: 39287470

[The impact of coronavirus disease 2019 \(COVID-19\) pandemic experiences on attitudes towards vaccinations: on the social, cultural and political determinants of preferred vaccination organization models in Poland.](#)

Žuk P, Žuk P. Health Res Policy Syst. 2024 Sep 19;22(1):128. doi: 10.1186/s12961-024-01214-7. PMID: 39300562

[Influenza **vaccine** hesitancy among healthcare workers in a Northeastern province in Thailand: Findings of a cross-sectional survey.](#)

Shrestha M, Sherer PP, Paek SC, Prasert K, Chawalchitiporn S, Praphasiri P. PLoS One. 2024 Sep 19;19(9):e0310761. doi: 10.1371/journal.pone.0310761. eCollection 2024. PMID: 39298526

[The inactivated herpes zoster **vaccine** HZ/su induces a varicella zoster virus specific cellular and humoral immune response in patients on dialysis.](#)

Hielscher F, Schmidt T, Enders M, Leyking S, Gerhart M, van Bentum K, Mihm J, Schub D, Sester U, Sester M. EBioMedicine. 2024 Oct;108:105335. doi: 10.1016/j.ebiom.2024.105335. Epub 2024 Sep 11. PMID: 39265505

[Usability of a Web-Based App for Increasing Adolescent Vaccination in Primary Care Settings: Think-Aloud and Survey Assessment.](#)

Staras SAS, Tauscher J, Vinson M, Thompson LA, Gerend MA, Shenkman EA. JMIR Form Res. 2024 Sep 19;8:e56559. doi: 10.2196/56559. PMID: 39298761

[New Onset of Neuro-Sjogren's Syndrome Nine Months After the Third COVID-19 **Vaccine** Dose: A Case Report.](#)

Bakhsh R, Dairi K, Almadabgy E, Albiladi A, Gamal L, Almatrafi D, AlShariff F, Alsefri A. Cureus. 2024 Sep 16;16(9):e69562. doi: 10.7759/cureus.69562. eCollection 2024 Sep. PMID: 39421077

[Erratum for the Research Article "Adjuvantation of a SARS-CoV-2 mRNA **vaccine** with controlled tissue-specific expression of an mRNA encoding IL-12p70" by B. Brook et al.](#)

[No authors listed] Sci Transl Med. 2024 Sep 11;16(764):eads5741. doi: 10.1126/scitranslmed.ads5741. Epub 2024 Sep 11. PMID: 39259814

[Erratum: First step results from a phase II study of a dendritic cell **vaccine** in glioblastoma patients \(CombiG-vax\).](#)

Frontiers Production Office. Front Immunol. 2024 Sep 19;15:1494021. doi: 10.3389/fimmu.2024.1494021. eCollection 2024. PMID: 39364401

[Recent Occurrence, Diversity, and Candidate **Vaccine** Virus Selection for Pandemic H5N1: Alert Is in the Air.](#)

Medina-Armenteros Y, Cajado-Carvalho D, das Neves Oliveira R, Apetito Akamatsu M, Lee Ho P. Vaccines (Basel). 2024 Sep 12;12(9):1044. doi: 10.3390/vaccines12091044. PMID: 39340074

[Are HPV Vaccines Well Accepted among Parents of Adolescent Girls in China? Trends, Obstacles, and Practical Implications for Further Interventions: A Five-Year Follow-Up Study.](#)

Huang Y, Ling J, Zhao X, Lv Q, Wang L, Wu Q, Xu S, Zhang X. *Vaccines (Basel)*. 2024 Sep 19;12(9):1073. doi: 10.3390/vaccines12091073. PMID: 39340103

[Neonatal and maternal outcomes of mRNA versus Non-mRNA COVID-19 vaccines in pregnant patients: a systematic review and meta-analysis.](#)

Oliveira JA, da Silva EG, Karasu AFG, Silva AMN, Philip CE. *Rev Bras Ginecol Obstet*. 2024 Sep 18;46:e-rbgo69. doi: 10.61622/rbgo/2024rbgo69. eCollection 2024. PMID: 39380590

[A Magnetically Driven Biodegradable Microsphere with Mass Production Capability for Subunit **Vaccine** Delivery and Enhanced Immunotherapy.](#)

Zhang Q, Qu Y, Zhao H, Chen S, Liu Z, Li J, Li Y, Li J, Sun D. *ACS Appl Mater Interfaces*. 2024 Sep 25;16(38):50344-50359. doi: 10.1021/acsami.4c10301. Epub 2024 Sep 12. PMID: 39265074

[The surveillance of viral infections by the unconventional Type I NKT cell.](#)

Rajashekar V, Stern L, Almeida CF, Slobedman B, Abendroth A. *Front Immunol*. 2024 Sep 17;15:1472854. doi: 10.3389/fimmu.2024.1472854. eCollection 2024. PMID: 39355244

[COVID-19 **vaccine** related anxiety mediates the association between COVID-19 related anxiety and student adjustment to college during the pandemic: Correspondence.](#)

Daungsupawong H, Wiwanitkit V. *J Am Coll Health*. 2025 Apr;73(4):1294. doi: 10.1080/07448481.2024.2393100. Epub 2024 Sep 20. PMID: 39303071

[Heterologous SARS-CoV-2 booster **vaccine** for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA **vaccine** series.](#)

Sherman AC, van Haren SD, Borberg E, Swank Z, Aleissa M, Tong A, Rooks R, Kanwal U, Levine H, Yates B, Izaguirre N, Ryff K, Thomas S, Parisi L, Li X, Walt DR, Levy O, Walsh SR, Issa NC, Baden LR. *Vaccine*. 2024 Sep 17;42(22):126054. doi: 10.1016/j.vaccine.2024.05.081. Epub 2024 Jun 10. PMID: 38862310

[Associations Between Demographic Factors, Clinical Variables, Social Determinants of Health, **Vaccine** Hesitancy, **Vaccine** Behavior, and Revaccination Status: A Survey of Adult HCT Survivors in the United States.](#)

Wickline MM, Carpenter PA, Harris JR, Iribarren SJ, Reding KW, Pike KC, Lee SJ, Lee CJ, Oshima MU, Vo PT, Berry DL. *Transplant Cell Ther*. 2024 Dec;30(12):1221.e1-1221.e13. doi: 10.1016/j.jtct.2024.09.012. Epub 2024 Sep 19. PMID: 39303986

[Comparative effectiveness of pneumococcal vaccination strategies to prevent invasive pneumococcal disease: a population-based cohort study at the veterans health administration in the United States.](#)

Hasegawa S, Jones MP, Kakiuchi S, Perencevich EN, Goto M. *Clin Microbiol Infect*. 2025 Mar;31(3):402-407. doi: 10.1016/j.cmi.2024.09.006. Epub 2024 Sep 17. PMID: 39299558

[Attitudes of pregnant women in the Dominican Republic towards a future maternal Group B *Streptococcus vaccine*.](#)

Job MJ, Kim D, Acosta F, Valera S, Fernandez A, Laycock KM, Ratner AJ, Steenhoff AP, Feemster K, Geoghegan S. *Vaccine*. 2024 Sep 17;42(22):126169. doi: 10.1016/j.vaccine.2024.126169. Epub 2024 Aug 9. PMID: 39126829

[Vaccine coverage and timeliness among children of adolescent mothers: A community-based study in the Eastern Cape, South Africa.](#)

Wittesaele C, Toska E, Cluver L, Weiss HA, Collins C, Amponsah-Dacosta E, Doyle AM. *Vaccine*. 2024 Dec 2;42(26):126318. doi: 10.1016/j.vaccine.2024.126318. Epub 2024 Sep 17. PMID: 39293297

[Seroprotection achieved with standard four-dose schedule of hepatitis B *vaccine* in people with chronic kidney disease: A real-life data.](#)

Singh S, Mishra AK, Yachha M, Singh TP, Katiyar H, Kaul A, Dhiman RK, Bhadauria DS, Goel A. *Indian J Gastroenterol*. 2025 Feb;44(1):88-94. doi: 10.1007/s12664-024-01685-0. Epub 2024 Sep 19. PMID: 39298024

[Complete Cure of Inoperable Stage IV Locally Advanced Hypopharyngeal Squamous Cell Carcinoma by an Innovative Combination Cancer Immunotherapy Consisting of Radiation, Immune Checkpoint Inhibitors, and Dendritic Cell *Vaccine*.](#)

Iwasaki T, Yazaki Y, Myojo T, Masuko T, Nishimura T. *Cureus*. 2024 Sep 14;16(9):e69429. doi: 10.7759/cureus.69429. eCollection 2024 Sep. PMID: 39411614

[Lessons learnt on infectious bronchitis virus lineage GI-23.](#)

Finger A, Ashash U, Goldenberg D, Raviv Z. *Avian Pathol*. 2025 Feb;54(1):27-39. doi: 10.1080/03079457.2024.2398030. Epub 2024 Sep 16. PMID: 39190026

[Influenza *vaccine* effectiveness in immunocompromised patients with cancer: A Danish nationwide register-based cohort study.](#)

Amdisen L, Pedersen L, Abildgaard N, Benn CS, Cronin-Fenton D, Sørup S. *Cancer*. 2025 Jan 1;131(1):e35574. doi: 10.1002/cncr.35574. Epub 2024 Sep 22. PMID: 39306693

[Old concepts, new tricks: How peptide vaccines are reshaping cancer immunotherapy?](#)

Liu Q, Wu P, Lei J, Bai P, Zhong P, Yang M, Wei P. *Int J Biol Macromol*. 2024 Nov;279(Pt 4):135541. doi: 10.1016/j.ijbiomac.2024.135541. Epub 2024 Sep 11. PMID: 39270889

[Use of recombinant proteins for the diagnosis and prevention of *Mycoplasma bovis*: a systematic review.](#)

Gomes CP, da Silva LSC, Santos Júnior MN, Barbosa MS, Neves WS, Ribeiro VG, Bastos BL, Marques LM. *Front Vet Sci*. 2024 Sep 13;11:1397145. doi: 10.3389/fvets.2024.1397145. eCollection 2024. PMID: 39346959

[Impact of vaccination on Omicron's escape variants: Insights from fine-scale modelling of waning immunity in Hong Kong.](#)

Zou Y, Lo WC, Ming WK, Yuan HY. *Infect Dis Model*. 2024 Sep 16;10(1):129-138. doi: 10.1016/j.idm.2024.09.006. eCollection 2025 Mar. PMID: 39380722

[Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review.](#)

Renduchintala K, Arevalo M, Fonseca G, Haver MK, Gwede CK, Pabbathi S, Christy SM. *Vaccine*. 2024 Sep 17;42(22):125995. doi: 10.1016/j.vaccine.2024.05.043. Epub 2024 May 27. PMID: 38802291

[Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection.](#)

Kerfua SD, Haydon DT, Wilsden G, Ludi A, King DP, Okurut RA, Atim S, Dhikusooka MT, Kyakuwa I, Motta P, Paton DJ. *Vaccine*. 2024 Dec 2;42(26):126325. doi: 10.1016/j.vaccine.2024.126325. Epub 2024 Sep 12. PMID: 39270355

[Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.](#)

Sritipsukho P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, Mahasirimongkol S, Sawaengdee W, Fukpho W, Khawcharoenporn T. *Vaccine*. 2024 Sep 17;42(22):126025. doi: 10.1016/j.vaccine.2024.05.073. Epub 2024 Jun 8. PMID: 38852039

[Multi-omics analysis reveals regime shifts in the gastrointestinal ecosystem in chickens following anticoccidial vaccination and *Eimeria tenella* challenge.](#)

Liu P-Y, Liaw J, Soutter F, Ortiz JJ, Tomley FM, Werling D, Gundogdu O, Blake DP, Xia D. *mSystems*. 2024 Oct 22;9(10):e0094724. doi: 10.1128/msystems.00947-24. Epub 2024 Sep 17. PMID: 39287379

[Therapeutic and vaccinomic potential of moonlighting proteins for the discovery and design of drugs and vaccines against schistosomiasis.](#)

Motlathledi K, Pilusa NB, Ndaba T, George M, Masamba P, Kappo AP. *Am J Transl Res*. 2024 Sep 15;16(9):4279-4300. doi: 10.62347/BXRT7210. eCollection 2024. PMID: 39398578

[Rabies post-exposure prophylaxis: A retrospective analysis of timing of initiation and antibody responses in a Belgian cohort.](#)

Hens M, Declercq S, Berens-Riha N, Maniewski U, Theunissen C, Van Den Broucke S, De Bièvre F, Brosius I, Liesenborghs L, Van Dijck C, Burm C, Nauwelaers I, Balliauw K, Visser BJ, Bottieau E, Soentjens P. *Travel Med Infect Dis*. 2024 Nov-Dec;62:102761. doi: 10.1016/j.tmaid.2024.102761. Epub 2024 Sep 19. PMID: 39306187

[Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.](#)

Kawasuji H, Morinaga Y, Tani H, Yamada H, Yoshida Y, Ezaki M, Koshiyama Y, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Nagaoka K, Niimi H, Yamamoto Y. *Vaccine*. 2024 Sep 17;42(22):126029. doi: 10.1016/j.vaccine.2024.05.077. Epub 2024 Jun 4. PMID: 38839519

[Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee \(IVIR-AC\) ad hoc meeting, 28 June - 1 July 2024.](#)

Lambach P, Silal S, Sbarra AN, Crowcroft NS, Frey K, Ferrari M, Vynnycky E, Metcalf CJE, Winter AK, Zimmerman L, Koh M, Sheel M, Kim SY, Munywoki PK, Portnoy A, Aggarwal R, Farooqui HH, Flasche S, Hogan AB, Leung K, Moss WJ, Wang XY. *Vaccine*. 2024 Dec 2;42(26):126307. doi: 10.1016/j.vaccine.2024.126307. Epub 2024 Sep 14. PMID: 39276622

[Blocking HXA₃-mediated neutrophil elastase release during *S. pneumoniae* lung infection limits pulmonary epithelial barrier disruption and bacteremia.](#)

Xu S, Tan S, Romanos P, Reedy JL, Zhang Y, Mansour MK, Vyas JM, Meccas J, Mou H, Leong JM. *mBio*. 2024 Sep 11;15(9):e0185624. doi: 10.1128/mbio.01856-24. Epub 2024 Aug 9. PMID: 39120139

[From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health.](#)

Kajal, Pandey A, Mishra S. *Biotech*. 2024 Oct;14(10):242. doi: 10.1007/s13205-024-04075-7. Epub 2024 Sep 22. PMID: 39319014

[Fed-batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells.](#)

Silva CAT, Kamen AA, Henry O. *Biotechnol Prog*. 2025 Jan-Feb;41(1):e3506. doi: 10.1002/btpr.3506. Epub 2024 Sep 17. PMID: 39286892

[Civil society activism for Africa's **vaccine** and local manufacturing agenda: Can mpox be the test case?](#)

Ndembi N, Kimathi G, Prabhala A, Kiarie J. *PLOS Glob Public Health*. 2024 Sep 17;4(9):e0003738. doi: 10.1371/journal.pgph.0003738. eCollection 2024. PMID: 39288123

[Recent Advances of Nipah Virus Disease: Pathobiology to Treatment and **Vaccine** Advancement.](#)

Saha S, Bhattacharya M, Lee SS, Chakraborty C. *J Microbiol*. 2024 Oct;62(10):811-828. doi: 10.1007/s12275-024-00168-3. Epub 2024 Sep 18. PMID: 39292378

[The effect of alcohol, tobacco, and other drug use on **vaccine** acceptance, uptake, and adherence: a systematic review.](#)

Havelka EM, Sanfilippo JE, Juneau PL, Sherman G, Cooper D, Leggio L. *Alcohol Alcohol*. 2024 Sep 21;59(6):agae057. doi: 10.1093/alcalc/agae057. PMID: 39371015

[Cultural and social attitudes towards COVID-19 vaccination and factors associated with **vaccine** acceptance in adults across the globe: A systematic review.](#)

Begum T, Efsthathiou N, Bailey C, Guo P. *Vaccine*. 2024 Sep 17;42(22):125993. doi: 10.1016/j.vaccine.2024.05.041. Epub 2024 May 27. PMID: 38806355

[Safety and efficacy of toll-like receptor agonists as therapeutic agents and **vaccine** adjuvants for infectious diseases in animals: a systematic review.](#)

Oboge H, Riitho V, Nyamai M, Omondi GP, Lacasta A, Githaka N, Nene V, Aboge G, Thumbi SM. *Front Vet Sci.* 2024 Sep 17;11:1428713. doi: 10.3389/fvets.2024.1428713. eCollection 2024. PMID: 39355141

[Sulfated lactosyl archaeol \(SLA\) archaeosomes as a **vaccine** adjuvant.](#)

Akache B, McCluskie MJ. *Hum Vaccin Immunother.* 2024 Dec 31;20(1):2395081. doi: 10.1080/21645515.2024.2395081. Epub 2024 Sep 15. PMID: 39278862

[Analysis of Complexome Profiles with the Gaussian Interaction Profiler \(GIP\) Reveals Novel Protein Complexes in *Plasmodium falciparum*.](#)

van Strien J, Evers F, Cabrera-Orefice A, Delhez I, Kooij TWA, Huynen MA. *J Proteome Res.* 2024 Oct 4;23(10):4467-4479. doi: 10.1021/acs.jproteome.4c00414. Epub 2024 Sep 12. PMID: 39262370

[The association between the timing of initial hepatitis B vaccination and seropositivity in healthcare personnel.](#)

Lees EH, Murad MH, Breeher LE, Swift MD. *Infect Control Hosp Epidemiol.* 2024 Nov;45(11):1347-1349. doi: 10.1017/ice.2024.107. Epub 2024 Sep 16. PMID: 39279734

[Vaccinations at home: a new strategy to contain **vaccine** hesitancy? The experience of ASL Napoli 1 Centro, Italy.](#)

Tesorone M, Ungaro C, Graziano L, Vitagliano A, Luminoso I, Corvino M, Papa M, Verdoliva C. *Ann Ig.* 2025 Mar-Apr;37(2):235-240. doi: 10.7416/ai.2024.2651. Epub 2024 Sep 12. PMID: 39263944

[Evolving dengue serotype distribution with dominance of dengue virus- 3 in Bangalore: critical insights for **vaccine** efficacy and implementation.](#)

Uppoor S, Damodar T, Lodha L, Huluvadi Nagarajaiah M, Mani RS. *Lancet Reg Health Southeast Asia.* 2024 Sep 14;30:100485. doi: 10.1016/j.lansea.2024.100485. eCollection 2024 Nov. PMID: 39315002

[Seasonal influenza vaccination: A global review of national policies in 194 WHO member states in 2022.](#)

Goldin S, Brooks D, Jorgensen P, Wijesinghe P, Cho H, Attia R, Doshi R, Nogareda F, Herring B, Dumolard L, Gibson R, Chadwick C, Desai S, Vilajeliu A, Lindstrand A, Tempia S, Mott J, Hess S. *Vaccine.* 2024 Dec 2;42(26):126274. doi: 10.1016/j.vaccine.2024.126274. Epub 2024 Sep 18. PMID: 39299001

[Navigating the Evolving Landscape of COVID-19: Strategies to Increase **Vaccine** Confidence and Improve Vaccination Rates in the United States.](#)

Mansi JA, Hensler HR, Dawson R, Tuckson R, Wolynn T. *Vaccines (Basel).* 2024 Sep 19;12(9):1072. doi: 10.3390/vaccines12091072. PMID: 39340102

[Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review.](#)

Miskovic R, Radovic S, Arandjelovic S, Plavsic A, Reljic V, Peric J, Brkovic V, Stojanovic M. *Rheumatol Int.* 2024 Nov;44(11):2621-2635. doi: 10.1007/s00296-024-05718-x. Epub 2024 Sep 16. PMID: 39284920

[An overview of occult hepatitis B infection \(OBI\) with emphasis on HBV vaccination.](#)

Delghandi S, Raoufinia R, Shahtahmasbi S, Meshkat Z, Gouklani H, Gholoobi A. *Heliyon*. 2024 Aug 28;10(17):e37097. doi: 10.1016/j.heliyon.2024.e37097. eCollection 2024 Sep 15. PMID: 39281486

[Acute immune system activation exerts time-dependent effects on inhibitory control: Results of both a randomized controlled experiment of influenza vaccination and a systematic review and meta-analysis - ISPNE 2024 Dirk Hellhammer Award.](#)

Shields GS, Hunter CL, Buckner Z, Tolliver MDM, Makhanova A. *Psychoneuroendocrinology*. 2025 Jan;171:107186. doi: 10.1016/j.psyneuen.2024.107186. Epub 2024 Sep 19. PMID: 39426040

[A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.](#)

Pather S, Charpentier N, van den Ouweland F, Rizzi R, Finlayson A, Salisch N, Muik A, Lindemann C, Khanim R, Abduljawad S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of Vaccines by Technology Working Group (BRAVATO; ex-V3SWG). *Vaccine*. 2024 Sep 17;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Epub 2024 Aug 27. PMID: 39197299

[An overview of the COVID-19 pediatric vaccine program - The U.S. experience vaccinating children ages 6 months through 17 years.](#)

Chatham-Stephens K, Carter RJ, Duggar C, Woodworth KR, Carnes CA, Bhatt A, Ottis C, Voegeli C, Stokley S, Vogt T. *Vaccine*. 2024 Sep 17;42 Suppl 3:125702. doi: 10.1016/j.vaccine.2024.02.019. Epub 2024 Feb 29. PMID: 38429152

[Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review.](#)

Palmieri C, Moscara L, Tafuri S, Stefanizzi P. *Hum Vaccin Immunother*. 2024 Dec 31;20(1):2396220. doi: 10.1080/21645515.2024.2396220. Epub 2024 Sep 12. PMID: 39263919

[From promise to progress: the dynamic landscape of glioblastoma immunotherapy.](#)

Ijaz M, Ullah Z, Aslam B, Khurshid M, Chen P, Guo B. *Drug Discov Today*. 2024 Nov;29(11):104188. doi: 10.1016/j.drudis.2024.104188. Epub 2024 Sep 20. PMID: 39307298

[HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives.](#)

Yagi A, Ueda Y, Kimura T. *Vaccine*. 2024 Sep 17;42(22):125859. doi: 10.1016/j.vaccine.2024.03.080. Epub 2024 Apr 14. PMID: 38616440

[Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025.](#)

Panagiotakopoulos L, Moulia DL, Godfrey M, Link-Gelles R, Roper L, Havers FP, Taylor CA, Stokley S, Talbot HK, Schechter R, Brooks O, Daley MF, Fleming-Dutra KE, Wallace M. *MMWR Morb Mortal Wkly Rep*. 2024 Sep 19;73(37):819-824. doi: 10.15585/mmwr.mm7337e2. PMID: 39298394

[Changes in Phenotypic and Molecular Features of Naïve and Central Memory T Helper Cell Subsets following SARS-CoV-2 Vaccination.](#)

Mosavie M, Rynne J, Fish M, Smith P, Jennings A, Singh S, Millar J, Harvala H, Mora A, Kaloyirou F, Griffiths A, Hopkins V, Washington C, Estcourt LJ, Roberts D, Shankar-Hari M. *Vaccines* (Basel). 2024 Sep 11;12(9):1040. doi: 10.3390/vaccines12091040.PMID: 39340069

[Enhancing COVID-19 Vaccination Awareness and Uptake in the Post-PHEIC Era: A Narrative Review of Physician-Level and System-Level Strategies.](#)

See KC. *Vaccines* (Basel). 2024 Sep 11;12(9):1038. doi: 10.3390/vaccines12091038.PMID: 39340068

[Necrotic enteritis in chickens: a comprehensive review of **vaccine** advancements over the last two decades.](#)

Shamshirgaran MA, Golchin M. *Avian Pathol.* 2025 Feb;54(1):1-26. doi: 10.1080/03079457.2024.2398028. Epub 2024 Sep 18.PMID: 39190009

[Accelerating HPV vaccination in Africa for health equity.](#)

Asempah E, Ikpebe E. *Glob Health Res Policy.* 2024 Sep 19;9(1):37. doi: 10.1186/s41256-024-00380-z.PMID: 39294815

[The Role of the CX3CR1-CX3CL1 Axis in Respiratory Syncytial Virus Infection and the Triggered Immune Response.](#)

Rivas-Fuentes S, Salgado-Aguayo A, Santos-Mendoza T, Sevilla-Reyes E. *Int J Mol Sci.* 2024 Sep 11;25(18):9800. doi: 10.3390/ijms25189800.PMID: 39337288

[The Mpox outbreak is a public health emergency of international concern: Implications for mental health and global preparedness.](#)

Torales J, Barrios I, Castaldelli-Maia JM, Ventriglio A. *Int J Soc Psychiatry.* 2025 Feb;71(1):203-208. doi: 10.1177/00207640241280714. Epub 2024 Sep 11.PMID: 39258377

[Improving United States HPV vaccination rates: Factors predictive of parental attitudes towards middle school entry requirements.](#)

Desch J, Thompson E, Beckstead J, Owens H, Richardson Cayama M, Hernandez P, Valencia J, Zimet G, Vamos C, Daley E. *Hum Vaccin Immunother.* 2024 Dec 31;20(1):2390231. doi: 10.1080/21645515.2024.2390231. Epub 2024 Sep 13.PMID: 39268680

['Why did nobody ask us?': A mixed-methods co-produced study in the United Kingdom exploring why some children are unvaccinated or vaccinated late.](#)

Skirrow H, Lewis C, Haque H, Choudary-Salter L, Foley K, Whittaker E, Costelloe C, Bedford H, Saxena S. *Vaccine.* 2024 Sep 17;42(22):126172. doi: 10.1016/j.vaccine.2024.126172. Epub 2024 Aug 21.PMID: 39173435

[Severe cerebral amyloid angiopathy related inflammation \(CAA-ri\) associated with vaccination: Case report and literature review.](#)

Tang M, Kim J, Lau KK, Chan KH. J Neuroimmunol. 2024 Sep 15;394:578406. doi: 10.1016/j.jneuroim.2024.578406. Epub 2024 Jul 23. PMID: 39094435

[Emerging Thrombotic Disorders Associated with Virus-Based Innovative Therapies: From VITT to AAV Gene Therapy-Related Thrombotic Microangiopathy.](#)

Benemei S, Gatto F, Marcucci R, Gresele P. Thromb Haemost. 2025 Jun;125(6):513-522. doi: 10.1055/a-2413-4345. Epub 2024 Sep 11. PMID: 39260400

[VacSol-ML\(ESKAPE\)\(: Machine learning empowering vaccine antigen prediction for ESKAPE pathogens.](#)

Nasir S, Anwer F, Ishaq Z, Saeed MT, Ali A. Vaccine. 2024 Sep 17;42(22):126204. doi: 10.1016/j.vaccine.2024.126204. Epub 2024 Aug 9. PMID: 39126830

[Impact of Bacille Calmette-Guérin vaccination on the therapeutic schedule of infantile epileptic spasms syndrome: A 25-year Japanese single-center survey.](#)

Kobayashi H, Inoue H, Matsushige T, Hoshide M, Kohno F, Hidaka I, Hasegawa S. Vaccine X. 2024 Sep 18;20:100558. doi: 10.1016/j.jvacx.2024.100558. eCollection 2024 Oct. PMID: 39381543

[Pharmaceutical chitosan hydrogels: A review on its design and applications.](#)

Chellathurai MS, Chung LY, Hilles AR, Sofian ZM, Singha S, Ghosal K, Mahmood S. Int J Biol Macromol. 2024 Nov;280(Pt 2):135775. doi: 10.1016/j.ijbiomac.2024.135775. Epub 2024 Sep 20. PMID: 39307491

[Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design.](#)

Khurana S, Grubbs G, Ravichandran S, Cluff E, Kim J, Kuehne AI, Zak S, Dye JM, Lutwama JJ, Herbert AS. Nat Commun. 2024 Sep 17;15(1):8133. doi: 10.1038/s41467-024-51021-5. PMID: 39285186

[A HABA dye-based colorimetric assay to detect unoccupied biotin binding sites in an avidin-containing fusion protein.](#)

Mukherjee S, Leblanc P, Poznansky MC, Sluder AE. Biotechniques. 2024 Oct;76(10):485-494. doi: 10.1080/07366205.2024.2397288. Epub 2024 Sep 13. PMID: 39268899

[Evaluation of BVDV E2 proteins based on recombinant baculovirus expression system production as diagnostic antigens and immunogens.](#)

He J, Deng X, Ma X, Yao L, Li Y, Chen C, He Y. Protein Expr Purif. 2025 Feb;226:106611. doi: 10.1016/j.pep.2024.106611. Epub 2024 Sep 22. PMID: 39317297

[Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.](#)

Wang Q, Mellis IA, Ho J, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M, Lee C, Shapiro L, Gordon A, Guo Y, Ho DD, Liu L. Emerg Microbes Infect. 2024 Dec;13(1):2402880. doi: 10.1080/22221751.2024.2402880. Epub 2024 Sep 16. PMID: 39259045

[Adenovirus infections: new insights for the clinical laboratory.](#)

Kajon AE. J Clin Microbiol. 2024 Sep 11;62(9):e0083622. doi: 10.1128/jcm.00836-22. Epub 2024 Aug 27. PMID: 39189703

[Assessment of Neutralizing Antibodies Against COVID-19: The Impact of Vaccination in Western Rajasthan.](#)

Choudhary V, Khatri PK, Khinvasara P, Aseri GK, Jain N. Indian J Clin Biochem. 2026 Aug;41(4):533-542. doi: 10.1007/s12291-024-01258-0. Epub 2024 Sep 18. PMID: 42500335

[Changes in Attitudes towards Influenza and Pneumococcal Vaccination during the Subsiding COVID-19 Pandemic-Results of a Longitudinal Survey Study among Risk Groups in Germany between 2021 and 2023.](#)

Born S, Schwarzkopf D, Rose N, Pletz MW, Reinhart K, Fleischmann-Struzek C. Vaccines (Basel). 2024 Sep 21;12(9):1080. doi: 10.3390/vaccines12091080. PMID: 39340110

[Sputnik V-Induced Antibodies against SARS-CoV-2 Variants during the Dissemination of the Gamma Variant in Venezuela.](#)

Franco C, Cornejo A, Rodríguez M, García A, Belisario I, Mayora S, Garzaro DJ, Jaspe RC, Hidalgo M, Parra N, Liprandi F, Zambrano JL, Rangel HR, Pujol FH. Viruses. 2024 Sep 18;16(9):1480. doi: 10.3390/v16091480. PMID: 39339956

[India should invest in the expansion of genomic epidemiology for vector-borne diseases filariasis, malaria and visceral leishmaniasis that are targeted for elimination.](#)

Singh N, Sharma A. IJID Reg. 2024 Sep 18;13:100453. doi: 10.1016/j.ijregi.2024.100453. eCollection 2024 Dec. PMID: 39430599

[Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer.](#)

Mahajan I, Kadam A, McCann L, Ghose A, Wakeham K, Dhillon NS, Stanway S, Boussios S, Banerjee S, Priyadarshini A, Sirohi B, Torode JS, Mitra S. Ecancermedicalscience. 2024 Sep 11;18:1762. doi: 10.3332/ecancer.2024.1762. eCollection 2024. PMID: 39430092

[Rapid PRRSV-2 ORF5-based lineage classification using Nextclade.](#)

Zeller MA, Chang J, Trevisan G, Main RG, Gauger PC, Zhang J. Front Vet Sci. 2024 Sep 13;11:1419340. doi: 10.3389/fvets.2024.1419340. eCollection 2024. PMID: 39346961

[Serum-Free Media Formulation Using Marine Microalgae Extracts and Growth Factor Cocktails for Madin-Darby Canine Kidney and Vero Cell Cultures.](#)

Park A, Lee YJ, Jo E, Park GH, Heo SY, Koh EJ, Lee SH, Cha SH, Heo SJ. Int J Mol Sci. 2024 Sep 12;25(18):9881. doi: 10.3390/ijms25189881. PMID: 39337368

[Governance matters: Exploring the impact of governance on routine immunization performance in 54 African countries: A 10-year \(2012-2021\) analysis using linear mixed models.](#)

Kamadjeu R, Wyka K, Kelvin EA. Vaccine. 2024 Dec 2;42(26):126293. doi: 10.1016/j.vaccine.2024.126293. Epub 2024 Sep 11. PMID: 39265457

[Deletion of Card9 eliminates the detrimental facets of mycobacterial adjuvants.](#)

Mitsuyama H, Iizasa E, Kukita A, Toda S, Yoshida H, Inoue H, Hara H. *Heliyon*. 2024 Sep 19;10(19):e38139. doi: 10.1016/j.heliyon.2024.e38139. eCollection 2024 Oct 15. PMID: 39386804

[Effectiveness and Safety of mRNA Vaccines in the Therapy of Glioblastoma.](#)

Strika Z, Petković K, Likić R. *J Pers Med*. 2024 Sep 19;14(9):993. doi: 10.3390/jpm14090993. PMID: 39338247

[Clinical analysis of influenza in the neonatal intensive care unit.](#)

Jia C, Jia W, Yi X, Fu S, Cui Y, Li P, Song C. *Ital J Pediatr*. 2024 Sep 18;50(1):184. doi: 10.1186/s13052-024-01742-6. PMID: 39294774

[Current Challenges of Vaccination in Fish Health Management.](#)

Kumar A, Middha SK, Menon SV, Paital B, Gokarn S, Nelli M, Rajanikanth RB, Chandra HM, Mugunthan SP, Kantwa SM, Usha T, Hati AK, Venkatesan D, Rajendran A, Behera TR, Venkatesamurthy S, Sahoo DK. *Animals (Basel)*. 2024 Sep 16;14(18):2692. doi: 10.3390/ani14182692. PMID: 39335281

[Molecular characterization of emerging recombinant African swine fever virus of genotype I and II in Vietnam, 2023.](#)

Lee K, Vu TTH, Yeom M, Nguyen VD, Than TT, Nguyen VT, Jeong DG, Ambagala A, Le VP, Song D. *Emerg Microbes Infect*. 2024 Dec;13(1):2404156. doi: 10.1080/22221751.2024.2404156. Epub 2024 Sep 22. PMID: 39258419

[Difficulties in ophthalmic symptom interpretation in a patient with COVID-19.](#)

Stawowski AR, Stawowski SS, Moniuszko-Malinowska A, Guziejko K, Snarska KK, Konopińska J, Groth M, Choraży M. *Przegl Epidemiol*. 2024 Sep 18;78(2):150-158. doi: 10.32394/pe/191135. Epub 2024 Jul 16. PMID: 39295181

[ASIA syndrome after BNT162b2 vaccination: Is it a distinct rheumatoid arthritis phenotype?](#)

Pekdiker M, Ketenci S. *Immunol Res*. 2024 Dec;72(6):1424-1431. doi: 10.1007/s12026-024-09540-2. Epub 2024 Sep 16. PMID: 39285049

[Molecular characterization of the IgH locus and V\(D\)J recombination in large yellow croaker \(*Larimichthys crocea*\).](#)

Shi Y, Zhu Z, Li Q, Chen Q, Jiang W, Chen C, Chen X. *Fish Shellfish Immunol*. 2024 Nov;154:109909. doi: 10.1016/j.fsi.2024.109909. Epub 2024 Sep 14. PMID: 39284538

[Whole genome sequence analysis of turkey orthoreovirus isolates reveals a strong viral host-specificity and naturally occurring co-infections in commercial turkeys.](#)

Alvarez Narvaez S, Harrell TL, Day JM, Conrad SJ. *Virology*. 2024 Dec;600:110216. doi: 10.1016/j.virol.2024.110216. Epub 2024 Sep 11. PMID: 39293236

[5-Bromo-2'-deoxyuridine inhibits African swine fever virus \(ASFV\) replication via interfering viral DNA replication and suppressing the formation of viral factories.](#)

Long F, Ou W, Liu Z, Su G, Lin Q, Su G, Liu J, Chen J, Luo D. *Virology*. 2024 Dec;600:110237. doi: 10.1016/j.virol.2024.110237. Epub 2024 Sep 12. PMID: 39288610

[Determination of G and P genotypes of bovine group A rotavirus with emergence of unusual G- and P-type combinations from neonatal calf diarrhea in Kashmir, India.](#)

Hassan MN, Shah IH, Farooq S, Wani SA, Qureshi S. *Acta Vet Hung*. 2024 Aug 27;72(3):148-154. doi: 10.1556/004.2024.01020. Print 2024 Sep 12. PMID: 39190486

[Synthesis and Thermodynamic Evaluation of Sialyl-Tn MUC1 Glycopeptides Binding to Macrophage Galactose-Type Lectin.](#)

Ayyalasomayajula R, Boneva I, Ormaza D, Whyte A Jr, Farook K, Gorlin Z, Yancey E, André S, Kaltner H, Cudic M. *ChemBiochem*. 2024 Sep 16;25(18):e202400391. doi: 10.1002/cbic.202400391. Epub 2024 Jul 30. PMID: 38877657

[Global and regional genetic diversity of HIV-1 in 2010-21: systematic review and analysis of prevalence.](#)

Nair M, Gettins L, Fuller M, Kirtley S, Hemelaar J. *Lancet Microbe*. 2024 Nov;5(11):100912. doi: 10.1016/S2666-5247(24)00151-4. Epub 2024 Sep 12. PMID: 39278231

[Disproportionality Analysis and Characterisation of Medication Errors in EudraVigilance: Exploring Findings on Sexes and Age Groups.](#)

Pera V, Kors JA, van Mulligen EM, de Wilde M, Rijnbeek PR, Verhamme KMC. *Drug Saf*. 2025 Jan;48(1):59-74. doi: 10.1007/s40264-024-01478-6. Epub 2024 Sep 19. PMID: 39300043

[Development of Biolayer Interferometry \(BLI\)-Based Double-Stranded RNA Detection Method with Application in mRNA-Based Therapeutics and Vaccines.](#)

Silas DS, Juneja B, Kaur K, Narayanareddy Gari M, You Y, Moon Y, Chen Y, Arora S, Hansen J, Muthusamy K, Fu Y, Palackal N, Pyles EA. *Pharmaceutics*. 2024 Sep 19;16(9):1227. doi: 10.3390/pharmaceutics16091227. PMID: 39339263

[Review of the Highly Pathogenic Avian Influenza in Argentina in 2023: Chronicle of Its Emergence and Control in Poultry.](#)

Vagnozzi AE. *Pathogens*. 2024 Sep 19;13(9):810. doi: 10.3390/pathogens13090810. PMID: 39339001

[COVID-19 vaccination anti-cancer impact on the PI3K/AKT signaling pathway in MC4L2 mice models.](#)

Deldadeh N, Shahbazi S, Ghiasvand S, Shahriari F, Javidi MA. *Microb Pathog*. 2024 Nov;196:106955. doi: 10.1016/j.micpath.2024.106955. Epub 2024 Sep 18. PMID: 39303961

[Bovine Respiratory Syncytial Virus Nanovaccine Induces Long-Lasting Humoral Immunity in Mice.](#)

Grego E, Kelly SM, McGill JL, Wannemuehler M, Narasimhan B. *ACS Pharmacol Transl Sci*. 2024 Sep 17;7(10):3205-3215. doi: 10.1021/acsptsci.4c00375. eCollection 2024 Oct 11. PMID: 39421663

[Molecular analysis of canine distemper virus H gene in the golden jackal \(*Canis aureus*\) population from Serbia.](#)

Glišić D, Kuručki M, Ćirović D, Šolaja S, Mirčeta J, Milićević V. BMC Vet Res. 2024 Sep 21;20(1):426. doi: 10.1186/s12917-024-04284-5. PMID: 39306660

[Intranasal vaccination with engineered BCG expressing CCL2 induces a stronger immune barrier against Mycobacterium tuberculosis than BCG.](#)

Guo S, Ouyang J, Hu Z, Cao T, Huang C, Mou J, Gu X, Liu J. Mol Ther. 2024 Nov 6;32(11):3990-4005. doi: 10.1016/j.ymthe.2024.09.021. Epub 2024 Sep 18. PMID: 39295146

[Clostridium perfringens chitinases, key enzymes during early stages of necrotic enteritis in broiler chickens.](#)

Dierick E, Callens C, Bloch Y, Savvides SN, Hark S, Pelzer S, Ducatelle R, Van Immerseel F, Goossens E. PLoS Pathog. 2024 Sep 16;20(9):e1012560. doi: 10.1371/journal.ppat.1012560. eCollection 2024 Sep. PMID: 39283899

[A Multi-Functional Nanoadjuvant Coupling Manganese with Toll-Like 9 Agonist Stimulates Potent Innate and Adaptive Anti-Tumor Immunity.](#)

Liu Z, Li S, Xiao Y, Liu X, Zhang B, Zeng Q, Ao Q, Zhang X. Adv Sci (Weinh). 2024 Nov;11(41):e2402678. doi: 10.1002/advs.202402678. Epub 2024 Sep 11. PMID: 39258810

[Anti-Tumor Immunity to Patient-Derived Breast Cancer Cells by Vaccination with Interferon-Alpha-Conditioned Dendritic Cells \(IFN-DC\).](#)

Lapenta C, Santini SM, Antonacci C, Donati S, Cecchetti S, Frittelli P, Catalano P, Urbani F, Macchia I, Spada M, Vitale S, Michelini Z, Corsi DC, Zeuner A, Dattilo R, Tamburo De Bella M. Vaccines (Basel). 2024 Sep 17;12(9):1058. doi: 10.3390/vaccines12091058. PMID: 39340087

[Epidermal Growth Factor Receptor Emerges as a Viable Target for Reducing Tumorigenicity of MDCK Cells.](#)

Yang D, Liao Y, Huang L, Shi J, Wang J, Qiao Z, Ma Z, Yu S. Genes (Basel). 2024 Sep 14;15(9):1208. doi: 10.3390/genes15091208. PMID: 39336799

[A Multi-Pathogen Retrospective Study in Patients Hospitalized for Acute Gastroenteritis.](#)

Zizza A, Guido M, Sedile R, Benelli M, Nuzzo M, Paladini P, Romano A, Grima P. Diseases. 2024 Sep 12;12(9):213. doi: 10.3390/diseases12090213. PMID: 39329882

[Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral families.](#)

Vukovich MJ, Shiakolas AR, Lindenberger J, Richardson RA, Bass LE, Barr M, Liu Y, Go EP, Park CS, May AJ, Sammour S, Kambarami C, Huang X, Janowska K, Edwards RJ, Mansouri K, Spence TN, Abu-Shmais AA, Manamela NP, Richardson SI, Leonard SEW, Gripenstraw KR, Setliff I, Saunders KO, Bonami RH, Ross TM, Desaire H, Moore PL, Parks R, Haynes BF, Sheward DJ, Acharya P, Sautto GA, Georgiev IS. PLoS Pathog. 2024 Sep 18;20(9):e1012499. doi: 10.1371/journal.ppat.1012499. eCollection 2024 Sep. PMID: 39292703

[Trends in Vaccination Coverage among Children Aged 2-6 Years in Tennessee Counties, 2017-2023.](#)

Alali WQ, Huang Q, Goodin K, Gonzalez-Lozano A. *Vaccines* (Basel). 2024 Sep 13;12(9):1048. doi: 10.3390/vaccines12091048. PMID: 39340078

[Extracellular vesicle-based anti-HOXB7 CD8⁺ T cell-specific vaccination strengthens antitumor effects induced by vaccination against Her2/neu.](#)

Ferrantelli F, Manfredi F, Donnini M, Leone P, Pugliese K, Olivetta E, Giovannelli A, Di Virgilio A, Federico M, Chiozzini C. *Cancer Gene Ther*. 2024 Nov;31(11):1688-1695. doi: 10.1038/s41417-024-00831-2. Epub 2024 Sep 19. PMID: 39300218

[Predictive modeling of hepatitis B viral dynamics: a caputo derivative-based approach using artificial neural networks.](#)

Turab A, Shafqat R, Muhammad S, Shuaib M, Khan MF, Kamal M. *Sci Rep*. 2024 Sep 19;14(1):21853. doi: 10.1038/s41598-024-70788-7. PMID: 39300092

[Phylogenetic analyses and antigenic characterization of foot-and-mouth disease virus PanAsia lineage circulating in China between 1999 and 2023.](#)

Zhang X, Ma W, Liu B, Shen C, Yang F, Yang Y, Lv L, Wu J, Liu Y, Shang Y, Guo J, Zhu Z, Liu X, Zheng H, He J. *Virol Sin*. 2024 Oct;39(5):747-754. doi: 10.1016/j.virs.2024.09.006. Epub 2024 Sep 16. PMID: 39293543

[Genome-wide fitness analysis of *Salmonella enterica* reveals *aroA* mutants are attenuated due to iron restriction *in vitro*.](#)

Rooke JL, Goodall ECA, Pullela K, Da Costa R, Martinelli N, Smith C, Mora M, Cunningham AF, Henderson IR. *mBio*. 2024 Oct 16;15(10):e0331923. doi: 10.1128/mbio.03319-23. Epub 2024 Sep 17. PMID: 39287440 **Fr**

[Repeat modules and N-linked glycans define structure and antigenicity of a critical enterotoxigenic *E. coli* adhesin.](#)

Berndsen ZT, Akhtar M, Thapa M, Vickers TJ, Schmitz A, Torres JL, Baboo S, Kumar P, Khatoon N, Sheikh A, Hamrick M, Diedrich JK, Martinez-Bartolome S, Garrett PT, Yates JR 3rd, Turner JS, Laird RM, Poly F, Porter CK, Copps J, Ellebedy AH, Ward AB, Fleckenstein JM. *PLoS Pathog*. 2024 Sep 16;20(9):e1012241. doi: 10.1371/journal.ppat.1012241. eCollection 2024 Sep. PMID: 39283948

[Systematic analysis of SARS-CoV-2 Omicron subvariants' impact on B and T cell epitopes.](#)

Al Khalaf R, Bernasconi A, Pinoli P. *PLoS One*. 2024 Sep 19;19(9):e0307873. doi: 10.1371/journal.pone.0307873. eCollection 2024. PMID: 39298436

[Influenza virus antibodies inhibit antigen-specific *de novo* B cell responses in mice.](#)

Goodwin E, Gibbs JS, Yewdell JW, Eisenlohr LC, Hensley SE. *J Virol*. 2024 Sep 17;98(9):e0076624. doi: 10.1128/jvi.00766-24. Epub 2024 Aug 28. PMID: 39194245

[The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis.](#)

Antony F, Kinha D, Nowińska A, Rouse BT, Suryawanshi A. *Clin Microbiol Rev*. 2024 Sep 12;37(3):e0000624. doi: 10.1128/cmr.00006-24. Epub 2024 Jul 30. PMID: 39078136

[Humoral response to anti SARS-CoV2 vaccination at one and seven months is not different in shift workers and non-shift workers.](#)

Faioni EM, Imeri L, Bonomi A, Galotta A, Guerra V, Pase L, Bianchi S, Biondi ML. *Brain Behav Immun Health*. 2024 Sep 16;41:100869. doi: 10.1016/j.bbih.2024.100869. eCollection 2024 Nov. PMID: 39328274

[Cluster sampling methodology to evaluate immunization coverage.](#)

Sharma A, Jain RB, Satija J, Sharma A, Sharma A, Shekhawat S. *World J Methodol*. 2024 Sep 20;14(3):92344. doi: 10.5662/wjm.v14.i3.92344. eCollection 2024 Sep 20. PMID: 39310233

[In Silico Evaluation of HIV Protease and RNA Polymerase Inhibitors as Potential COVID-19 Therapeutics.](#)

Devaraji M, Ravikumar L. *Cureus*. 2024 Sep 17;16(9):e69576. doi: 10.7759/cureus.69576. eCollection 2024 Sep. PMID: 39421085

[Current and emerging approaches for eliminating *Borrelia burgdorferi* and alleviating persistent Lyme disease symptoms.](#)

Zafar K, Azuama OC, Parveen N. *Front Microbiol*. 2024 Sep 13;15:1459202. doi: 10.3389/fmicb.2024.1459202. eCollection 2024. PMID: 39345262

[Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors.](#)

Bear AS, Nadler RB, O'Hara MH, Stanton KL, Xu C, Saporito RJ, Rech AJ, Baroja ML, Blanchard T, Elliott MH, Ford MJ, Jones R, Patel S, Brennan A, O'Neil Z, Powell DJ Jr, Vonderheide RH, Linette GP, Carreno BM. *J Clin Invest*. 2024 Sep 17;134(21):e175790. doi: 10.1172/JCI175790. PMID: 39287991

[COVID-19 Infection and Vaccination Effects on Breast Implant Illness: A Case Report.](#)

Bohac M, Chotárová M, Mitevová D, Mayer A. *Cureus*. 2024 Sep 20;16(9):e69772. doi: 10.7759/cureus.69772. eCollection 2024 Sep. PMID: 39429336

[Sonication-Assisted Self-Assembled Resveratrol Nanoparticles with Enhanced Antiviral and Anti-inflammatory Activity against Respiratory Syncytial Virus-Induced Pneumonia.](#)

Chang C, Lu C, Zheng Y, Ji J, Lin L, Chen L, Chen Z, Chen R. *ACS Appl Mater Interfaces*. 2024 Sep 25;16(38):50442-50458. doi: 10.1021/acsami.4c11525. Epub 2024 Sep 16. PMID: 39282958

[MPO-ANCA-positive rapidly progressive glomerulonephritis after COVID-19 vaccination during treatment of plaque psoriasis with bimekizumab.](#)

Sugiura T, Doke T, Tanaka A, Sato Y, Maeda K, Furuhashi K, Kato N, Kosugi T, Maruyama S. *CEN Case Rep*. 2025 Apr;14(2):194-199. doi: 10.1007/s13730-024-00927-6. Epub 2024 Sep 19. PMID: 39297892

[Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.](#)

Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T, Mulder E, L'Abbate L, Marques FB, Furci F, Farcas A, Giele-Eshuis J, Morton K, Sonderlichová S, Thurin NH, Villalobos F, Riefolo F, Sturkenboom MC, Trifirò G. *Vaccines (Basel)*. 2024 Sep 17;12(9):1059. doi: 10.3390/vaccines12091059. PMID: 39340089

[False-Positive Human Immunodeficiency Virus-1 Test Results With Rapid Seroreversion After Third-Trimester Tdap Booster Vaccination.](#)

Yu KOA, Glassman SR, Link HM. *Obstet Gynecol.* 2024 Dec 1;144(6):e125-e128. doi: 10.1097/AOG.0000000000005726. Epub 2024 Sep 16. PMID: 39265172

[Severe Invasive Pneumococcal Disease Caused by Serotype 19A in Children Under Five Years in Tāmaki Makaurau Auckland, Aotearoa New Zealand.](#)

Burton C, Webb R, Anglemeyer A, Humphrey A, Tuato'o A, Best E. *Pediatr Infect Dis J.* 2025 Jan 1;44(1):90-96. doi: 10.1097/INF.0000000000004528. Epub 2024 Sep 11. PMID: 39259857

[Disproportionate preponderance of HPV genotypes associated with anogenital warts among HIV-positive MSM.](#)

Borena W, Kitchen M, Gisinger M, Taylor N, Oberkofler H, Dewasurendra D, Widschwendter A, Stoiber H, von Laer D, Sarcletti M. *Front Public Health.* 2024 Sep 20;12:1437309. doi: 10.3389/fpubh.2024.1437309. eCollection 2024. PMID: 39371203

[COVID-19 vaccines: anaphylaxis and anxiety : A case study from an allergy unit.](#)

Teufelberger AR, Dan AR, Irmeler L, Wolf P, Kränke B. *Wien Klin Wochenschr.* 2024 Nov;136(21-22):590-597. doi: 10.1007/s00508-024-02435-0. Epub 2024 Sep 11. PMID: 39259224

[Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study.](#)

Russell TW, Townsley H, Hellewell J, Gahir J, Shawe-Taylor M, Greenwood D, Hodgson D, Hobbs A, Dowgier G, Penn R, Sanderson T, Stevenson-Leggett P, Bazire J, Harvey R, Fowler AS, Miah M, Smith C, Miranda M, Bawumia P, Mears HV, Adams L, Hatipoglu E, O'Reilly N, Warchal S, Ambrose K, Strange A, Kelly G, Kjar S, Papineni P, Corrah T, Gilson R, Libri V, Kassiotis G, Gamblin S, Lewis NS, Williams B, Swanton C, Gandhi S, Beale R, Wu MY, Bauer DLV, Carr EJ, Wall EC, Kucharski AJ. *Lancet Infect Dis.* 2025 Jan;25(1):80-93. doi: 10.1016/S1473-3099(24)00484-5. Epub 2024 Sep 11. PMID: 39276782

[Role of circulating T follicular helper subsets following Ty21a immunization and oral challenge with wild type *S. Typhi* in humans.](#)

Booth JS, Rapaka RR, McArthur MA, Fresnay S, Darton TC, Blohmke CJ, Jones C, Waddington CS, Levine MM, Pollard AJ, Sztein MB. *Front Immunol.* 2024 Sep 12;15:1384642. doi: 10.3389/fimmu.2024.1384642. eCollection 2024. PMID: 39328410

[De novo assembly of sialotranscriptome of *Hyalomma anatolicum* and insights into expression dynamics in response to *Theileria annulata* infection.](#)

Abbasi AM, Nasir S, Bajwa AA, Akbar H, Artigas-Jerónimo S, Muñoz-Hernández C, Sánchez-Sánchez M, Moraga-Fernández A, de Mera IGF, de la Fuente J, Rashid MI. *Exp Appl Acarol.* 2024 Dec;93(4):887-906. doi: 10.1007/s10493-024-00962-z. Epub 2024 Sep 13. PMID: 39271544

[Seroprevalence of SARS-CoV-2 nucleocapsid antibody among sex workers during the 5th epidemic wave with Omicron variant in Chiang Mai, Thailand.](#)

Hongjaisee S, Guntala R, Tangmunkongvorakul A, Ngo-Giang-Huong N, Khamduang W. *Heliyon*. 2024 Aug 23;10(17):e36807. doi: 10.1016/j.heliyon.2024.e36807. eCollection 2024 Sep 15. PMID: 39263051

[Systematic Evaluation of Regiochemistry and Lipidation of Aryl Trehalose Mincle Agonists.](#)

Riel AMS, Rungelrath V, Elwaie TA, Rasheed OK, Hicks L, Ettenger G, You DC, Smith M, Buhl C, Abdelwahab W, Miller SM, Smith AJ, Burkhardt D, Evans JT, Ryter KT. *Int J Mol Sci*. 2024 Sep 18;25(18):10031. doi: 10.3390/ijms251810031. PMID: 39337517

[DENV Peptides Delivered as Spherical Nucleic Acid Constructs Enhance Antigen Presentation and Immunogenicity in vitro and in vivo.](#)

Zhao J, He J, Ding X, Zhou Y, Liu M, Chen X, Quan W, Hua D, Tong J, Li J. *Int J Nanomedicine*. 2024 Sep 20;19:9757-9770. doi: 10.2147/IJN.S467427. eCollection 2024. PMID: 39318604

[Research Note: Effects of on-farm and hatchery hatching on broiler performance, intestinal lesions, and immune response during a subclinical necrotic enteritis challenge.](#)

Boothe SM, Calik A, Emami NK, Dalloul RA. *Poult Sci*. 2024 Dec;103(12):104323. doi: 10.1016/j.psj.2024.104323. Epub 2024 Sep 11. PMID: 39305613

[Changes in the epidemiology of pediatric brain abscesses pre- and post-COVID-19 pandemic: a single-center study.](#)

Liu Y, Bai Z, Yang T, Yuan B, Han Y, Xiang Y, Zhou R, Sun J, Chen M, Hao C, Wang H. *BMC Pediatr*. 2024 Sep 21;24(1):600. doi: 10.1186/s12887-024-05082-6. PMID: 39306664

[Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults.](#)

Gelderloos AT, Verheul MK, Middelhof I, de Zeeuw-Brouwer ML, van Binnendijk RS, Buisman AM, van Kasteren PB. *Immun Ageing*. 2024 Sep 14;21(1):63. doi: 10.1186/s12979-024-00466-9. PMID: 39272189

[Generation of antigen-specific memory CD4 T cells by heterologous immunization enhances the magnitude of the germinal center response upon influenza infection.](#)

Sircy LM, Ramstead AG, Gibbs LC, Joshi H, Baessler A, Mena I, García-Sastre A, Emerson LL, Fairfax KC, Williams MA, Hale JS. *PLoS Pathog*. 2024 Sep 16;20(9):e1011639. doi: 10.1371/journal.ppat.1011639. eCollection 2024 Sep. PMID: 39283916

[Development and Evaluation of In-House ELISAs for the Detection of SARS-CoV-2-Specific Antibodies in COVID-19 Patients in Sri Lanka.](#)

Pathirana SL, Deepachandi B, Gunasekara P, Fernando N, Perera IC, Gangani D, Thambyarajah J, Dasanayake D, de Silva R, Premawansa S, Nitsche A, Handunnetti SM. *Int J Microbiol*. 2024 Sep 19;2024:1331067. doi: 10.1155/2024/1331067. eCollection 2024. PMID: 39346702

[*Streptococcus pneumoniae*-associated hemolytic uremic syndrome Canadian Immunization Monitoring Program ACTive National Pediatric Surveillance \(1991 to 2019\).](#)

Lee LD, Vadlamudi NK, Yu K, Sadarangani M, Le Saux N, Embree J, Kellner JD, Morris SK, Halperin SA, Bettinger JA; for Members of the Canadian Immunization Monitoring Program, Active (IMPACT). *Paediatr Child Health*. 2024 Sep 20;30(2):78-82. doi: 10.1093/pch/pxae055. eCollection 2025 May. PMID: 40452749

[Isolation and identification of BRV G6P\[1\] strain in Heilongjiang province, Northeast China.](#)

Li C, Wang X, Zhu Q, Sun D. *Front Vet Sci*. 2024 Sep 20;11:1416465. doi: 10.3389/fvets.2024.1416465. eCollection 2024. PMID: 39372897

[Low prevalence of HIV in the northern Cameroon: contribution of some AIDS restriction genes and potential implications for gene therapy.](#)

Djataou P, Djuidje Ngounoue M, Nkenfou-Tchinda CN, Ngoufack MN, Elong E, Tiga A, Muluh C, Kadji Kameni J, Djaouda M, Ndjolo A, Nkenfou CN. *Front Genet*. 2024 Sep 13;15:1447971. doi: 10.3389/fgene.2024.1447971. eCollection 2024. PMID: 39346778

[Unveiling the Burden of Hepatitis A in Salerno, Italy: A Comprehensive 9-Year Retrospective Study \(2015-2023\) on the Seroprevalence of HAV Antibodies and Age/Sex Distribution.](#)

Serretiello E, Iervolino D, Di Siervi G, Gallo L, Bernardi FF, Pagliano P, Boccia G, Folliero V, Franci G, Rinaldi L. *J Clin Med*. 2024 Sep 18;13(18):5534. doi: 10.3390/jcm13185534. PMID: 39337021

[Structural and genomic evolutionary dynamics of Omicron variant of SARS-CoV-2 circulating in Madhya Pradesh, India.](#)

Dhankher S, Yadav P, Sharma S, Gupta E, Yadav RG, Dash PK, Parida M. *Front Med (Lausanne)*. 2024 Sep 11;11:1416006. doi: 10.3389/fmed.2024.1416006. eCollection 2024. PMID: 39323472

[Calf immunization protocols with low-virulence isolates of *Anaplasma marginale*: Analysis of post-inoculation effects and protection against natural challenge.](#)

Mendonça FLM, Coelho MF, Bastos CV, da Silveira JAG, Nicolino RR, Uribe JAZ, Ribeiro MFB, Silvestre BT, Meneses RM, de Carvalho AU, Moreira TF, Facury-Filho EJ. *Ticks Tick Borne Dis*. 2025 Jan;16(1):102394. doi: 10.1016/j.ttbdis.2024.102394. Epub 2024 Sep 20. PMID: 39305677

[Prevalence of menstrual alterations following COVID-19 vaccination: systematic review & meta-analysis.](#)

Al Shahrani A, Alhumaidan N, Alzefawi L, AlDosari L, Alhindawi Z, Alotaibi N, Aljohani R. *BMC Womens Health*. 2024 Sep 19;24(1):523. doi: 10.1186/s12905-024-03349-9. PMID: 39300461

[Knowledge, attitudes and behaviour towards ticks and tick-borne diseases-A survey among Lyme borreliosis cases in Bavaria in 2019.](#)

Böhm S, Fingerle V, Beyerlein A, Wildner M, Böhmer MM. *Ticks Tick Borne Dis*. 2025 Jan;16(1):102396. doi: 10.1016/j.ttbdis.2024.102396. Epub 2024 Sep 16. PMID: 39288531

[Molecular epidemiology of *Streptococcus pneumoniae* isolates causing invasive and noninvasive infection in Ethiopia.](#)

Sharew B, Moges F, Yismaw G, Mihret A, Lobie TA, Abebe W, Fentaw S, Frye S, Vestrheim D, Tessema B, Caugant DA. *Sci Rep*. 2024 Sep 13;14(1):21409. doi: 10.1038/s41598-024-72762-9. PMID: 39271789

[Statistically Significant Associations Between HPV33, HPV35, and HPV56 With Anal HSIL in a Population of MSMLWH.](#)

Jair K, Abbott SE, Aldous A, Rivas KI, Connors KA, Klein DA, Hoke ES, Jordan JA. *J Low Genit Tract Dis.* 2025 Jan 1;29(1):99-103. doi: 10.1097/LGT.0000000000000837. Epub 2024 Sep 11. PMID: 39258977

[Host WD repeat-containing protein 5 inhibits protein kinase R-mediated integrated stress response during measles virus infection.](#)

BenDavid E, Yang C, Zhou Y, Pfaller CK, Samuel CE, Ma D. *J Virol.* 2024 Sep 17;98(9):e0102024. doi: 10.1128/jvi.01020-24. Epub 2024 Aug 28. PMID: 39194235

[An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.](#)

Koutsoumpli G, Stasiukonyte N, Hoogeboom BN, Daemen T. *Vaccine.* 2024 Sep 17;42(22):126032. doi: 10.1016/j.vaccine.2024.05.080. Epub 2024 Jul 3. PMID: 38964950

[Emerging fatal gout disease in Chinese goslings linked to acute kidney injury induced by novel goose astrovirus infection.](#)

Bi Z, Lv X, Zhang Z, Cai L, Zhang M, Li W, Ding Y, Liu H, Yang K, Zhu Y, Liu G, Wang G. *Front Cell Infect Microbiol.* 2024 Sep 18;14:1470808. doi: 10.3389/fcimb.2024.1470808. eCollection 2024. PMID: 39359936

[Screening high-efficiency promoter to construct trans-vp28 gene Anabaena sp. PCC7120 against white spot syndrome virus of Litopenaeus vannamei.](#)

Chen XY, Yu DJ, Jia R. *Fish Shellfish Immunol.* 2024 Nov;154:109912. doi: 10.1016/j.fsi.2024.109912. Epub 2024 Sep 18. PMID: 39299405

[Research protocol for bridging research, accurate information and dialogue \(BRAID\)-clinical trials: a mixed-methods study of a community-based intervention to improve trust and diversify participation in clinical trials.](#)

Gutnick DN, Lozano P, Rodriguez Martinez S, Wang KW, Williams DA, Rapkin BD, Gonzalez-Lepage N. *Front Public Health.* 2024 Sep 16;12:1407726. doi: 10.3389/fpubh.2024.1407726. eCollection 2024. PMID: 39351035

[COVID 19: Prevention and treatment through the Indian perspective.](#)

Chandra H, Yadav A, Prasad R, Sagar K, Bhardwaj N, Kumar Gupta K, Singh Thakur G, Nigam M, Pezzani R, Paulo Martins de Lima J, Douglas Melo Coutinho H, Prakash Mishra A. *Cytokine.* 2024 Nov;183:156756. doi: 10.1016/j.cyto.2024.156756. Epub 2024 Sep 15. PMID: 39284260

[An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population.](#)

Fridh AC, Palmborg A, Ta A, Freigofaite D, Warren S, Perdrizet J. *Hum Vaccin Immunother.* 2024 Dec 31;20(1):2400751. doi: 10.1080/21645515.2024.2400751. Epub 2024 Sep 15. PMID: 39279284

[Vaccination governance in protracted conflict settings: the case of northwest Syria.](#)

Baatz RK, Ekzayez A, Najib Y, Alkhalil M, Salem M, Alshiekh MA, Patel P. BMC Health Serv Res. 2024 Sep 12;24(1):1056. doi: 10.1186/s12913-024-11413-1. PMID: 39267075

[Epigenetic programming of host lipid metabolism associated with resistance to TST/IGRA conversion after exposure to *Mycobacterium tuberculosis*.](#)

Dill-McFarland KA, Simmons JD, Peterson GJ, Nguyen FK, Campo M, Benchek P, Stein CM, Vaisar T, Mayanja-Kizza H, Boom WH, Hawn TR. mSystems. 2024 Sep 17;9(9):e0062824. doi: 10.1128/msystems.00628-24. Epub 2024 Aug 20. PMID: 39162406

[A health equity science approach to assessing drivers of COVID-19 vaccination coverage disparities over the course of the COVID-19 pandemic, United States, December 2020-December 2022.](#)

Woolfork MN, Haire K, Farinu O, Ruffin J, Nelson JM, Coronado F, Silk BJ, Harris L, Walker C, Manns BJ. Vaccine. 2024 Sep 17;42 Suppl 3(Suppl 3):126158. doi: 10.1016/j.vaccine.2024.126158. Epub 2024 Aug 1. PMID: 39095277

[Diarrhea and cholera surveillance for early warning and preparedness to prevent epidemics among Rohingya Myanmar nationals in Cox's Bazar, Bangladesh.](#)

Khan AI, Islam MT, Tanvir NA, Khan ZH, Amin MA, Firoj MG, Afrad MMH, Begum YA, Bhuiyan ATMRH, Hasan AM, Shirin T, Qadri F. Heliyon. 2024 Sep 6;10(17):e37562. doi: 10.1016/j.heliyon.2024.e37562. eCollection 2024 Sep 15. PMID: 39296070

[Influenza Hemagglutinin Antibody Levels in the Elderly: Impact of Sex, Age, and Influenza/COVID-19 Vaccination Status During the 2021/2022 Epidemic Season in Warsaw, Poland.](#)

Proniewska-Sadowska M, Poznańska A, Brydak LB. Med Sci Monit. 2024 Sep 17;30:e945002. doi: 10.12659/MSM.945002. PMID: 39285625

[Changes in memory and cognition during the SARS-CoV-2 human challenge study.](#)

Trender W, Hellyer PJ, Killingley B, Kalinova M, Mann AJ, Catchpole AP, Menon D, Needham E, Thwaites R, Chiu C, Scott G, Hampshire A. EClinicalMedicine. 2024 Sep 21;76:102842. doi: 10.1016/j.eclinm.2024.102842. eCollection 2024 Oct. PMID: 39364271

[Antibody sequence determinants of viral antigen specificity.](#)

Abu-Shmais AA, Vukovich MJ, Wasdin PT, Suresh YP, Marinov TM, Rush SA, Gillespie RA, Sankhala RS, Choe M, Joyce MG, Kanekiyo M, McLellan JS, Georgiev IS. mBio. 2024 Oct 16;15(10):e0156024. doi: 10.1128/mbio.01560-24. Epub 2024 Sep 12. PMID: 39264172

[The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A cross-sectional study.](#)

Koirala A, McRae J, Britton PN, Downes M, Prasad SA, Nicholson S, Winkler NE, O'Sullivan MVN, Gondalwala F, Castellano C, Carey E, Hendry A, Crawford N, Wadia U, Richmond P, Marshall HS, Clark JE, Francis JR, Carr J, Bartlett A, McMullan B, Skowno J, Hannah D, Davidson A, von Ungern-Sternberg BS, Lee-Archer P, Burgoyne LL, Waugh EB, Carlin JB, Naing Z, Kerly N, McMinn A, Hunter G, Heath C, D'Angelo N, Finucane C, Francis LA, Dougherty S, Rawlinson W, Karapanagiotidis T, Cain N, Brizuela R, Blyth CC,

Wood N, Macartney K. PLoS One. 2024 Sep 18;19(9):e0300555. doi: 10.1371/journal.pone.0300555. eCollection 2024. PMID: 39292730

[Phytase, 25-hydroxyvitamin D₃ and cocci vaccination to broilers fed a calcium and phosphorus-reduced diet under *Eimeria* spp. challenge: effects on growth performance and intestinal health.](#)

Shi H, Paneru D, Sharma MK, Lee J, Naeini HRR, Mahdavi FS, Kim WK. Poult Sci. 2024 Dec;103(12):104326. doi: 10.1016/j.psj.2024.104326. Epub 2024 Sep 12. PMID: 39342689

[Botanical Bioflavonoid Composition from *Scutellaria baicalensis*- and *Acacia catechu*-Protected Mice against D-Galactose-Induced Immunosenescence, and Cyclophosphamide Induced Immune Suppression.](#)

Yimam M, Horm T, O'Neal A, Chua P, Jiao P, Hong M, Jia Q. Nutrients. 2024 Sep 18;16(18):3144. doi: 10.3390/nu16183144. PMID: 39339746

[Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial resistance trends among children in Portugal, after introduction of PCV13 in National Immunization Program: A cross-sectional study.](#)

Candeias C, Almeida ST, Paulo AC, Simões AS, Ferreira B, Cruz AR, Queirós M, Touret T, Brito-Avô A, de Lencastre H, Sá-Leão R. Vaccine. 2024 Sep 17;42(22):126219. doi: 10.1016/j.vaccine.2024.126219. Epub 2024 Aug 14. PMID: 39146858

[Biofluid GPNMB/osteoactivin as a potential biomarker of ageing: A cross-sectional study.](#)

Liu YY, Pang J, Zhang C, Zeng LT, Wang Y, Wang SB, Fan GQ, Zhang LQ, Shen T, Li XF, Li CB, Cao SY, Zhang TM, Cai JP, Cui J. Heliyon. 2024 Aug 22;10(17):e36574. doi: 10.1016/j.heliyon.2024.e36574. eCollection 2024 Sep 15. PMID: 39263169

[Genetic characteristics of human parainfluenza viruses 1-4 associated with acute lower respiratory tract infection in Chinese children, during 2015-2021.](#)

Zhu Y, Sun Y, Li C, Lu G, Jin R, Xu B, Shang Y, Ai J, Wang R, Duan Y, Chen X, Xie Z. Microbiol Spectr. 2024 Oct 3;12(10):e0343223. doi: 10.1128/spectrum.03432-23. Epub 2024 Sep 12. PMID: 39264196

[Group A Streptococcus infections in children and adolescents in the post-COVID-19 era: a regional Italian survey.](#)

Cinicola BL, Sani I, Pulvirenti F, Capponi M, Leone F, Spalice A, Montalbano A, Macari A, Fonte MT, Giampietro PG, Buonsenso D, Zicari AM, Rongai T; Italian Pediatrician Federation (FIMP), Lazio Region. Ital J Pediatr. 2024 Sep 16;50(1):177. doi: 10.1186/s13052-024-01750-6. PMID: 39285296

[Epidemiology of COVID-19 in Berlin-Neukölln nursing homes.](#)

Roth A, Gehre L, Gerke J, Lutz M, Manafa G, Schmitz T, Lambio C, Zhuang S, Butler J, Lakes T, Savaskan N. J Infect Public Health. 2024 Nov;17(11):102546. doi: 10.1016/j.jiph.2024.102546. Epub 2024 Sep 20. PMID: 39321605

[Population-based age- and type-specific prevalence of human papillomavirus among non-vaccinated women aged 30 years and above in Germany.](#)

Liang LA, Tanaka LF, Radde K, Bussas U, Ikenberg H, Heideman DAM, Meijer CJLM, Blettner M, Klug SJ. *BMC Infect Dis.* 2024 Sep 19;24(1):1008. doi: 10.1186/s12879-024-09827-7. PMID: 39300354

[Understanding the change of in-hospital mortality and respiratory failure between Delta and Omicron waves from a tertiary hospital in Southern Thailand: A retrospective cohort study.](#)

Meesoontorn S, Pakdee W, Cheranakhorn C, Sangkaew S. *IJID Reg.* 2024 Sep 12;13:100446. doi: 10.1016/j.ijregi.2024.100446. eCollection 2024 Dec. PMID: 39430602

[Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey.](#)

Prochazka M, Vinti P, Hoxha A, Seale A, Mozalevskis A, Lewis R, Sagastume RM, Scherzer M, Dore L, Doherty M. *Lancet Infect Dis.* 2024 Dec;24(12):1309-1318. doi: 10.1016/S1473-3099(24)00531-0. Epub 2024 Sep 18. PMID: 39305907

[Aversion to pragmatic randomised controlled trials: three survey experiments with clinicians and laypeople in the USA.](#)

Vogt RL, Heck PR, Mestechkin RM, Heydari P, Chabris CF, Meyer MN. *BMJ Open.* 2024 Sep 17;14(9):e084699. doi: 10.1136/bmjopen-2024-084699. PMID: 39289015

[Prevalence and factors influencing long COVID among primary healthcare workers after epidemic control policy adjustment in Jiangsu, China.](#)

Chen H, Qian Y, Lu B, Ma R, Miao P, Fu M, Guo H, Shen Y, Shen Z, Li Y, Xu B, Zhang Y, Xu J, Chen B. *BMC Infect Dis.* 2024 Sep 12;24(1):964. doi: 10.1186/s12879-024-09764-5. PMID: 39266971

[New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020.](#)

Hui Z, Yu W, Fuzhen W, Liping S, Guomin Z, Jianhua L, Feng W, Ning M, Jian L, Guowei D, Tongtong M, Lin T, Shuang Z, Mingshuang L, Yuan L, Xiaoqi W, Qianqian L, Qian Z, Dan W, Tingting Y, Qidong S, Miao W, Li L, Qian H, Yixing L, Yi L, Shaodong Y, Zhijie A, Rodewald LE, Jidong J, Huaqing W, Wenzhou Y, Zhongfu L, Qun L, Zijian F, Zundong Y, Yu W. *Lancet Reg Health West Pac.* 2024 Sep 14;51:101193. doi: 10.1016/j.lanwpc.2024.101193. eCollection 2024 Oct. PMID: 39315090

[Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 \(COPCOV\): A double-blind, randomised, placebo-controlled trial.](#)

Schilling WHK, Mukaka M, Callery JJ, Llewelyn MJ, Cruz CV, Dhorda M, Ngernseng T, Waithira N, Ekkapongpisit M, Watson JA, Chandna A, Nelwan EJ, Hamers RL, Etyang A, Beg MA, Sow S, Yavo W, Allabi AC, Basnyat B, Sharma SK, Amofa-Sekyi M, Yonga P, Adler A, Yuentrakul P, Cope T, Thaipadungpanit J, Rienpradub P, Imwong M, Abdad MY, Blacksell SD, Tarning J, Goudjo FF, Dossou AD, Konaté-Touré A, Assi SB, Ouffoué K, Nasronudin N, Rachman BE, Romadhon PZ, Dewanto DD, Heryana MO, Novi T, Pasaribu AP, Mutiara M, Nasution MPR, Khairunnisa K, Dalimunthe FA, Airlangga E, Fahrezzy A, Subronto Y, Ananda NR, Rahardjani M, Romainar A, Lucinde RK, Timbwa M, Onyango OE, Agutu C, Akech S, Hamaluba M, Kipyego J, Ngachi O, Haidara FC, Traoré OY, Diarra F, Khanal B, Dahal P, Shrestha S, Rijal S, Kabore Y, Adehossi E, Guindo O, Qamar FN, Kazi AM, Woodrow CJ, Laird S, Cheeba M, Ayles H, Cheah PY, Taylor

WRJ, Batty EM, Chotivanich K, Pukrittayakamee S, Phumratanaprapin W, von Seidlein L, Dondorp A, Day NPJ, White NJ; COPCOV Collaborative Group. *PLoS Med.* 2024 Sep 12;21(9):e1004428. doi: 10.1371/journal.pmed.1004428. eCollection 2024 Sep. PMID: 39264960

Patentes registradas en Patentscope

Estrategia de búsqueda: (Vaccine) AND DP:([01.09.2026 TO 12.09.2026]) as the publication date 63 records.

1. WO/2026/185293 ANTI-CANCER PEPTIDE VACCINE

WO - 10.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2026/055872 Solicitante EBERHARD KARLS UNIVERSITÄT TÜBINGEN (MEDIZINISCHE FAKULTÄT) Inventor/a WALZ, Juliane

The invention provides a vaccine composition comprising at least one peptide comprising or consisting of an amino acid sequence set forth in SEQ ID NO: 1, 6 or 7, respectively, and further a peptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 8. The invention also provides a vaccine formulation comprising said vaccine composition and an adjuvant. The vaccine composition and vaccine formulation are also provided for use in the treatment of cancer. The invention further provides a diagnostic method, wherein the MHC presentation of at least one peptide comprising or consisting of an amino acid sequence set forth in SEQ ID NO: 1-10 by cells of the cancer of a patient to be treated is determined and the MHC presentation of one or more of said peptides indicates that the patient may benefit from administration of the vaccine composition or the vaccine formulation of the invention.

2. WO/2026/187616 RECOMBINANT VACCINE AGAINST HIGHLY PATHOGENIC AVIAN INFLUENZA: COMPOSITIONS AND METHODS OF USE

WO - 10.09.2026

Clasificación Internacional A61K 39/235Nº de solicitud PCT/US2026/017153 Solicitante EDGE ANIMAL HEALTH, INC. Inventor/a HAVEN, Michelle Lynn

An avian influenza H5 virus vectored bait vaccine for reducing an avian influenza viral load in an avian subject in need thereof comprising inserting a H5 gene into a viral vector to create an avian influenza H5 vaccine and incorporating the avian influenza H5 vaccine into formulations into a bait, wherein administration of the avian influenza H5 vectored bait vaccine decreases avian influenza outbreak in poultry.

3. 20260263585 UNIVERSAL INFLUENZA MRNA VACCINE AND USE THEREOF

US - 10.09.2026

Clasificación Internacional A61K 39/145Nº de solicitud 19166221 Solicitante SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD. Inventor/a Jian LUO

A universal influenza mRNA vaccine is used to encode a protein. The resulting protein encoded by the universal influenza mRNA vaccine has a matrix protein 2 extracellular domain (M2e), a hemagglutinin (HA) stem LAH region and a nucleoprotein (NP) of an influenza A virus. The universal influenza mRNA vaccine is

used in a mouse animal model. The universal influenza mRNA **vaccine** can induce strong humoral immune and cellular immune responses, and can protect animal model mice against various influenza A viruses.

4. 20260260737 **VACCINE** MANAGEMENT SYSTEM FOR PREVENTING VACCINATION ACCIDENTS DUE TO MISVACCINATION AND MISREGISTRATION OF VACCINES, AND METHOD FOR PROVIDING VACCINATION SERVICE PERFORMED IN THE **VACCINE** MANAGEMENT SYSTEM

US - 03.09.2026

Clasificación Internacional G16H 40/20Nº de solicitud 19211500Solicitante REAL TIME MEDI CHECK CORP.Inventor/a Hee KIM

A system for preventing vaccination accidents due to misvaccination and misregistration of vaccines include an on-site vaccination information recognition device for recognizing a subject identification code of a subject to be vaccinated and information on **vaccine** for vaccination printed on a syringe or vial; and an on-site terminal for displaying check information that must be confirmed for vaccination of the subject to be vaccinated based on the subject identification code and information on **vaccine** for vaccination transmitted from the on-site vaccination information recognition device, on a screen. The screen of the on-site terminal includes: a first display area for displaying the identity information of the subject to be vaccinated corresponding to the subject identification code of the check information; and a second display area for displaying the vaccination information corresponding to the information on **vaccine** for vaccination of the check information.

5. 4802084 IMPFSTOFF GEGEN DEN VIRUS DER VESIKULÄREN STOMATITIS VIRUS LASSA

EP - 09.09.2026

Clasificación Internacional C12N 15/86Nº de solicitud 24887096Solicitante INT AIDS **VACCINE** INITIATIVE INCInventor/a PARKS CHRISTOPHER L

Lassa fever is a zoonotic viral hemorrhagic disease caused by Lassa virus (LASV), endemic in multiple west African countries where the multimammate rat is a main virus reservoir. The broad geographic range of the rodent host places a large population at risk of serious illness. LASV is also a bioterrorism threat. A LASV **vaccine** is an unmet need. Applicants advance a **vaccine** based on a live vesicular stomatitis virus vector for immunizing against the LASV surface glycoprotein. Preclinical evaluation exhibited high efficacy in cynomolgus macaques. The animals developed serum antibodies that could mediate antiviral effector functions including direct neutralization of virus infectivity. This **vaccine** candidate elicited robust protective immunity in cynomolgus macaques that prevented development of detectable viremia and disease for at least 1 year after vaccination. These protective immune response features provide valuable data for comparison to an ongoing phase 1 clinical trial and planned phase 2b/3 clinical trials.

6. 20260263354 BIODISSOLVABLE MICRONEEDLE ARRAY-METAL-ORGANIC FRAMEWORK-**VACCINE** BIOCOMPOSITES FOR EFFECTIVE SKIN IMMUNIZATION AND MANUFACTURING THEREOF

US - 10.09.2026

Clasificación Internacional A61K 9/00Nº de solicitud 19165553Solicitante University of Pittsburgh - Of the Commonwealth System of Higher EducationInventor/a Louis D. Faló

Disclosed herein are aspects of a microneedle array comprising a metal-organic framework (MOF)-**vaccine** biocomposite and methods for using the same. The microneedle array further comprises a dissolvable material that dissolved when inserted into the skin of a subject, thereby releasing the MOF-

vaccine biocomposite. The MOF may be selected to dissolve in an acidic environment, thereby targeting the vaccine delivery to specific cellular compartments. Methods for making the MOF-vaccine biocomposite and the microneedle array also are disclosed.

7. 4803097 NANOPARTIKELIMPFSTOFF ZUR VORBEUGUNG EINER INFEKTION MIT MYCOBACTERIUM TUBERCULOSIS UND HERSTELLUNGSVERFAHREN DAFÜR

EP - 09.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud 24884552Solicitante YANTAI PATRONUS BIOTECH CO LTDInventor/a DING YANBIN

Disclosed is a Mycobacterium tuberculosis vaccine. Specifically, the vaccine comprises an immune composition comprising an antigen component and a particulate protein component. The particulate protein component comprises nanoparticle protein. The antigen component and the particulate protein component are covalently bound by means of a binding peptide 1 and a binding peptide 2 to form an immunogenic complex. The vaccine has excellent cell immunogenicity and antibody immunogenicity. The present invention also relates to a preparation method for the mycobacterium tuberculosis vaccine.

8. WO/2026/182568 PB2-BASED, LOW-PATHOGENIC, AND HIGH-GROWTH RECOMBINANT INFLUENZA A VIRUS AND VACCINE COMPOSITION USING SAME

WO - 03.09.2026

Clasificación Internacional C12N 15/86Nº de solicitud PCT/KR2026/003246Solicitante GENINER CO., LTD.Inventor/a KWON, Hyuk Joon

The present invention relates to a PB2-based, low-pathogenic, and high-growth recombinant influenza A virus and a vaccine composition using same, and can ensure safety while improving the productivity of a vaccine seed virus, provides broad protective efficacy against homologous and heterologous subtype influenza viruses through mucosal immunity, and thus can be effectively used as an influenza A virus vaccine strain.

9. 4800111 MRNA-IMPfstoff gegen Tollwutviren und Herstellungsverfahren dafür

EP - 02.09.2026

Clasificación Internacional C12N 15/47Nº de solicitud 23956345Solicitante CSPC MEGALITH BIOPHARMACEUTICAL CO LTDInventor/a MA CHENGXIN

The present application belongs to the technical field of biological medicines, and particularly relates to a mRNA vaccine against rabies viruses and a preparation method therefor, the nucleotide sequence of said vaccine being shown as any one of SEQ ID NO. 1-3. The mRNA vaccine obtained by the present application can generate neutralizing antibodies at a high level, has broad-spectrum neutralizing activity on representative strains of seven pandemic populations of rabies viruses in China, effectively induces B cell immunity and T cell immunity, and provides good protection effects for mice challenged with viruses in pre-exposure and post-exposure immune tests. In addition, the vaccine can be preserved stably for a long period under a condition of -20 °C, thereby satisfying the requirements of use in countries and regions of various economic conditions.

10. 20260263587 PROTEIN AND VACCINE AGAINST INFECTION BY SARS-COV-2 OMICRON VARIANT STRAIN AND SUBTYPE THEREOF

US - 10.09.2026

Clasificación Internacional A61K 39/215Nº de solicitud 19147928 Solicitante WestVac Biopharma Co., Ltd. Inventor/a Xiawei WEI

The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-COV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-COV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-COV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-COV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-COV-2 Omicron mutant strain and subtype viruses thereof.

11. 20260256905 BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

US - 03.09.2026

Clasificación Internacional A61K 39/215Nº de solicitud 19675204 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a Lbachir BenMohamed

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN- γ +TNF α +CD4+ and CD69+IFN- γ +TNF α +CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

12. 20260256902A VACCINE FOR PROTECTING A PREGNANT SWINE AGAINST AFRICAN SWINE FEVER

US - 03.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19162985 Solicitante INTERVET INC. Inventor/a Erwin VAN DEN BORN

The invention pertains to a live attenuated African swine fever virus Georgia 2007 (ASFV-G) Δ 9GL/ Δ UK strain for use in a vaccine for protecting a pregnant swine against an infection with African swine fever virus (ASFV) by administering the vaccine comprising the live attenuated ASFV-G- Δ 9GL/ Δ UK strain to the pregnant swine.

13. WO/2026/183992 NON-NEUROTOXIC RECOMBINANT LIVE VIRUS VECTOR RABIES VACCINE

WO - 10.09.2026

Clasificación Internacional C12N 7/01Nº de solicitud PCT/CN2025/103798Solicitante HEFEI BAIYU BIOTECHNOLOGY CO., LTDInventor/a FAN, Yao

Disclosed in the present invention is a non-neurotoxic recombinant live virus vector rabies **vaccine**, which is obtained by means of replacing a G protein of a vesicular stomatitis virus with a G protein of the HEP-Flury rabies strain or a G protein mutant of the HEP-Flury rabies strain, and rescuing a recombinant virus VSV-HEP-Flury by using reverse genetic operation technology. The recombinant live virus vector rabies **vaccine** has no neurotoxicity after vaccination.

14. 20260263581RSV **VACCINE** COMPOSITION, METHOD AND USE THEREOF

US - 10.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19491388Solicitante SICHUAN CLOVER BIOPHARMACEUTICALS, INC.Inventor/a Joshua LIANG

An immunogenic composition comprising a recombinant peptide and a protein, wherein the recombinant peptide and the protein comprise a respiratory syncytial virus (RSV) viral antigen and an immunogen such as an RSV F protein peptide. The immunogenic composition comprises a secreted fusion protein, the secreted fusion protein comprises a soluble RSV virus antigen, and the soluble RSV virus antigen is linked with the C-terminal part of collagen by means of in-frame fusion to form a disulfide bond-linked trimer fusion protein. The immunogenic composition can be used for producing an immune response, for example for treating or preventing RSV infection. The immunogenic composition can be used in a **vaccine** composition, for example as part of a prophylactic and/or therapeutic **vaccine**. Further provided are a method for producing the recombinant peptide and protein, prevention, treatment and/or diagnosis methods and related kits.

15. 20260265702ADENOVIRAL VECTOR **VACCINE**, AND PREPARATION METHOD AND USE THEREOF

US - 10.09.2026

Clasificación Internacional C12N 7/02Nº de solicitud 19489222Solicitante CANSINO BIOLOGICS INC.Inventor/a Juan SHAO

Provided are a modified recombinant adenoviral vector, and a preparation method and use thereof. The modified adenoviral vector can reduce the negative charge level on the surface of adenovirus particles, so as to reduce interaction between the adenoviral vector and PF4 (platelet factor 4). By administering the modified adenovirus vector, the risk of thrombus can be reduced, **vaccine** safety and effectiveness are improved, and the **vaccine** is more suitable for high-risk crowds such as elder people, children and pregnant women. The recombinant adenovirus can be widely used for gene therapy, tumor immunization and/or antiviral vaccination, including the use of initiating a primary immune response in a human or mammal to initiate a reinforced immune response for destroying the tolerance of a host to an autoantigen. The modified recombinant adenovirus can be used for developing a mucosal administration formulation. Compared with injection, the mucosal administration formulation has compliance and also lower dosage, and can generate triple protection effects of humoral immunity, cellular immunity and mucosal immunity.

16. 20260263589PORCINE EPIDEMIC DIARRHEA VIRUS **VACCINE**

US - 10.09.2026

Clasificación Internacional A61K 39/215Nº de solicitud 19550913Solicitante UIF (University Industry Foundation), Yonsei UniversityInventor/a Jae-Chul PYUN

A vaccine for porcine epidemic diarrhea virus is disclosed. The vaccine may comprise peptides having the sequences of an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 1; (b) the amino acid sequence of SEQ ID NO: 2; (c) the amino acid sequence of SEQ ID NO: 3; and (d) the amino acid sequence of SEQ ID NO: 4.

17. 20260263574 COMBINATION THERAPY OF HER2 VACCINE AND IMMUNE CHECKPOINT INHIBITOR
US - 10.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19162333Solicitante Aston Science Inc.Inventor/a Hun Jung

The present disclosure relates to a combination therapy of a HER2 cancer vaccine and a PD-1 inhibitor or a PD-L1 inhibitor. The combination therapy according to the present disclosure overcomes treatment limitations of the PD-1 inhibitor or the PD-L1 inhibitor and exhibits excellent immunological antitumor activity.

18. WO/2026/185881 A PROTEIN SUBUNIT VACCINE COMPOSITION AGAINST *MYCOBACTERIUM TUBERCULOSIS*

WO - 10.09.2026

Clasificación Internacional A61K 39/04Nº de solicitud PCT/IN2026/050371Solicitante INSTITUTE OF LIFE SCIENCESInventor/a RAGHAV, Dr. SUNIL KUMAR

The present invention relates to an antigenic protein (generated using protein engineering approaches) and a vaccine composition comprising this protein against *Mtb*. The antigenic protein is a C-terminal truncated Hsp16.3 protein of *Mtb* (Hsp16.3ΔC4). The present invention further reveals that the coadministration of this protein with BCG significantly elicits cellular and humoral immunity against pulmonary tuberculosis.

19. 20260263579 IMMUNOGENIC COMPOSITION

US - 10.09.2026

Clasificación Internacional A61K 39/095Nº de solicitud 18869582Solicitante GLAXOSMITHKLINE BIOLOGICALS SAINventor/a Agnese MARCELLI

The present invention relates to an improved immunogenic composition against *N. meningitidis* serogroups A, C, W135 and Y in solid form, and to a reconstituted vaccine against *N. meningitidis* serogroups A, B, C, W135, Y obtained by reconstitution with a liquid immunogenic composition of Men B antigens. Kits and methods for the prevention and treatment of meningococcal infection and disease with the immunogenic composition or the reconstituted vaccine are also provided.

20. 4803629 MULTIVALENTER INFLUENZA-MRNA-IMPfstoff

EP - 09.09.2026

Clasificación Internacional C12N 15/62Nº de solicitud 24884866Solicitante RINUAGENE BIOTECHNOLOGY CO LTDInventor/a CEN SHAN

Provided is an isolated mRNA molecule, which contains a nucleotide sequence encoding a chimeric immunogenic polypeptide, wherein the chimeric immunogenic polypeptide contains an immunogenic fragment of hemagglutinin (HA) of influenza A H5N1, an immunogenic fragment of hemagglutinin (HA) of influenza A H1N1, and an immunogenic fragment of hemagglutinin (HA) of influenza B Victoria, which are

linked to each other. Further provided are a composition and vaccine containing the mRNA, a fusion protein encoded thereby, and a method using same for inducing an immune response to influenza virus in a subject.

21. 4798232 SHIGELLA-IMPFSTOFFZUSAMMENSETZUNGEN

EP - 02.09.2026

Clasificación Internacional A61K 39/02Nº de solicitud 24883194Solicitante VAXCYTE
INCInventor/a FAIRMAN JEFF

Provided herein are vaccine compositions useful in preventing and protecting against Shigella-based infection. Specifically, the disclosure provides a composition comprising a Shigella virulence factor VirG (or IcsA) protein comprising an amino acid sequence at least 90% identical to the sequence set forth in SEQ ID NO: 2 or a fragment comprising about 100-400 amino acids thereof.

22. 20260263583 VACCINE COMPOSITIONS AND METHODS FOR CONTROL OF FOOT AND MOUTH DISEASE

US - 10.09.2026

Clasificación Internacional A61K 39/135Nº de solicitud 19167830Solicitante INDIAN COUNCIL OF AGRICULTURAL RESEARCHInventor/a Madhusudan HOSAMANI

This disclosure provides a method of preventing foot lesions caused by FMD virus infection in ruminants through the use of vaccine presented as emulsion containing one or several adjuvants and viral antigens.

23. 20260263577 TUBERCULOSIS VACCINE COMPOSITION CONTAINING IMMUNE-ACTIVE SITE FUSION PROTEIN

US - 10.09.2026

Clasificación Internacional A61K 39/04Nº de solicitud 18875647Solicitante MYCO-RAPHA INC.Inventor/a Hwa Jung KIM

The present invention provides a fusion protein vaccine composition by the identification of immune-active domains (sites or segments) of Rv2299c protein, the removal of unnecessary sites or the selection of only necessary portions, and linkage to different immune-active proteins or sites, to effectively activate an immune response in tuberculosis patients, and thus can significantly contribute to the prevention and treatment of tuberculosis.

24. 20260256903 DENGUE VACCINE

US - 03.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19553925Solicitante VLP Therapeutics, Inc.Inventor/a Wataru AKAHATA

Provided is a dengue virus like particle specific for type 4 dengue virus (DENV4 VLP), comprising a chimeric dengue structural protein, and a composition or vaccine comprising thereof, its use in the prevention or treatment of dengue infection. The chimeric dengue structural protein comprises prM and envelope regions and is a chimera of parts each derived from DENV1, DENV3 and DENV4.

25. WO/2026/185497 VACUNA SUBUNITARIA CONTRA LA SEPTICEMIA HEMORRÁGICA

WO - 10.09.2026

Clasificación Internacional C07K 14/28Nº de solicitud PCT/ES2026/070104Solicitante UNIVERSITAT DE VALÈNCIAInventor/a AMARO GONZÁLEZ, Carmen

La presente invención se refiere a una composición que comprende una proteína de unión a la transferrina, una proteína que confiere resistencia al complemento y a la fagocitosis, o la combinación de ambas proteínas; para uso como adyuvante o como vacuna subunitaria que activa la respuesta inmunitaria contra la septicemia hemorrágica causada por bacterias patógenas tales como: *Vibrio vulnificus*, *Vibrio harveyi*, *Photobacterium damsela* subsp. *damsela*, *Vibrio parahaemolyticus* y *Aeromonas salmonicida*.

26.20260256907OLIGONUCLEOTIDES FOR USE IN MODULATING IMMUNE RESPONSES AGAINST HEPATITIS B VIRAL INFECTION

US - 03.09.2026

Clasificación Internacional A61K 39/29Nº de solicitud 19366428Solicitante AUSPERBIO THERAPEUTICS INC.Inventor/a Guofeng CHENG

Provided herein are **vaccine** compositions comprising an oligonucleotide and a Hepatitis B viral antigen, either present in the same composition, or in separate compositions, useful for prevention or treatment of Hepatitis B viral infection in a subject. The **vaccine** compositions can exert a sustained immunomodulatory effect and lead to the reduction of HBV antigen levels in an infected subject. Also provided herein are methods of making and use thereof.

27.WO/2026/186709DENGUE **VACCINE**

WO - 10.09.2026

Clasificación Internacional C12N 15/40Nº de solicitud PCT/JP2026/007823Solicitante VLP THERAPEUTICS, INC.Inventor/a AKAHATA, Wataru

Provided is a dengue virus like particle specific for type 4 dengue virus (DENV4 VLP), comprising a chimeric dengue structural protein, and a composition or **vaccine** comprising thereof, its use in the prevention or treatment of dengue infection. The chimeric dengue structural protein comprises prM and envelope regions and is a chimera of parts each derived from DENV1, DENV3 and DENV4.

28.4798233ORALE HUNDEIMPFFSTOFFE UND VERABREICHUNGSVERFAHREN

EP - 02.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud 24802376Solicitante ZOETIS SERVICES LLCInventor/a AMEISS KEITH ALLEN

This disclosure provides a method of protecting a canine against canine distemper virus, the method comprising administering a recombinant oral **vaccine** comprising a modified live canine adenovirus type 2 (CAV-2) vector carrying a Canine Distemper Virus (CDV) antigen to said canine, wherein the **vaccine** is administered orally.

29.20260256904LOW-SUGAR CORONAVIRUS **VACCINE** AND METHODS THEREOF

US - 03.09.2026

Clasificación Internacional A61K 39/215Nº de solicitud 19640107Solicitante Rock BioMedical, Inc.Inventor/a Chung-Yi WU

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

30.4803550IMMUNZUSAMMENSETZUNGSPRODUKT ZUR PRÄVENTION ODER BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT NEISSERIA MENINGITIDIS GRUPPE B UND HERSTELLUNGSVERFAHREN DAFÜR

EP - 09.09.2026

Clasificación Internacional C07K 19/00Nº de solicitud 24884951Solicitante YANTAI PATRONUS BIOTECH CO LTDInventor/a TIAN SIYU

An immune composition product for preventing or treating diseases related to Neisseria meningitidis group B, and a preparation method therefor. The immune composition product comprises an fHbp fusion protein, wherein the fusion protein is constructed by means of disassembling two domains of three fHbp variants and then recombining same to construct a chimeric protein, and then on the basis of the chimeric protein, constructing a fusion protein containing characteristic amino acid sequences of the three fHbp variants. Furthermore, a nanoparticle vaccine is prepared by means of using such fusion protein as a vaccine antigen. The fusion protein has better immunological effects than those brought about by simply mixing the three fHbp variants.

31.20260263578IMMUNOGENIC COMPOSITION

US - 10.09.2026

Clasificación Internacional A61K 39/095Nº de solicitud 18869341Solicitante GLAXOSMITHKLINE BIOLOGICALS SAInventor/a Agnese MARCELLI

The present invention relates to an immunogenic composition against *N. meningitidis* serogroup B in liquid form, and to a reconstituted vaccine against *N. meningitidis* serogroups A, B, C, W135, and Y comprising the liquid composition. Kits and methods for the prevention and treatment of meningococcal infection and disease with the immunogenic composition or the reconstituted vaccine are also provided.

32.WO/2026/185415T CELL BROAD BETACORONAVIRUS VACCINE

WO - 10.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2026/056133Solicitante NEC ONCOIMMUNITY ASInventor/a ODAINIC, Alexandru

The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the prophylactic or therapeutic treatment of an infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2.

33.20260263572NEMATODE VACCINE

US - 10.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19167281Solicitante AGRESEARCH LIMITEDInventor/a Saleh UMAIR

The present invention is directed to a **vaccine** comprising recombinant antigens derived from the parasitic nematode *Teladorsagia circumcincta*, which will raise an immune response in farmed and wild ruminants that are susceptible or predisposed to infection by one or more nematode worm species.

34.20260263576DNA **VACCINE** TARGETING OVEREXPRESSED ANTIGENS IN COLORECTAL CANCER

US - 10.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19165403Solicitante UNIVERSITY OF WASHINGTONInventor/a Mary L. Disis

A **vaccine** in the form of a five-antigen poly-epitope DNA plasmid and related molecules designed to optimize anti-genicity, immunogenicity and physicochemical properties of the encoded fusion protein. All proteins in the construct were confirmed to be expressed and vaccination generated high magnitude IFN- γ in the majority of animals evaluated. No toxicities attributable to vaccination were observed. Anti-tumor efficacy of vaccination is confirmed in treated mice. The epitopes include certain portions of CDC25B; COX2; HIF-1alpha; CDH3; and EGFR.

35.WO/2026/184614RESPIRATORY SYNCYTIAL VIRUS **VACCINE**

WO - 10.09.2026

Clasificación Internacional C07K 14/135Nº de solicitud PCT/CN2026/081265Solicitante RINUAGENE BIOTECHNOLOGY CO., LTD.Inventor/a DONG, Yijie

Provided are a polypeptide, a polynucleotide, a delivery carrier or a composition thereof for inducing an immune response against respiratory syncytial virus (RSV). Also provided are an RSV F protein variant and a method for using same. The variant can form a stable prefusion conformation. Also provided are a fusion protein and a method therefor using same. The fusion protein comprises an RSV M2-1 protein and a central conserved region of a G protein. The F protein variant can be further combined with the fusion protein to prepare a **vaccine** in the form of mRNA, so as to exert an optimal RSV prevention effect.

36.20260256705LIPID NANOPARTICLE FORMULATIONS FOR VACCINES

US - 03.09.2026

Clasificación Internacional A61K 9/51Nº de solicitud 18875296Solicitante GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULCInventor/a Pierrot Harvie

Provided is a lipid formulation capable of forming a lipid-based nanoparticle comprising an ionizable lipid to phospholipid molar ratio of 0.1-1.30 of in association with a nucleic acid payload, and in some embodiments, a stabilizing agent. In embodiments, the nucleic acid payload is a **vaccine** genetic element.

37.20260263580HIGH-YIELD GENOTYPE 1A, 2A AND 3A HCV

US - 10.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud 18876529Solicitante Hvidovre HospitalInventor/a Garazi Pena Alzua

The present invention relates to nucleic acid sequences that encode high-yield hepatitis C viruses (HCV) of genotype 1a, 2a or 3a that are useful in the fundamental research of HCV as well as in the search of antivirals and vaccines against HCV. In particular, the present invention relates to nucleic acid sequences that comprise HCV, which are capable of expressing the virus when transfected into cells and are capable of replication or infectivity in cultured cells as well as being functional as a **vaccine**.

38.WO/2026/182475RECOMBINANT ADENOVIRUS COMPRISING SARS-COV-2-DERIVED RECEPTOR-BINDING DOMAIN AND ANTIBODY FC REGION, AND USE THEREOF

WO - 03.09.2026

Clasificación Internacional C12N 15/86Nº de solicitud PCT/KR2026/002882Solicitante THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)Inventor/a SHIN, Hyun Jin

The present invention relates to a recombinant adenovirus comprising a SARS-CoV-2-derived receptor-binding domain and an antibody Fc region, and a use thereof, and provides: a polynucleotide comprising a SARS-CoV-2 spike-derived receptor-binding domain and an antibody Fc region; a recombinant adenovirus comprising the polynucleotide; and a **vaccine** composition for preventing SARS-COV-2 infection, comprising the recombinant adenovirus as an active ingredient.

39.4646564KØLEOPBEVARINGSANORDNING OG FREMGANGSMÅDE TIL DRIFT AF DENNE

DK - 07.09.2026

Clasificación Internacional F25D 11/00Nº de solicitud 24720520Solicitante B Medical Systems S.à.r.l.Inventor/a BRUNO, Simone

An RFID enabled cold storage device, notably a **vaccine** storage device, has a cold storage compartment separated from an ice lining by a thermal barrier. The thermal barrier comprises a layer of thermal insulation material and a planar temperature distributing metal sheet, with the planar temperature distributing metal sheet providing an RFID antenna.

40.WO/2026/185533A SERIES OF SYNTHETIC BLOOD-STAGE MALARIA **VACCINE** IMMUNOGENS PRESENTING THE EPITOPES FOR GROWTH-INHIBITORY ANTIBODIES FROM PFRH5

WO - 10.09.2026

Clasificación Internacional A61K 39/015Nº de solicitud PCT/GB2026/050266Solicitante OXFORD UNIVERSITY INNOVATION LIMITEDInventor/a HIGGINS, Matthew

The present invention provides a portion of Plasmodium falciparum Reticulocyte-binding protein Homologue 5 (PfRH5) antigens, pharmaceutical formulations and vaccines. The present invention also provides methods of treating or preventing Plasmodium infection and/or disease by administering the modified portion of Plasmodium falciparum Reticulocyte-binding protein Homologue 5 (PfRH5), pharmaceutical formulations and vaccines.

41.20260256906EPSTEIN-BARR-VIRUS **VACCINE**

US - 03.09.2026

Clasificación Internacional A61K 39/245Nº de solicitud 18879731Solicitante Bavarian Nordic
A/SInventor/a Robin Steigerwald

The present invention relates to vaccines based on a viral vector for the delivery of antigens targeting an infectious disease. Specifically, the invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) encoding antigens of EBV causing infectious mononucleosis (IM) and different cancer types. The invention further relates to medical uses of the recombinant MVA in the prevention of diseases caused by EBV.

42.20260263612MODIFIED VIRUS-LIKE PARTICLES OF CMV

US - 10.09.2026

Clasificación Internacional A61K 47/64Nº de solicitud 19573958Solicitante SAIBA AGInventor/a Martin
BACHMANN

The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, **vaccine** platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.

43.WO/2026/1844135'UTR FOR EFFICIENT EXPRESSION, NUCLEIC ACID, AND USE THEREOF

WO - 10.09.2026

Clasificación Internacional C12N 15/113Nº de solicitud PCT/CN2026/078988Solicitante BEIJING
NEOCURNA BIOTECHNOLOGY CORPORATIONInventor/a WANG, Yi

Provided is a 5'UTR for efficient expression of mRNA. The sequence of the 5'UTR sequentially comprises SEQ ID NO: 27, a sequence selected from SEQ ID NO: 28 and SEQ ID NO: 29, a linking sequence, and a sequence selected from SEQ ID NO: 30 and TCCGTA. Also provided are a nucleic acid molecule having the 5'UTR, such as mRNA and a **vaccine**, and a use thereof. The 5'UTR can regulate the translation of corresponding mRNA to efficiently express a target protein, and can be used in the preparation of mRNA vaccines and gene drugs.

44.WO/2026/187814EXTRACELLULAR VESICLES AS MODULATORS OF IMMUNE RESPONSES TO ADENO ASSOCIATED VIRUS (AAV) GENE THERAPY VECTORS

WO - 10.09.2026

Clasificación Internacional A61K 9/1272Nº de solicitud PCT/US2026/017530Solicitante THE BOARD OF
TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventor/a HAMILTON, Bradley

Compositions and methods are provided for reducing immune responses, including without limitation innate immune responses and humoral immune responses, by administration of an effective dose of free extracellular vesicles (EVs). In some embodiments the immune responses are associated with administration of a gene therapy vector. In some embodiments the gene therapy vector is a viral vector including, without limitation, adeno-associated virus (AAV) vectors, adenoviral vectors, lentiviral vectors, retroviral vectors,

herpes simplex viral vectors, vaccinia viral vectors, and pox viral vectors. In some embodiments, the viral vector is an AAV vector. A feature of the disclosure is that the virus vector is not encapsulated by the EVs.

45. WO/2026/183459 IMPROVED NOROVIRUS VACCINE SEQUENCES

WO - 03.09.2026

Clasificación Internacional C12N 15/85Nº de solicitud PCT/US2026/017062 Solicitante VAXART, INC. Inventor/a SUN, William

Codon-optimized nucleic acids encoding the Norovirus VP1 protein and their use are provided.

46. 4798720 RIBONUKLEINSÄUREKONSTRUKT ZUR INDUKTION EINER IMMUNANTWORT SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNG UND KIT DAMIT

EP - 02.09.2026

Clasificación Internacional C12N 15/117Nº de solicitud 24808559 Solicitante UNIV BONN RHEINISCHE FRIEDRICH WILHELMS Inventor/a HARTMANN GUNTHER

The present invention relates to a ribonucleic acid construct capable of inducing an immune response, comprising a double-stranded ribonucleic acid sequence with a length of 8 to 17 ribonucleotides comprising at least one triphosphate at the 5'-end of at least one strand of said sequence, and a single-stranded overhang at at least one strand of said sequence, wherein the single-stranded overhang comprises at least one guanosine. The present invention also relates to the use of said construct as a vaccine or as an immune adjuvant as well as to the ribonucleic acid construct for use as a medicament or for use in a method of treatment or prevention of a disease, specifically for use in a method of treatment or prevention of viral infections or cancer. The present invention further relates to a pharmaceutical composition and kit comprising said ribonucleic acid construct.

47. 20260265719 METHOD FOR PREVENTION AND TREATMENT OF VIRAL DISEASE

US - 10.09.2026

Clasificación Internacional C12N 9/24Nº de solicitud 19686064 Solicitante MOREHOUSE SCHOOL OF MEDICINE Inventor/a Barney S. GRAHAM

A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprising a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

48. 4801548 INVARIANTER NATÜRLICHER KILLER-T-ZELLEN-AKTIVIERENDER IMPFSTOFF GEGEN BAKTERIELLE INFESTIONEN

EP - 09.09.2026

Clasificación Internacional A61K 39/09Nº de solicitud 24798512 Solicitante UNIV DANMARKS TEKNISKE Inventor/a CLAUSEN MADS HARTVIG

49. WO/2026/185557 TIME TEMPERATURE INDICATORS

WO - 10.09.2026

Clasificación Internacional G01K 3/04Nº de solicitud PCT/GB2026/050337 Solicitante ADVANCED MATERIAL DEVELOPMENT LIMITED Inventor/a WATERS, Thomas

The present invention relates to time temperature indicators (TTIs). In particular, the present invention relates to a TTI comprising a polymer film, the polymer film comprising a plurality of polymer particles, wherein the plurality of polymer particles are configured to coalesce over time. The plurality of polymer particles may comprise two or more different species of polymer particles. The plurality of polymer particles may comprise (i) a photonic crystal, (ii) a photonic glass, or (iii) a disordered plurality of polymer particles. The present invention extends to consumables comprising the TTIs, uses of the TTIs and methods of making the TTIs. The invention also relates to use of the TTIs as **vaccine** vial monitors (VVMs).

50. WO/2026/188147 COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES

WO - 10.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/US2026/018091 Solicitante UNM RAINFOREST INNOVATIONS Inventor/a BHASKAR, Kiran

A pharmaceutical formulation includes an active agent that targets pT181 in an amount effective to ameliorate at least one symptom or clinical sign of the tauopathic condition in a subject. In one or more embodiments of either aspect, the active agent includes a **vaccine**. In one or more embodiments of either aspect, the active agent includes an inhibitory polynucleotide. The pharmaceutical formulation can be administered to a subject to treat a tauopathic condition in a subject. Treatment may be prophylactic or therapeutic.

51. 20260263594 METHOD FOR MANUFACTURING RECOMBINANT TRANSFERRIN BINDING PROTEINS AND **VACCINE** COMPOSITIONS COMPRISING SAME

US - 10.09.2026

Clasificación Internacional A61K 39/39Nº de solicitud 19121349 Solicitante SERUM INSTITUTE OF INDIA PRIVATE LIMITED Inventor/a Abhijeet Jagannath KARALE

The present disclosure relates to manufacturing transferrin binding proteins. Specifically, the present disclosure relates to a simple, scalable, commercially viable fermentation and purification process for obtaining recombinant transferrin binding protein (rTbp-B) along with high recovery, low impurity/aggregate content, and at the same time retains the integrity of the protein. The method uses a single chromatographic step and does not require tagging of proteins as compared to multiple chromatographic steps used previously and still manages to provide r-Tbp-B with at least 95% purity.

52. 20260265684 EIMERIA **VACCINE**

US - 10.09.2026

Clasificación Internacional C12N 3/00Nº de solicitud 19662380 Solicitante Eimeria Pty Ltd. Inventor/a Vladimir Vrba

The present disclosure relates to methods and compositions for the production of oocysts from protozoa, such as *Eimeria*. The present disclosure also relates compositions comprising the oocysts and use of these composition for the treatment and/or prevention of infections.

53. 48020783'-UTR MIT VERBESSERTER TRANSLATIONSEFFIZIENZ, SYNTHETISCHES NUKLEINSÄUREMOLEKÜL DAMIT UND IMPFSTOFF ODER THERAPEUTISCHE ZUSAMMENSETZUNG DAMIT

EP - 09.09.2026

Clasificación Internacional C12N 15/67Nº de solicitud 24886200Solicitante GREEN CROSS CORPInventor/a JUNG JAESUNG

54. WO/2026/181032HBV THERAPEUTIC **VACCINE** AND METHODS OF USE THEREOF

WO - 03.09.2026

Clasificación Internacional A61K 39/29Nº de solicitud PCT/IB2026/051930Solicitante XIAMEN AMOYTOP BIOTECH CO., LTD.Inventor/a ZHU, Huabin

A composition comprises a first nucleic acid encoding an HBV surface antigen or a variant or fragment thereof, and a second nucleic acid encoding an HBV core-associated antigen or a variant or fragment thereof.

55. WO/2026/180687RNA POLYMERASE

WO - 03.09.2026

Clasificación Internacional C12N 9/12Nº de solicitud PCT/EP2026/055437Solicitante RIBOPRO B.V.Inventor/a TURRA, Gino

The invention relates to RNA polymerases, and to variant RNA polymerases. The invention is especially concerned with variant T7 RNA polymerases which generate a modulated amount of double stranded RNA (dsRNA) contamination compared to the parental T7 RNA polymerase during transcription. The invention extends to encoding nucleic acid and protein sequences of such mutant RNA polymerases, and to their use in methods for manufacturing RNA, for example in *in vitro* transcription (IVT) reactions. The invention extends to RNA manufacturing kits, and to RNA manufactured using such kits, especially for use as **vaccine**.

56. 20260256899PORPHYROMONAS GINGIVALIS ANTIGENIC CONSTRUCTS

US - 03.09.2026

Clasificación Internacional A61K 39/02Nº de solicitud 19450935Solicitante SANOFIInventor/a Yves GIRERD-CHAMBAZ

This invention relates to compositions (e.g. **vaccine** compositions) which can be used to immunise against *P. gingivalis* infections. The compositions comprise *P. gingivalis* antigens and antigen combinations which can be used to immunise against *P. gingivalis*, used in the form of nucleic acids (e.g. mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

57. 4800102REKOMBINANTER LEBENDER ATTENUierter HERPES-SIMPLEX-VIRUS-TYP-2-IMPfSTOFF

EP - 02.09.2026

Clasificación Internacional C12N 7/01Nº de solicitud 24882371Solicitante UNIV TOKYOInventor/a KAWAGUCHI YASUSHI

A virus of the present disclosure is a multiple mutant virus in which: two or more genes of herpes simplex virus type 2 (HSV-2) are modified; and a modification of the two or more genes involves a loss or reduction in gene function.

58.4799638IMMUNOLOGISCHE ADJUVANSZUSAMMENSETZUNG, HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON

EP - 02.09.2026

Clasificación Internacional A61K 39/39Nº de solicitud 24902716Solicitante GRAND THERAVAC LIFE SCIENCE NANJING CO LTDInventor/a GE JUN

Provided are an immunological adjuvant composition, a preparation method and use thereof. The immunological adjuvant composition comprises an immune activator and a liposome for loading the immune activator, wherein the immune activator includes a saponin and a CpG oligodeoxynucleotide. The immunological adjuvant composition is capable of eliciting an immune response against human herpesvirus and/or hepatitis B virus in a mammal and inducing a strong level of cellular immune response. By using the liposome to simultaneously load QS21 and the CpG oligodeoxynucleotide, the two components exhibit a favorable synergistic effect in promoting cellular immunity, and can induce a stronger level of cellular immune response compared to the commercially available **vaccine** Shingrix.

59.WO/2026/185545MODIFIED PFCYRPA PROTEINS AND THEIR USE AS BLOOD-STAGE MALARIA **VACCINE** IMMUNOGENS.

WO - 10.09.2026

Clasificación Internacional A61K 39/015Nº de solicitud PCT/GB2026/050317Solicitante OXFORD UNIVERSITY INNOVATION LIMITEDInventor/a HIGGINS, Matthew

The present invention provides a modified portion of Plasmodium falciparum cysteine-rich protective antigen (PfCyRPA), antigens, pharmaceutical formulations and vaccines. The present invention also provides methods of treating or preventing Plasmodium infection and/or disease by administering the modified portion of Plasmodium falciparum cysteine-rich protective antigen (PfCyRPA), pharmaceutical formulations and vaccines.

60.4801544KOMBINATION VON INTERLEUKIN 7 UND TUMORASSOZIIERTEM ANTIGENIMPfstoff

EP - 09.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud 24794864Solicitante OSE IMMUNOTHERAPEUTICSInventor/a MORELLO AURORE

61.20260257018SYSTEMS AND METHODS FOR BLOW-FILL-SEAL (BFS) TEAR-ACTIVATION VALVES

US - 03.09.2026

Clasificación Internacional A61M 5/28Nº de solicitud 19654446Solicitante Koska Family LimitedInventor/a Marc Andrew Koska

A pre-filled medical delivery assembly configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) vial to a patient. The delivery assembly including a tear-activation valve that provides for an internal, mechanical BFS vial opening, and defines an Auto-Disable (AD) feature that prevents refilling or re-use of the assembly.

62.4800101REKOMBINANTER LEBENDER ATTENUierter HERPES-SIMPLEX-VIRUS-TYP-1-IMPfstoff

EP - 02.09.2026

Clasificación Internacional C12N 7/01Nº de solicitud 24882370Solicitante UNIV TOKYOInventor/a KAWAGUCHI YASUSHI

A virus of the present disclosure is a multiple mutant virus in which: two or more genes of herpes simplex virus type 1 (HSV-1) are modified; and a modification of the two or more genes involves a loss or reduction in gene function.

63.20260263633MIXED NANO-LIPID DELIVERY SYSTEM FOR MRNA, PREPARATION METHOD THEREFOR AND USE THEREOF

US - 10.09.2026

Clasificación Internacional A61K 48/00Nº de solicitud 19162865Solicitante Beijing Dama Fangcheng Biotechnology Co., LtdInventor/a Zhenjun YANG

Disclosed are a mixed nano-lipid delivery system for mRNA, and a preparation method therefor and a use thereof. The delivery system is composed of an anionic and cationic mixed lipid, PEG2000-DSPE, a buffer system and mRNA; the anionic and cationic mixed lipid is composed of anionic nucleoside phospholipid TPS or CPS and cationic peptide lipid CLD or CLDA; and the buffer system is a PBS or Opti-MEM™ buffer system containing Ca²⁺ having a concentration 0.1 mM. The delivery system can efficiently deliver mRNA into cells and mice, and can realize long-time stable expression of proteins in vivo. In addition, an HPV E7 mRNA vaccine provided by the present disclosure can successfully activate humoral and cellular immunity in mice, reduce the mortality rate of HPV-related cervical cancer mice, and have good safety.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búsqueda: *vaccine.ti. AND @PD>="20260901"<=20260912* 30 records

Document ID	Title	Inventor	Applicant Name
US 20260263589 A1	PORCINE EPIDEMIC DIARRHEA VIRUS VACCINE	PYUN; Jae-Chul	UIF (University Industry Foundation), Yonsei University
US 20260265312 A1	VACCINES TARGETING PSEUDOMONAS AERUGINOSA	Møller; Niels Iversen et al.	EVAXION BIOTECH A/S
US 20260263582 A1	NOROVIRUS MRNA VACCINES	Bollman; Brooke et al.	ModernaTX, Inc.
US 20260263585 A1	UNIVERSAL INFLUENZA MRNA VACCINE AND USE THEREOF	LUO; Jian et al.	SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.
US 20260263574 A1	COMBINATION THERAPY OF HER2 VACCINE AND IMMUNE CHECKPOINT INHIBITOR	Jung; Hun et al.	Aston Science Inc.
US 20260263594 A1	METHOD FOR MANUFACTURING RECOMBINANT TRANSFERRIN BINDING PROTEINS AND VACCINE COMPOSITIONS COMPRISING SAME	KARALE; Abhijeet Jagannath et al.	SERUM INSTITUTE OF INDIA PRIVATE LIMITED
US 20260263577 A1	TUBERCULOSIS VACCINE COMPOSITION CONTAINING IMMUNE-ACTIVE SITE FUSION PROTEIN	KIM; Hwa Jung et al.	MYCO-RAPHA INC.
US 20260263587 A1	PROTEIN AND VACCINE AGAINST INFECTION BY SARS-COV-2 OMICRON VARIANT STRAIN AND SUBTYPE THEREOF	WEI; Xiawei et al.	WestVac Biopharma Co., Ltd.

US 20260263354 A1	BIODISSOLVABLE MICRONEEDLE ARRAY- METAL-ORGANIC FRAMEWORK-VACCINE BIOCOMPOSITES FOR EFFECTIVE SKIN IMMUNIZATION AND MANUFACTURING THEREOF	Falo; Louis D. et al.	University of Pittsburgh - Of the Commonwealth System of Higher Education
US 20260263583 A1	VACCINE COMPOSITIONS AND METHODS FOR CONTROL OF FOOT AND MOUTH DISEASE	HOSAMANI; Madhusudan et al.	INDIAN COUNCIL OF AGRICULTURAL RESEARCH,ZOETIS PHARMACEUTICAL RESEARCH PRIVATE LIMITED
US 20260263576 A1	DNA VACCINE TARGETING OVEREXPRESSED ANTIGENS IN COLORECTAL CANCER	Disis; Mary L. et al.	UNIVERSITY OF WASHINGTON
US 20260263572 A1	NEMATODE VACCINE	UMAIR; Saleh	AGRESEARCH LIMITED
US 20260265702 A1	ADENOVIRAL VECTOR VACCINE, AND PREPARATION METHOD AND USE THEREOF	SHAO; Juan et al.	CANSINO BIOLOGICS INC.
US 20260263581 A1	RSV VACCINE COMPOSITION, METHOD AND USE THEREOF	LIANG; Joshua et al.	SICHUAN CLOVER BIOPHARMACEUTICALS, INC.
US 20260265684 A1	EIMERIA VACCINE	Vrba; Vladimir et al.	Eimeria Pty Ltd.
US 12728157 B2	Autologous cancer tumour associated extrachromosomal circular DNA for use as a therapeutic vaccine	Nilsson; Jonas	CIRCULAR BIOTECH AB

US 12728159 B2	Coronavirus vaccines compositions and method of using same	Baker; Susan et al.	LOYOLA UNIVERSITY OF CHICAGO, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
US 12728161 B2	Use of membrane inhibitors to enhance vaccine development against enveloped viruses	Aguilar-Carreno; Hector et al.	CORNELL UNIVERSITY
US 12728160 B2	Vaccine using M2/BM2-deficient influenza vectors	Moser; Michael J. et al.	FluGen, Inc.
US 20260259196 A1	ASSAYS FOR THE EVALUATION OF SEASONAL COVID-INFLUENZA COMBINATION VACCINES	KALKERl; Raj et al.	NOVAVAX, INC.
US 20260256904 A1	LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF	WU; Chung-Yi et al.	Rock BioMedical, Inc.
US 20260256903 A1	DENGUE VACCINE	AKAHATA; Wataru	VLP Therapeutics, Inc.
US 20260256906 A1	Epstein-Barr-Virus Vaccine	Steigerwald; Robin et al.	Bavarian Nordic A/S
US 20260256902 A1	A VACCINE FOR PROTECTING A PREGNANT SWINE AGAINST AFRICAN SWINE FEVER	VAN DEN BORN; Erwin et al.	INTERVET INC.

US 20260260737 A1	VACCINE MANAGEMENT SYSTEM FOR PREVENTING VACCINATION ACCIDENTS DUE TO MISVACCINATION AND MISREGISTRATION OF VACCINES, AND METHOD FOR PROVIDING VACCINATION SERVICE PERFORMED IN THE VACCINE MANAGEMENT SYSTEM	KIM; Hee et al.	REAL TIME MEDI CHECK CORP.
US 20260256905 A1	BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE	BenMohamed; Lbachir	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
US 20260256705 A1	LIPID NANOPARTICLE FORMULATIONS FOR VACCINES	Harvie; Pierrot et al.	GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC
US 12721885 B2	Vaccine against Heamophilus parasuis	Jacobs; Antonius Arnoldus Christiaan et al.	Intervet Inc.
US 12721887 B2	Vaccine composition comprising plant-expressed recombinant zika virus envelope protein and preparation method therefor	Hahn; Tae-Wook et al.	BIOAPPLICATIONS INC., INNOVAC CORPORATION
US 12721886 B2	Virus-like particles containing CST1 protein and toxoplasma vaccine using same	Quan; Fu-Shi et al.	University—Industry Cooperation Group of Kyung Hee University

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad

en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

